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9Preface
Trans2Care project is an operation of the Cross-Border Cooperation Programme 
Italy-Slovenia 2007-2013, funded by the European Regional Development Fund and 
some national funds.
This project, started on 1st April 2011, will be implemented through a period of three 
and half years by a consortium of 13 Partners, lead by the University of Trieste. It 
aims at translating results of their biomedical research into innovative products and 
services to improve health. 
The kick-off meeting of Trans2Care took place in Trieste on 21st-22nd November 
2011. The venue was the Narodni Dom, i.e. the Trieste National Hall, a multimodal 
building of the Slovene minority in the city, which formerly included the Slovene 
theatre and a hotel (Hotel Balkan). 
Narodni Dom was built on 1904 on the plan of Max Fabiani, one of the greatest 
Mittel-European architects. Burnt by the Italian fascists in 1920, it hosted later the 
Hotel Regina. Ultimately restored in 1990, it now hosts the Slovenski informativni 
center (Slovene information center) and the Advanced School of Modern Languages 
for Translators and Interpreters of the University of Trieste.  
On 21st November, the project was presented to the Partners, the academic and 
public authorities, and the general public, as reported in Section I.
On 22nd November, the Partners had an internal meeting, aimed at laying down the 
scientific contents and objectives of their collaboration, described in the 21 chapters 
of Section II.
The project’s proposal has had a unique trajectory during the 2-step evaluation 
process, recapitulated in Section III. The latter also hosts the points of view on the 
project by external observers.
Sabina Passamonti
team manager of the Lead Partner
Trieste, December 2013
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TRANS2CARE. Working plans: 
consciousness and perspectives
The project started on 1st April 2011 and will end on 30th September  2014.The project received a budget of € 2,611,118 from the Italy-Slovenia 2007-2013 
Cross-border Cooperation Programme.
Seven universities and research institutions, five hospitals and a center for technology 
transfer distributed over the Programme area constitute the “Interregional network 
for innovation and technology transfer for health improvement”, which will 
continuously develop new protocols and biotechnological devices for the prevention, 
early diagnosis and treatment of neurodegenerative, cardiovascular, orthopaedic and 
oncological diseases.
Why IS IT STRATEGIC?
The high and heterogeneous technical and scientific skills of team managers ensure the cohesion of the partnership and the project’s quality in its three main 
phases: network set-up, network’s operational implementation, its consolidation and 
enlargement.
The identification of targeted goals, which will at every working stage and level ensure 
the integrated action of partners, is of crucial importance. An increased efficiency 
depends on a considerable amount of management capacity. The partnership 
cohesion and its operational efficiency will attract new partners, including industrial, 
and new sources of funding. These elements will have a positive impact on the cross-
border area, not only in socio-economic terms, but also in terms of an integration 
model to imitate.
TRANS2CARE
The project started on 1st April 2011 and will end on 30th September  2014. The project received a budget of € 2,611,118 from the Italy-Slovenia 2007-2013 Cross-
border Cooperation Programme. The project’s objective is to set up an “Interregional 
network for innovation and technology transfer for health improvement”. The project 
can be summarized as follows:
Passamonti S. (Editor)
The Partners and the Objectives of Trans2Care, an Italy-Slovenia
cross-border network of science and healthcare institutions
pp. 13-23 / ISBN 978-88-8303-512-8 Transregional Network for Innovation and Technology 
Transfer to Improve Health Care
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•	Lead Partner
Università degli Studi di Trieste
•	Project Partner 1
Kemijski Inštitut Ljubljana
•	Project Partner 2
Scuola Internazionale Superiore 
di Studi Avanzati
•	Project Partner 3
Univerza v Novi Gorici
•	Project Partner 4
Università di Ferrara
•	Project Partner 5 
Treviso Tecnologia
•	Project Partner 6
Splošna Bolnišnica Dr. Franca Derganca
•	Project Partner 7
Università Ca’ Foscari di Venezia
•	Project Partner 8 
Università di Udine
•	Project Partner 9
IRCCS Burlo Garofalo
•	Project Partner 10
Zavod Republike Slovenije 
Za Transfuzijsko Medicino
•	Project Partner 11
Ortopedska Bolnišnica Valdoltra
•	Project Partner 12
Univerza na Primorskem 
Fakulteta za Vede o Zdravju
PP7
PP5
PP4
PP8
PP3
PP6
PP9
PP2
LP
PP1
PP10
PP11
PP12
Adriatic Sea
Mare Adriatico
Jadransko morje
TRANS2CARE
Figure 1: List of project partners 
and their location 
in the Programme area.
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WORKING PLANS: CONSCIOUSNESS AND PERSPECTIVES
It is our intent to illustrate the “structural” characteristics of the project, rather than its content. The structural characteristics analysis should help us to grasp its 
strategic nature, in order to apply it, if necessary, to other scientific or socioeconomic 
projects, which may widely differ from our TRANS2CARE.
The analysis is based on the following question: how does TRANS2CARE interpret the 
notion of strategic?
Besides the formal requirements of the public call, such as the number and 
geographical distribution of partners, duration and budget, are there any original 
operational aspects, which contribute to the strategic nature of the project?
Firstly, we will analyse the project’s working plans in order to single out the expected 
strategic operational aspects.
A) SETTING UP ThE NETWORK
The preliminary stages of the network set-up were:
1 Study of the Italy-Slovenia 2007-2013 Operational Programme. 
Under Section 2 the Operational Programme points out the reference framework:
•	 “Research and development are key factors in the creation of an economic 
environment” (p. 32);
•	 “In the Programme area, universities provide a wide range of courses, covering 
the major disciplines … omissis ... it should not be difficult to develop cooperation 
projects between universities that teach  the same subjects and deal with the 
same fields of interest and research projects. In this perspective, it is desirable that 
more or less recent universities of the Programme area are able to enhance the 
bilateral cooperation. “(p. 34);
•	 “The health sector, both in Italy and in Slovenia, takes us a large proportion of GDP 
devoted to public spending.” (p. 35).
•	 Under Section 4 - Programme strategy, several policy objectives of the Priority axis 
no. 2 - Competitiveness and knowledge-based society are identified; the University 
of Trieste and its partners could contribute to achieving them:
•	 “The improvement of research and technological innovation and the strengthening 
of cooperation between universities, research centers and businesses are the 
prerequisite to enhance the competitiveness of the Programme area. Considering 
the rich potential of scientific and research- and innovation-oriented center in 
the Programme area, it is important to support the technology transfer between 
companies and research institutions, to promote the adoption of innovative “highly 
technological” solutions and especially to foster the creation of networks between 
Italian and Slovenian R&TD.” (p. 63);
•	 “To ensure the development of valuable human resources in the Programme area, 
actions need to be supported by joint interventions of professional training aimed, 
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among other things, at retraining workers and promoting the integration of qualified 
personnel into the cross-border labour market. By doing so, it will be possible to 
optimally use the results of research and technological innovation activities, while 
contributing at the same time to prevent the so-called “brain drain.” (p. 64);
•	 “The health and social sectors are the key elements for ensuring an increase in the 
quality of life in the Programme area.” (p. 67).
2 Conceiving the project idea:
Create a cross-border network of universities, research centers, hospitals and 
company specialized in technology transfer with the objective of sharing technical-
scintific skills and applying them to the development of innovative health products 
and services. The main actors of the project idea are supported by 14 highly qualified 
researchers.
3 Haring the project idea with colleagues, the so-called team managers, be  
longing to 13 different institutions, and two-stage networking: informal agreements 
between colleagues, and formal agreements between institutions.
CONSCIOUSNESS
The data summarized in the table below chronologically mark the network 
achievements:
Achievement Phase Date Type of agreement
1. Expression of interes Call no. 1/2008 01.12.2008 Letter of intent
2. Project proposal Call no. 1/2009 10.09.2009 Letter of intent
3. Admission to funding List scrolling 10.03.2011 -
4. Beginning of activities Activities begin 01.04.2011 Informal agreement
5. Signing of the partner-
ship agreement
- 22.04.2011 Partnership 
agreement
6. Delivery of first report - 10.11.2011 -
7. Kick-off event - 21.11.2011 -
It should be noted that without any funds, the network has been stable for twenty-
nine months (from 01.12.2008 to 22.04.2011). In addition, partners informally 
agreed the start the activities (01.04.2011) before signing the partnership contract 
(22.04.2011).
Which are the factors of stability?
1. The quality of the people, expressed through various competences:
 a. High scientific and cultural skills;
18
 b. Ability to share their scientific expertise, despite the fact that high   
 specialization inevitably involves a lack in communication;
 c. Willingness to interact with different people with different ethnic,   
 linguistic, cultural, social background, or even with people not known before  
 (curiosity as a tolerance factor for individual growth).
2. The quality of the project idea, due to two elements:
 a. Good correspondence to the Operational Programme: the project resisted  
 the “stress tests” of the multiple stages of evaluation;
 b. An optimal solution to overcome the inherent limit to the full utilization   
 of the individual scientific-technological potential: sharing and    
 complementary use of human resources and infrastructure, in order to   
 build up a suitable operating mass to achieve otherwise unattainable goals;
 c. The team managers forecasted that by operating as a network, partners   
 would  achieve the project objectives (project feasibility).
3.  A technical language: English. A century ago it was German, two centuries 
ago, Latin.
PERSPECTIVES
If the network has resisted for such a long period of time without funds, it will 
probably be strengthened when funds will be allocated, not only to achieve the project 
objectives, but also to enable related initiatives, for example in first, second and 
third level training, or identifying new research contexts and promoting knowledge 
transfer.
Thus, quality and stability are two sides of the same coin, key reference features for 
other projects, other programmes, other contexts.
B) OPERATION OF ThE NETWORK
When the funds will be allocated the project will provide the following:1. Networking: for sharing objectives, knowledge and skills through:
 a. Information and communication technologies 
 (e-mail, website and content management system);
 b. Meetings (on average 1/month);
 c. Exchanges of researchers.
2. Training of researchers: to expand their technology skills and promote the 
acquisition of essential skills for self-sustainability of research and self-
employment (continuous search for sources of funding, creation of employment 
opportunities);
3. Management: to ensure and/or increase productivity:
 a. Promptly perform the activities, which are necessary to achieve the   
 objectives;
 b. Coordinate the activities in order to increase its efficiency and effectiveness.
4. Administration & reporting: to ensure traceability of project costs, and the 
correspondence between costs and their reimbursement to the partners. 
19
CONSCIOUSNESS
The objectives
At this stage the most critical task is to keep partners focused on the project’s 
objectives. Specifically allocated funds may trigger a paradoxical reaction: funds 
may be used in a manner that is different from the purposes of the project and 
disconnected from the activities of the partners. This is obvious, since every partner 
has some ongoing activities and these indiscriminately need any available financial 
resources.
To avoid this risk, it is necessary to identify common goals that are achievable over 
a short period of time. One of the major factors of cohesion will be the achievement 
of results over a short period of time, as a result of the synergies created between 
workgroups. Thus, project activities must be carefully studied and their scientific 
and management aspects coordinated. Our project is born and grows with careful 
scientific planning, together with a careful management control.
Management
Among various university projects, this one stands out due to the strategic importance 
of its management. By entrusting the management to an external company we 
have given an added value to the project, since we have fostered the creation of 
an interface between the team managers, who work in publicly funded non-profit 
organizations, and the corporate funded company personnel responsible for the 
project management. This synergy of two completely different mentalities becomes 
a factor of success, because it creates a trans-disciplinary collaboration.
The training of researchers
The project’s ambition is to instill in the minds of the newly-recruited researchers, who 
until recently have been committed to learning scientific concepts and methods, which 
are increasingly more sophisticated and intellectually challenging, the importance of 
acquiring complementary skills, mainly of a managerial nature, in order to optimize 
not only their technical and scientific productivity, but also to actually transfer their 
knowledge and technology to biomedical companies, which have to generate profits 
for their financial sustainability.
Administrative and management tasks
In the first seven months the administrative and reporting tasks absorbed enormous 
energies. Why? Albeit with a few exceptions, the scientific and health partners do 
not have the practical experience to manage a complex project in terms of partners, 
thoroughness and rigidity of financial reporting standards and obligation to 
implement unusual activity for scientific bodies, such as those of the Work Package 
no. 8 - Communication (to non specialized or sectoral areas).
The public funds granted to these institutions are generally insignificant and also 
sporadic. The scientific and cultural quality may have been marginally affected, because, 
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at the same time, the spread of the internet and the freedom of access to information 
and data, and the implementation of digital technologies for communication between 
colleagues (e-mail, video conferencing, etc.), has allowed to mitigate the damage: a 
certain productivity at no cost has been allowed by computer networks. The cohesion 
of the partnership during the months in which it did not receive any funding has been 
maintained thanks to these infrastructures.
However, these public bodies, which are constantly required to adopt a “corporate” 
mentality, are not at all prepared to leave their simple “cover-the-operating-costs” 
mentality, which requires minimum management and long-term vision skills.
By receiving additional funds, public bodies were given the opportunity to make much 
more challenging financial investments, not only from an administrative point of 
view, but also from an intellectual point of view, since they had to stake that these 
funds would have made them achieve important results: it was the first time for 
many of us.
We can start by analysing the most common tasks that university administrative 
departments usually tackle first: recruitment of contract personnel for “research 
support”. Initially, the desired funds were intended to recruit highly qualified 
personnel not only for “research support” (in accordance with Italian Law n. 165/01), 
but also for the “future sustainability of research.” This is a delicate operation. 
The collaboration lasts far more than normal (36 months) and the need for high 
qualification and motivation is correspondingly higher than normal. It comes to 
writing a public notice of selection (call) by adopting a completely different mindset, 
bearing in mind that qualified candidates can be attracted simply by writing only a 
couple of specific sentences. Paradoxically, the strategic approach of the project is 
implemented through simple acts, such as few simple sentences, and during the 
candidates’ selection process, by focusing on the intuition of the selection committee.
In order to write down public notices for the selection of highly specialised external 
consultants, our administration department had to learn new skills and unusual 
administrative procedures, such as tenders.
Even more unusual was the creation of our own visual identity and website.
The involvement by gender
The table below summarizes the gender participation in the project:
CATEGORy FEMALE MALE TOT
N % N % N
Team managers 7 54 6 46 13
Project managers 1 33 2 66 3
Researchers 10 71 4 29 14
Total 18 60 12 40 30
21
The data indicate that women and men are equally balanced in the project, if we 
consider the senior members. Instead, in the category of researchers, there is a clear 
predominance of women, without any selection criteria beeing adopted for the benefit 
of women (as suggested by the OP, p. 114). This situation reflects the high level of 
expertise of young women and is in line with Eurostat data relating to the percentage 
rate of higher education among the population aged 30-34 years, recognized in 2010 
by Eurostat1 as shown in table below:
Tertiary educational attainment by sex, age group 30-34 (% of group)
ITALy SLOVENIA
TOTAL 19,8 34,8
MALE 15,5 26,4
FEMALE 24,2 44
Both in Italy and in Slovenia younger women are more educated.
PERSPECTIVES
Actually, the most important perspective is not the achievement of the project 
objectives, which must be achieved in any case. The most important perspective is the 
achievement of the objectives in a shorter time than expected, thanks to a prudent 
selection of intermediate goals (which should be achievable) and the optimization 
of activities. By doing so, we understand that the planning of activities could free up 
time and human resources, which could in turn start identifying other elements for 
the innovation and consolidation of the network.
For this reason, the mix of administration and management and scientific-
technological activities, which will fully affect the researchers, should provide them 
with the opportunity to develop the habit of planning work and forecasting results. 
This is precisely what defines a strategic approach.
Administration and management experiences are a typically strategic added value, 
which may attract new partners, new funding opportunities and thereby ensure the 
sustainability of the network and the applicability of this model in other areas.
This project contributes to balance the presence of women in the highly qualified 
labour market. If all female researchers, who have joined the network, will continue in 
their professional commitment, within 5 to 10 years after the end of the project they 
will have the qualifications and skills to meet leadership roles.
1 http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&plugin=1&language=en&pcode=t2020_41
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C) CONSOLIDATION AND EXTENSION OF ThE NETWORK
Once fully developed, the network will trigger new activities included in Work Package no. 7:
ACTIVITy NO.1 Animation campaign aimed at including new members
ACTIVITy NO.2 New collaborations between industry, health professionals and 
academies
ACTIVITy NO.3 Programs for the integration of young researches into companies
ACTIVITy NO.4 Participation to tenders for the future support of the network
ACTIVITy NO.5 Spin-off/Start-up
With these five activities, the network will try different approaches to ensure its 
existence in conditions of full efficiency. The network aims to become a reference 
point for attracting financial, human and technological resources.
CONSCIOUSNESS
The biggest challenge is to cooperate closely with the biomedical industry. This is 
a double challenge, which involves: a) verification of the applicability and potential 
profitability of the basic knowledge generated within the network, b), verification 
of the (academic) basic research system’s ability to intercept the innovation and 
competitiveness needs of industries and position itself as a reference that can offer 
scientific and technological solutions to health and sanitary needs. 
This will not be a “deadly embrace”, because from the activity plan we can expect the 
setting-up of (strategic) partnerships with other research institutes and universities, 
aimed at creating consortia to participate in public tenders that offer financial support 
to basic or applied research carried out at universities.
Within the network there is a strong awareness that knowledge base and study and 
research methodologies, and also strategies for the acquisition of financial resources, 
are the authentic socio-economic characteristics of university.
PERSPECTIVES
These future collaborations will allow the optimal use of the knowledge and skills 
acquired within the network. In the terminal phase of the project, the collaboration 
with companies will be of fundamental importance for achieving an operational 
critical mass, as the setting up of the network with 13 project partners has been in the 
beginning. Therefore, we will achieve the objective of the Operational Programme, i.e. 
the transfer of highly qualified, university-trained human resources to the industrial 
sector, which will foster innovation by leveraging on human capital.
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CONCLUSIONS
In reviewing the arguments exposed, the primordial strategic element is constituted by the competences of the participants and not by their study or cultural affinities. 
It is the competences that enable people with different cultural backgrounds to listen 
to each other, not the sound of familiar words or concepts or languages. At the same 
time, it is the diversity of skills that made us identify a distant, ambitious and unifying 
(thus strategic) goal: transfer our knowledge to young researchers and enable them 
to work. This objective is the only thing that brings together people, whose daily life 
is impossible to share, due to the strong specialization of their respective knowledge.
The project idea is broad, strongly supported and in accordance with the Operational 
Programme, and has withstood the test of time without specific funding.
In the implementation phase, it appears strategic that two or preferably more partners 
jointly identify common and “reachable” goals and achieve them in a short time, as 
expected when genuine synergies are being implemented. In the implementation 
phase we should reverse the perspective: only achievable objectives can demonstrate 
the value of sharing skills and maintaining the functionality of the network.
The introduction of shared methods for the management of project activities, ranging 
from the identification of objectives, synergies and perspectives, to the planning 
of activities, is new to the projects carried out by universities. The management 
objective is to optimize the complementarity of skills and infrastructures, promote 
time-planning and freeing up time for future planning and innovations testing.
At the same time, by adopting new management and administrative skills the 
network will acquire essential operational competences to access additional sources 
of funding for future sustainability. These funds could be procured both through 
partnerships with companies and participation to public calls.
Finding financial resources is a strategic factor of cohesion for a partnership.
24
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PART II 
TRANS2CARE PARTNERS 
AND ThEIR CONTRIBUTION 
TO BIOMEDICAL KNOWLEDGE
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Chemometrics: a versatile tool to 
explore large dataset 
 Špela Župerl, Katja Stopar, Marjana Novič
 
PP1-National Institute of Chemistry, Ljubljana
Abstract — Chemometrics is the field of science covering the development 
and application of mathematical and statistical methods to identify important 
chemical information. It is indispensable in the evaluation of experimental 
results and suitable for exploration of large data sets. Within the Trans2Care 
project we intend to apply chemometrics methods in several areas related to 
the problems explored by the Project partners. In particular we shall investigate 
transmembrane protein transport mechanism with data-driven modelling 
approach and also applying biomolecular simulations. We’ll combine our 
theoretical approach with experimental data provided by the Project partners, 
which will contribute to a better exploration of the available information in 
biomolecular systems studied, in the research of neurodegenerative diseases, 
in cardiovascular and pathohistological research. It will also intensify the 
collaboration, mobility of researchers and exchange of knowledge between 
partners. 
Index Terms  — chemometrics, data mining, predictive modelling, transmembrane 
proteins
———————————————————
1 ThE NATIONAL INSTITUTE OF ChEMISTRy
The National Institute of Chemistry (NIC) was established in 1946 by the Slovenian Academy of Arts and Sciences (SAZU) as the Chemistry Laboratory of the SAZU, 
later it was renamed to the Chemistry Institute of the SAZU. Following Slovenian 
independence in 1992 the National Institute of Chemistry (NIC) became a public 
research institution. The NIC has 290 employees and they carry out research work 
in 15 laboratories and two infrastructure centers. More than 25% of the Institute’s 
staff members represent young researchers, making NIC one of the leading Slovenian 
organizations for education of graduate students. Research activities of the Institute 
are oriented towards the development of new expertise, technologies and products, 
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which will help to ensure the long-term development of Slovenia. The Institute 
offers high-level research equipment including a Karl Zeiss Supra 35 VP Electronic 
Microscope with EDX analysis, a high resolution powder x-ray diffractometer, and an 
800 MHz NMR spectrometer, allowing researchers to engage in advanced research 
challenges at the world level. Industry is also an important partner to the Institute; 
several Slovenian as well as foreign companies has established a close long-term 
cooperation with the Institute.
2 LABORATORy OF ChEMOMETRICS
In the early seventies the beginning of the chemometrics research started in Slovenia which was completely new field also in the world. At the National Institute 
of Chemistry prof. Dušan Hadži implemented chemometrics in his group in 1973 and 
in 1993 the group became an independent Laboratory of Chemometrics, first dealing 
with systems for identification of compounds based on infrared spectra, the study of 
algorithms, expert systems and modelling. 
Today the Laboratory of Chemometrics has 14 associates, seven researchers, three 
PhD students, two post-doctoral students, one visiting professor and one professor 
emeritus. We are developing and applying chemometrics and statistical methods 
for solving problems in chemistry and related sciences, from visualization of many-
dimensional data to analysis of biologically relevant information in proteomics and 
genomics. The research work is financed through national research programme 
schemes and several European projects. In 2010, the Laboratory of Chemometrics was 
involved in three EU projects (TRACE, CAESAR, IBAAC), bilateral projects with Turkey, 
Argentina and USA and made a strong collaboration with industry of asphalts (IMS-
ADITOL). The laboratory has already established a strong long-term collaboration with 
University of Trieste and from 2010 we are partners in an international strategic project 
Trans2Care.
2.1 Research Areas 
The researchers of the Laboratory of Chemometrics are engaged in various research activities, such as (i) introduction of chemometrics to the research and development, 
(ii) modelling of chemical properties and processes - QSAR and mechanistic models, 
(iii) development and application of artificial neural network methods in chemistry, (iv) 
application of discrete mathematics in structural chemistry, QSAR studies, proteomics, 
and in genomics, (v) development of methodologies and programme packages for 
mechanistic and empirical models, and (vi) development of 3D representations of 
chemicals structures for applications in QSAR. 
We have successfully applied chemometrics methods in the field of traceability of food 
[1], in the prediction of toxic properties of various toxic data (developmental toxicity, 
mutagenicity, carcinogenicity, bio-concentration factor and skin sensitation) [2], in the 
optimization of pigment dyeing of polybenzimidazol fibres [3], in the optimization of bio-
organic catalysts for stereo-selective reduction of prochiral ketones [4], in the research 
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of anti-tuberculosis drugs [5,6], in the optimization of gradient profiles in ion-exchange 
chromatography [7], in the investigation of a transport mechanism of a membrane 
protein, bilitranslocase [8,9], and in the research of structural characterization of 
transmembrane proteins [10]. In the field of proteomics we have recently published a 
review paper of Graphical representation of proteins [11].
2.2 Structural Elucidation of Transmembrane Protein, Bilitranslocase
In the collaboration with University of Trieste, Department of Life Science we have started the research project in which we address the problem of structural 
elucidation of transmembrane proteins. The experimental work performed at the 
Department of Life Science was the basis for the application of computational 
methods in the Laboratory of Chemometrics. In-silico methods are strongly dependent 
on experimental data available and a combination of experimental and theoretical 
approach can lead to a successful resolution of the specific problem. Experimental 
data are treated with computer algorithms, whose output are theoretical predictions 
of biological properties, and the predictions can be directly validated in additional 
experimental work. Below is a schematic presentation of a QSAR model for prediction 
of biological properties from structural data (Fig.1).
Fig.1. Schematic presentation of a QSAR model for prediction of biological property from structural data.
In the latest publication [12] we have presented an approach towards structure 
elucidation of bilitranslocase, the membrane protein which transports bilirubin from 
blood to liver cells. In this research we combined two approaches: first, the prediction 
of transmembrane segments of the protein based on the mathematical descriptors 
obtained from the information of membrane proteins of known 3D structure, and 
second, the information about the transport mechanism from experimentally tested 
set of small molecules for their competitive inhibition of bilitranslocase. 
In the first approach the sequence and secondary structure information of 
transmembrane segments of proteins with known 3D structure available from 
public databases (PDB and PDBTP) was exploited to build a model for prediction of 
transmembrane segments of structurally unresolved target protein. The prediction 
error of the model for prediction of alpha transmembrane segments for the external 
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validation set was below 10%. The model was challenged with bilitranslocase and it 
proposed four transmembrane alpha helices, each containing around 20 amino acids, 
which is partially confirmed with experimental studies using particular antibodies 
corresponding to parts of amino acid sequences of bilitranslocase.
In the second approach we have tested a set of 89 non-congeneric compounds for 
their competitive inhibition constants in the investigated protein-substrate system. 
The information about 3D chemical structure of small molecules (represented by 
molecular descriptors) and the experimental data assessed by evaluating the kinetics 
of inhibition of bilitranslocase transport activity was used for development of a data-
driven model using artificial neural networks. 
QSAR models showed good predictive ability for bilitranslocase binding affinity. 
From the mechanistic interpretation of selected molecular descriptors, obtained 
with genetic algorithm, it was found that interactions between bilitranslocase and 
small molecules rely on the ability to establish hydrogen bonds, diminishing the 
involvement of charge interactions. The results of this work show that, contrary to 
dietary anthocyanins, most of dietary flavonols do not interact with bilitranslocase, 
whereas, some flavonol aglycones act as poor ligands of that carrier. In case of 
nucleobases and their derivatives the phosphate group in principle improved the 
transport ability by bilitranslocase. 
3 ChEMOMETRICS IN TRANS2CARE
3.1 Competences or what can we offer to T2C
The long term collaboration with the University of Trieste in the field of transmembrane proteins is the basis for the research work within the T2C project. 
As described in the paragraph above, we have recently studied transmembrane 
protein, bilitranslocase, its transport activity and transmembrane segments. We 
will continue with the development of the prediction models, either for inhibition 
constants or for transmembrane alpha helices of beta sheets. We will also study the 
3D structural model and the molecular dynamics simulations of bilitranslocase. A 
complementary study and characterization of the sequence of bilitranslocase isolated 
from plants will be another interesting research topic and will offer an interesting 
comparison with the bilitranslocase homologue obtained from rat liver. Furthermore, 
structure elucidation studies will be extended to other transmembrane transporters, 
such as SbmA transporter (protein present in the membrane of bacteria).
Chemometrics methods are suitable for exploration of large data sets, especially 
in the case when the information contained in the data is not obvious and the 
knowledge is not easily extracted. For this reason we intend to collaborate with 
the T2C partners whose role is a compilation of large amounts of data, not only in 
the research laboratories, but also in the hospitals, where a lot of data are collected 
during their everyday practise. 
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4 CONCLUSION
In Trans2Care project our priority will be to explore experimental data collected by several partners, from biochemical data on membrane transporters to various 
studies of the neurodegenerative disease on one side, and statistical analysis of 
different data-bases and registers on the other side. The interdisciplinary approach 
of our research work will offer a good opportunity for young researchers starting 
their research career. It will also straighten already established collaborations and 
connect the research institutes, universities and hospitals within the Project, having 
in mind a common goal, a network of participants for exchange of ideas, knowledge 
dissemination and technology transfer.
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Transcriptome analysis of prion 
disease animal models 
Maura Barbisin, Giuseppe Legname
PP2-International School for Advanced Studies, Trieste
Abstract — Prion diseases are incurable and fatal neurodegenerative disorders 
that affect both humans and animals. The causative agent is an infectious 
protein called prion (PrPSc), which is the pathological form of a normal protein 
(PrPC) present on the cell membrane. The molecular mechanisms underlying 
prion replication and subsequent degeneration of the Central Nervous System 
(CNS) are still poorly understood and therefore innovative approaches are 
needed to build diagnostic, therapeutic, taxonomic, and disease surveillance 
tools. We are going to adopt an unbiased genomic approach and conduct 
whole transcriptome analyses using microarray gene expression methods in 
brain and/or blood of infected animals versus healthy controls. We hope to 
identify a set of genes that can be used for early diagnosis and/or as targets 
for therapeutic strategies. Within the Trans2Care project we intend to promote 
collaboration and exchange of knowledge to facilitate all partners’ research 
objectives, and possibly find a common way to accelerate the process aimed at 
improving our healthcare system.
Index Terms — prion, prion protein, neurodegeneration, gene expression, 
genomics.
———————————————————
1 SISSA, INTERNATIONAL SChOOL FOR ADVANCED STUDIES
SISSA, International School for Advanced Studies was established in Trieste in 1978, and it is one of the leading scientific institutions in Italy for postgraduate 
training in Mathematics, Neuroscience and Physics. There are thirteen Ph.D. courses 
available, covering the three main research areas, three professional master’s courses 
and, thanks to an agreement with University of Trieste and University of Trento, three 
joint curricula for master’s degrees (laurea magistrale) in Mathematics, Physics and 
Neuroscience. Besides being a school, SISSA is also an international research center 
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with financial support granted by private and public entities (Friuli Venezia Giulia 
Region, Italian Government and European Research Council). In 2010-2011 alone, 
Italian funding amounted to some € 5.5 million, while international grants provided 
over € 10 million. The Neuroscience Department (hereafter Department) is built on 
Cognitive Neuroscience and Neurobiology. The Cognitive Neuroscience group focuses 
on how the brain generates behavior (language, perception, action) using methods 
from artificial neural networks to human neuropsychology. The Neurobiology 
component of the Department is devoted to research on the nervous system, using a 
combination of molecular, cellular and integrative approaches. One specialized division 
of the Neurobiology area is devoted to the study of neurodegenerative diseases (such 
as Alzheimer’s, Parkinson’s, Huntington’s and Prion diseases), focusing on Functional 
and Structural Genomics. The Prion Biology Laboratory is part of the Genomics branch 
of the Department.
2 ThE PRION BIOLOGy LABORATORy
The Prion Biology Laboratory currently includes one associate professor, four post-doctoral fellows, nine Ph.D. students and two undergraduate students. We have 
a Biosafety Level 2 facility with a cell culture room as well as protein expression and 
purification equipment. In addition, we have access to core facilities and technologies 
available in the Department such as an animal facility carrying transgenic animals, 
histology room, DNA sequencing, confocal microscopy, Real-Time PCR and Affymetrix 
micro-array platforms.
The laboratory is supported by various grants and organizations such as IIT, PRIN, 
FIRB, FP7, and so on. Just to mention one example, recently € 5 million were 
granted to our laboratory and another group in the same Department to identify the 
changes in the human genome leading to a number of incurable neurodegenerative 
diseases (FIRB-Programme agreements 2011; project title: Functional Genomics of 
Neurodegenerative Diseases). Within this same line of research we became partners 
of the international strategic project Trans2Care, FESR 2007-2013 for the cooperation 
between Italy and Slovenia.
2.1 Research Activities
The focus of the Prion Biology Laboratory is studying prion diseases, rare and fatal neurodegenerative maladies that affect humans and animals, for which there is 
no diagnostic tool, nor a cure [1, 2]. In mammals, prions reproduce by recruiting the 
normal, cellular isoform of the prion protein (PrPC) and stimulating its conversion 
into the disease-causing isoform (PrPSc). PrPC and PrPSc have the same amino acid 
sequence, but distinct conformations: PrPC is rich in αα-helical content and has little 
αβ-sheet structure, whereas PrPSc has less αα-helical content and is rich in αβ-sheet 
structure (Fig. 1). The conformational conversion of PrPC to PrPSc is the fundamental 
event underlying prion diseases, and it is still poorly understood. The main research 
lines of the laboratory are: therapy of prion disease [3], physiology of the prion protein 
[4], syntethic prions and molecular determinant to infectivity [5], structural biology 
37
and biophysics of the prion protein [6], transcriptomics and neurodegeneration [7], 
molecular mechanisms of neurodegeneration [8].
The project funded by the Trans2care grant is focused on the analysis of the whole 
transcriptome of animal models affected by prion disease. The goal is identifying genes 
that can become potential targets for diagnostic and/or therapeutic approaches. 
Our collaborators identified some candidate genes by microarray gene expression 
analyses in brain tissue of a primate model of prion disease and they appear to be 
very promising. Our objective is validating these candidates using a more sensitive 
and accurate technology such as qRT-PCR. A second model we are using is cattle 
infected with BSE (Bovine Spongiform Encephalopathy or mad cow disease). In this 
case the tissue is blood and we are performing some QC tests of the samples before 
embarking in the microarray gene expression analysis and subsequent validation 
with qRT-PCR. 
Recent findings support the idea that neurodegenerative diseases may all share a 
common mechanism that implies a prion-like behavior. Therefore, even though prion 
diseases are rare disorders, basic research on their mechanisms may be useful to 
explain all the neurodegenerative maladies, like Alzheimer’s and Parkinson’s disease, 
that affect large portions of the world population.
Fig.1. The conformational conversion of PrPC (A) to PrPSc (B).
3 ROLES IN TRANS2CARE
3.1  What we can offer to T2C
We have focused our research projects on exploring the infection mechanisms of prions from various angles; therefore we have gained expertise in many fields, 
from protein expression and purification to animal models, as well as gene expression 
analyses. We can provide T2C partners with our knowledge to facilitate the exchange 
of expertise within the network, and at the same time we can take advantage of other 
partners’ technological skills to further understand prion replication mechanisms and 
subsequent degeneration of the CNS. We have in fact an ongoing collaboration with 
ZTM - Blood Transfusion Centre of Slovenia (PP10) that we intend to exploit further. 
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So far PP10 has developed a panel of mAbs against different moieties of the prion 
protein and some of them can distinguish and differentiate between the wild type 
PrPC and its pathogenic form PrPSc. They will be tested in our laboratory mainly for 
the detection of PrP in immunohistochemical procedures (i.e. Western Blot, ELISA 
and IF), but they may also become important diagnostic and/or therapeutic tools. 
We are trying to expand this collaboration in the direction of targeted proteomics 
using Multiple Reaction Monitoring assays (MRM Proteomics). In this way markers 
obtained by transcriptomic analyses could be directly screened at the protein level in 
samples of either animal models or patients.
We are going to seek additional opportunities to collaborate with other project 
partners.
4. CONCLUSIONS
The aim of the Prion Biology Laboratory is conducting high level research in the field of neurodegeneration and in particular unraveling aspects of prion diseases that 
are still poorly understood. Within the Trans2Care framework, we intend to employ 
gene expression profiling methods to identify gene candidates that may become 
potential diagnostic biomarkers and/or therapeutic targets. The participation in 
the Trans2Care initiative can be very helpful in opening new collaborations with the 
partners or expanding existing ones that may lead to joint discoveries and publications. 
In addition, having the opportunity of interacting with such diverse partners ranging 
from basic research institutes to technology centers and clinics, may foster exchange 
of ideas that can lead to potential technology transfer opportunities to improve our 
healthcare system.
ACKNOWLEDGEMENT
The financial support of the Fondo europeo di sviluppo regionale (Evropski sklad za 
teritorialni razvoj) for the Trans2care project is greatly appreciated. 
REFERENCES
[1] Prusiner SB. Prions. Proc. Natl. Acad. Sci. 1998; 95: 13363-83
[2] Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol 2011; 3(1):a006833. 
[3] Bolognesi ML, Ai Tran HN, Staderini M, Monaco A, López-Cobeñas A, Bongarzone S, 
Biarnés X, López-Alvarado P, Cabezas N, Caramelli M, Carloni P, Menéndez JC, Legname 
G. Discovery of a class of diketopiperazines as antiprion compounds. ChemMedChem 
2010; 5 (8):1324 -34 
[4] Benvegnù S, Poggiolini I, Legname G. Neurodevelopmental expression and 
localization of the cellular prion protein in the central nervous system of the mouse. J 
Comp Neurol. 2010; 518(11):1879-91
[5] Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ, Prusiner 
SB. Synthetic mammalian prions. Science. 2004; 305(5684):673-6.
39
[6] Biljan I, Ilc G, Giachin G, Raspadori A, Zhukov I, Plavec J, Legname G. Toward the 
molecular basis of inherited prion diseases: NMR structure of the human prion protein 
with V210I mutation. J Mol Biol. 2011; 412(4):660-73
[7] Benetti F, Gasperini L, Zampieri M, Legname G. Gene expression profiling to identify 
druggable targets in prion diseases. Expert Opin Drug Discov. 2010; 5(2):177-202
[8] Didonna A, Legname G. Aberrant ERK 1/2 complex activation and localization in 
scrapie-infected GT1-1 cells. Mol Neurodegener. 2010; 5:29. 
CONTACT INFO
Maura Barbisin, Giuseppe Legname are with International School for Advanced Studies, Neuroscience 
Department, SISSA, Via Bonomea  265, 34136 Trieste, Italy.
 
40
41
Novel laser-based photothermal 
methods of chemical analysis 
Mitja Martelanc, Mladen Franko
PP3-University of Nova Gorica 
Abstract — University of Nova Gorica (UNG) provides access to knowledge, high 
quality education and incorporates nine different main research areas. One of 
them is covered by the Laboratory for Environmental Research which conducts 
basic and applied research in different areas of environmental sciences such 
as the investigation of photochemical and microbial degradation, and transport 
of pollutants in the environment; the development of laser-based methods, 
bioanalytical methods, and ecotoxicological tests for the identification and 
determination of toxic compounds and their effects on the environment; the 
development of new materials for applications in environmentally friendly 
technologies as well as the research in molecular biology and neurobiology. 
All in all, the main stream of our scientific work in TRANS2CARE project will 
be related to novel laser-based photothermal methods of chemical analysis 
coupled to bioanalytical assays and flow injection analysis.
Index Terms — Laser-based analytics, thermal lens spectrometry, flow-injection 
analysis, bioanalytical methods, chromatographic techniques
———————————————————
1 UNIVERSITy OF NOVA GORICA
Predecessor of the University of Nova Gorica (UNG) was the Faculty of Environmental Sciences, which was the first international postgraduate school in Slovenia. The 
Faculty had been founded on 24 September 1995 with an agreement from the Council 
of the Republic of Slovenia for Higher Education of 12 July 1995. It began operating in 
the 1995/96 study year. The founders of the Faculty were the Municipality of Nova 
Gorica and the “Jožef Stefan” Institute from Ljubljana. The Faculty was reorganized 
into the Nova Gorica Polytechnic in 1998. UNG became a university institution in 2006 
founded by Municipality of Nova Gorica, Municipality of Ajdovščina, the “Jožef Stefan” 
Institute and the Research Center of the Slovenian Academy of Sciences and Arts 
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from Ljubljana. Currently UNG offers a broad range of academic programs - seven 
undergraduate programs, five second level programs (Master’s), and seven third level 
programs (Doctoral). UNG has got 144 employees of whom 91 are Doctors of Science 
(80 of them are University professors), and 17 are young researchers (Ph.D. students). 
Over 32% of them are foreign scientists. 
1.1 Research departments
The research activity at UNG is carried out in five research laboratories (Laboratory for Astroparticle Physics, Laboratory for Multiphase Processes, Laboratory of Organic 
Matter Physics, Materials research laboratory and Laboratory for Environmental 
Research), three research centers (Centre for Atmospheric Research, Centre for 
Systems and Information Technologies, Wine Research Centre) and one Research 
Institute (Institute for Cultural Studies). The Laboratory for Environmental Research, 
which will take part in TRANS2CARE project, is composed of five research groups 
focusing on: Organic substances in the environment (monitoring, transformation 
and effects), Materials for (photocatalysis) environmental applications, Molecular 
biology and biotechnology, Modeling of natural processes in forests, Assessment of 
environmental changes and Laser-based analytical methods. The latter group will be 
mostly engaged in TRANS2CARE project.
2 ACTIVITIES AND ROLES IN TRANS2CARE PROjECT 
2.1 Laser-based methods for chemical analysis and characterization
Research related to laser-based methods for chemical analysis and characterization includes development of laser-based spectroscopic methods for qualitative and 
quantitative determination of various compounds present in environment, food and for 
studies of various chemical and biological processes. Highly sensitive novel analytical 
methods are being developed using thermal lens spectrometry (TLS) [1] coupled with 
bioanalytical techniques (acetylcholinesterase – AChE [2], transglutamninaze, and 
ELISA bioassays [3-4]), flow injection analytical (FIA) systems [5-6], liquid chromatography 
[5-6], or microscopic TLS (TLM) (shown on Fig.1) as detection technique for lab-on-
a-chip chemistry and study of processes on microspace and in microfluidic systems 
[7]. Photothermal beam deflection spectrometry [8] is utilized to study thermal and 
optical properties of thin nanofilms of photocatalysts and organic semiconductors 
for photovoltaic cells as well as for carbon nanomaterials. Newly developed methods, 
which offer sensitivities over two orders of magnitude superior to those of conventional 
transmission mode spectrometric techniques were successfully applied for determination 
of various toxic compounds such as pesticides, allergens, biogenic amines, heavy metals 
or their species, and recently toxins, as well as essential and beneficial compounds like for 
example carotenoids, anthocyanins, and other physiologically relevant compounds (i.e. 
bilirubin) in foodstuffs, as well as in environmental and biological samples [9-10]. Recent 
applications include TLS detection of metal nanoparticles and exploitation of FIA-TLS for 
determination of toxic silver ions (Ag+) [11].
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Fig. 1: Picture of a TLS microscope constructed at UNG by dr. Mingqiang Liu (left) and a sequence of 
TLS signals recorded by UNG PhD student Ambra Delneri during detection of phycoerythrine from 
cyanobacteria by the FIA-TLS technique (right) (triplicate injections of 200 μL samples: 5, 10, and 15 mg/mL).
2.2 Aims in TRANS2CARE project
The scope of our scientific contribution in TRANS2CARE project is the development of novel state of the art methods based on TLS detection in liquid flows such as in 
the case of high performance liquid chromatography (HPLC), capillary electrophoresis 
(CE), ion chromatography (IC), and FIA. These systems will enable the determination of 
various compounds (egg. free bilirubin, anthocyanins, glutene-derived peptides, and 
virus-like proteins) that might be in research focus of other TRANS2CARE partners. 
In addition, TLS itself will be offered as detection technique for already available 
bioanalytical assays such as ELISA, or those being developed by other project 
partners, which lack sufficient sensitivity. The research will focus also on applications 
of microscopic TLS relying on bioassays in combination with flow injection analysis 
on micro-chemical chips [4]. Such combinations provide ultra-high sensitivity, high 
sample throughput, reduced operational costs, simplicity and high reproducibility. 
It is also our aim to provide conditions for high quality training of young scientists, 
those employed by TRANS2CARE, as well as PhD students conducting research in 
fields related to this project, by enabling intensive contacts and exchange of expertise 
within the project consortium.
3 CONCLUSIONS
With an interdisciplinary approach and intensive collaboration of UNG with partners having expertise in fields other than analytical chemistry, TRANS2CARE project 
is expected to provide a stimulating environment, infrastructural conditions and 
opportunities for the development and application of novel state of the art analytical 
methods for the determination of various substances relevant in biomedical research 
and diagnostics. Other sectors beyond the scope of TRANS2CARE such as food quality 
and safety, environmental protection and others, shall also benefit from the outputs 
of the project. Finally, the industrial sector producing medical diagnostic tools shall 
benefit by the results of research conducted within the project and knowledge 
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transfer as well as by the availability of new highly trained young experts.
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Studies of bone mineral density 
in children affected by dietary 
intolerances  
Cristina Malaventura, Elisa Ballardini, Alessandro Baldan, 
Caterina Borgna-Pignatti
PP4-The Pediatric Department of the University of Ferrara 
Abstract — The Pediatric Department of the University of Ferrara has developed 
a special expertise in the field of hemoglobinopathies and has also an interest 
in gastrointestinal diseases. It has a long standing collaboration with the 
Department of Genetics of the University of Verona. The main fields of interest 
are thalassemia, gluten intolerance, and osteoporosis in its various aspects. 
Using our previous research experience as a platform, we plan to study Vitamin 
D metabolism, bone mineral density, the FGF23 and Klotho axis in patients with 
thalassemia, in patients with adult type lactose intolerance, in patients treated 
with antiepileptic drugs and in those who suffer from gluten intolerance. Finally, 
we intend to cooperate with another group (PP9) of the Trans2Care project in 
order to clarify the role of tissue antitransglutaminases in seronegative patients 
with symptoms of gluten intolerance. 
Index Terms — FGF23/Klotho, lactose intolerance, Bone metabolism, 
Thalassemia, gluten intolerance, pseudoxanthoma elasticum
———————————————————
1 INTRODUCTION
The University of Ferrara was founded by Alfonso I d’Este in 1321. It has been the Alma Mater to Paracelsus, Nikolaus Kopernikus, and Pico della Mirandola. 
Today, the Department of Pediatrics of the University of Ferrara is situated in the 
Sant’Anna Hospital in the city center centre. but It will be moved soon to a new 
facility 10 Km to the south where larger and newer spaces will be available. The staff 
comprises physicians, administrative personnel, one dietitian, and, with the support 
of Trans2Care, a new collaborator has just been enrolled. The Department has a 
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special expertise in the field of Thalassemia and other hemoglobinopathies, and in 
neurological disorders of childhood. In addition, part of our staff has an interest in 
gastrointestinal diseases. 
2 ONGOING RESEARCh
2.1 Multicentre Study of Survival in Thalassemia major. 
The team manager of PP4 has, for the past three decades, coordinated a cooperative study on survival, complications and diagnostic and therapeutic 
aspects of thalassemia. The results of the study on survival and complications have 
been regularly published [1], [2], [3], [4]. The most recent data, 20 years from the first 
collection, show that the prognosis of these patients has greatly improved. In fact, 
our results show a sharp decrease in mortality in the last few years, testifying to the 
efficacy of modern therapy. i.e. MRI for the quantification of iron in the heart [5] and 
liver, the oral iron chelators [6], [7], aggressive management of cardiac and hepatic 
complications.
2.2 Feasibility of a screening for hemoglobinopathies
In order to identify early the infants affected by hemogolobinopathies, in particular sickle cell anemia, we are collecting the cord blood from all the neonates who are 
born in Ferrara. In fact an early diagnosis of sickle cell anemia can prevent infection 
and death in the first years of life [8]. In the past year, 1600 samples were examined 
by HPLC and 19 were found to be abnormal.
2.3  Morbidity and Mortality according to sex 
It is well documented that, female patients with thalassemia major survive longer than males [9]. In order to clarify the origin of this phenomenon, we have measured 
by magnetic resonance imaging the iron concentration in the heart of 776 patients 
(370 males) and have compared the results obtained in males and females, with and 
without cardiac failure or arrhythmias. As expected, cardiac disease was higher in 
males than in females, but no difference in cardiac iron content was observed according 
to sex [10]. Therefore, we concluded that males and females are at the same risk of 
accumulating iron in their hearts but females seem to tolerate iron toxicity better, 
possibly as an effect of reduced sensitivity to chronic oxidative stress. This study was 
conducted in collaboration with the Myocardial Iron Network in Thalassemia.
2.4 Vitamin D and Osteopenia in Thalassemia 
Osteoporosis and osteopenia are frequent complications of thalassemia major and intermedia. In a cooperative study, [11] we found osteoporosis to be present in 
the great majority of patients with thalassemia intermedia and in 115/239 patients 
with thalassemia major. In thalassemia major, no association was found with 
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specific polymorphisms in candidate genes (vitamin D receptor, estrogen receptor, 
calcitonin receptor, and collagen type 1 alpha 1). Osteoporosis in female patients with 
thalassemia major was strongly associated with primary amenorrhea, while in male 
patients, hypogonadism was not significantly related to bone mineral density. Low 
bone mineral density was also associated with cardiomiopathy, diabetes mellitus, 
chronic hepatitis, and increased ALT.
2.5 Genetic of lactose intolerance
We studied the presence of a substitution of C to T- single nucleotide polymorphism (rs4988235, -13910C>T), at position -13910 bp upstream in the lactose gene 
(rs4988235), in a population of Italian children and their parents. The children were 
diagnosed as lactose intolerant on the basis of the breath hydrogen test [12]. The 
mutation, localized in a regulatory region, was found to be strongly associated with 
the lactase persistence phenotype in North-European population. We confirmed its 
presence in Southern Europeans. In fact, the correlation between the C/C genotype 
( corresponding to lactose non-digesters) and positive breath test in unrelated 
family founders was significant. The genetic test compared to the breath test had 
a sensitivity of 95% and 91% and a specificity of 48% and 55% in adults and children, 
respectively.
2.6 Collaborations
We have a long standing collaboration with the Department of Life and Reproduction, Section of Genetics of the University of Verona, with the Section of 
Genetics of the Department of Clinical and Experimental Medicine of the University of 
Ferrara and with the Laboratory of Hematology & Clinical Chemistry of the University 
Hospital, Ferrara. Our Thalassemia Center is a part of the MIOT project, which is a 
network of 6 Magnetic Resonance Imaging apparatuses and 56 Italian Thalassemia 
Centers which share a common clinical and diagnostic database. In addition all 
the cooperative studies on Thalassemia and its complications are performed in 
collaboration with seven Italian Centers for the treatment of Thalassemia as listed 
in [2].
3 FUTURE PROjECTS AND TRANS2CARE NETWORKING 
3.1 Mineral metabolism
In consideration of the work previously performed, as outlined above, we plan to clarify the bone mineral density, and the role of Vitamin D and the FGF23/Klotho 
axis in patients with thalassemia, in lactose intolerant children, in patients with 
gluten intolerance and in children treated with antiepileptic drugs. The components 
of the FGF23/Klotho axis have recently been recognized as important factors in the 
metabolism of calcium and phosphate. [13] Klotho functions as the obligate co-
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receptor of FGF23. Mice lacking both FGF23 and Klotho develop identical phenotypes 
resembling premature aging syndromes, with hypogonadotropic hypogonadism, 
muscle and skin atrophy. The Klotho gene was originally identified as a putative 
age-suppressing gene in mice that extends life span when over-expressed. [14] In 
addition, Klotho functions as a humoral factor with pleiotropic activities including 
suppression of oxidative stress. [14] FGF23 regulates excretion of phosphates and 
synthesis of active Vitamin D in kidneys.[13]
Patients with thalassemia major exhibit many aging-like symptoms including 
hypogonadism, skin atrophy, muscle wasting osteopenia [15], reminiscent of the 
Klotho-deficient mice. Vitamin D metabolism and the FGF23/Klotho complex will 
therefore be studied in these patients and also in different populations of children 
affected by neurological and gastroenterological disorders. 
 Bone mineral density will be measured in patients by means of an ultrasonographic apparatus, acquired with Trans2Care funds. that spares the children studied the 
radiations inevitable with the more commonly used DEXA. [16].
 3.2 Pseudoxanthoma elasticum in thalassemia
A subgroup of patients with thalassemia major or intermedia also suffer from Pseudoxanthoma elasticum, a condition in which widespread calcification of 
joints and arterial vessels develop without apparent cause unknown, [17] and in 
which the Klotho/FGF23 complex could be involved [18][19].
To clarify some of the aspects of this complication that (in the non-hereditary form) 
affects mainly patients with chronic hemolytic anemias and, in particular, patients 
with thalassemia major and intermedia, we plan to perform a PXE case-control study 
of the transcriptome using Next generation sequencing [20][21] of our patients with 
a and without PXE. 
3.3  Tissue anti-transglutaminases in patients affected by seronegative gluten   
 intolerance.
This part of the reaserch project will be conducted in collaboration with PP9. In fact, the pediatricians of the Burlo Garofalo Hospital in Trieste have already developed 
an expertise in this technique that we could use to plan a region-wide (Regione Emilia 
Romagna) study in seronegative symptomatic patients in whom gluten intolerance 
is suspected [22]. 
4 END SECTIONS
4.1 Acknowledgements
We wish to acknowledge the precious secretarial help of Ms Cinzia Tonioli. Most of the research projects cited were supported by funds provided by the Ministero 
Italiano dell’Università e della Ricerca scientifica 
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5 CONCLUSION
During the last few years, the Pediatric Department of the University of Ferrara has conducted research in the field of the hemoglobinopathies and in the field 
of gastroenterology. We intend to pursue the same lines of research, enriching them 
with the addition of bone ultrasonography and the study of the newly described 
FGF23/Klotho system that promises to clarify some of the mechanisms at the basis 
of osteoporosis and extra-osseous calcifications in various diseases. Interweaving 
with other groups of the Trans2Care net will hopefully allow us to obtain more detailed 
information on our fields of interest that will provide improvements in prevention, 
early diagnosis and treatment of chronic diseases and their complications. The 
training of the researcher recruited by the project will contribute to increase the 
education and the internationalization of this educated young scientist.
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Facilitating collaboration, mobility 
of researchers and exchange of 
knowledge between Partners 
Giorgia Favaro, Franca Bandiera
PP5-Treviso Technology  
Abstract — Treviso Tecnologia is a non-profit entity which offers the market 
innovative high value-added services together with the development of projects 
financed on a local, national and European scale that allow a high degree of 
operational independence. It stands out as a facilitator offering information, 
education and developing services to promote the continuous dissemination 
of innovation with companies, leveraging the network between the world of 
research, university, the chambers of commerce and public institutions. Within 
the Trans2Care project we intend to apply this approach to innovation methods 
in several areas related to the problems explored by the Project Partners with 
the aim of promote collaboration, mobility of researchers and exchange of 
knowledge between Partners. 
Index Terms — high value added services, projects, innovation, network, 
intellectual property
———————————————————
1 TREVISO TECNOLOGIA
Treviso Tecnologia, the Treviso Chamber of Commerce’s special agency for innovation, was founded in 1989 to promote an entrepreneurial culture oriented towards 
innovation. With its workforce of 50 employees and collaborators, Treviso Tecnologia 
has always invested in the continuous updating of in-company skills in order to 
better face the need of companies and of local context that is constantly evolving. In 
this way, Treviso Tecnologia promotes the growth and development of an ecosystem 
favorable to innovation through the development of factors such as the quality of 
work, the improvement of managerial skills, the diffusion of ict in every economic 
sector (Digital Business Ecosystem, according to the EU) and the enhancement of 
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intellectual property as the currency of the new millennium. Furthermore, Treviso 
Tecnologia aims at supporting the territory in its ongoing transformation process 
through the high value-added, innovative services, technological infrastructures and 
international awards, programmes for the development of skills and professionalism, 
innovation and technology transfer supporting companies at any level (local, national 
and European) and finding resources whose final beneficiaries are companies and 
others. In addition to the corporate headquarters in Lancenigo di Villorba where the 
Training and Business Services are based, the company also has a product testing 
and certification centre (CERT) in Rustignè di Oderzo and its Neroluce Laboratory in 
the Fornace dell’Innovazione in Asolo.
2 SERVICES
Our offer of services is organized into four lines of activity:Innovation and technology transfer: we promote the competitiveness of 
companies through the collaboration with centres of excellence in the science field 
within the framework of financed projects or specific projects;
Continuous development of advanced and innovative skills: we design and deliver 
educational pathways that connect education (high school and university) with the 
business world, in order to jointly support lifelong learning programmes for companies. 
These programmes are often financed by participating in local and international calls 
for tenders.
Delivery of services of excellence: we invest in infrastructures and competence to 
perform for products testing and certification, with high value-added services in the 
field of intellectual property protection and international technical regulations.
International network: through cross-functional networks and partnerships with 
outstanding parties on a European scale, we cooperate in actions and projects aimed 
at the development of research, innovation and technology. transfer.
2.1 Technology transfer activities
Specifically technology transfer activities can be organized in three lines of activities:
•	 Development and technology transfer: in this sense we conduct evaluation 
activities and development of Human-Centered design for the creation of high-
innovative product concepts. Furthermore, some actions of market foresight, focus 
group with beneficiaries and technology intelligence activities aiming at let emerge 
potential development projects are carried out. Consequently a multi-disciplinary 
team and market orientation are the ingredients for a better competitiveness.
•	 Tests and product certifications: we offer test and certification services for 
analyses in the agri-food sector, the oenological sector, in particular, as well as in 
the industrial sector also identifying the presence of harmful or toxic substances 
through the Chemical Laboratory. We can evaluate and certify the reaction to fire 
and the energy classification of building, we can test and certify products including 
wood and other construction materials for EC marking and we can measure the 
presence of harmful or toxic substances in fabrics and leathers. 
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•	 High value added services: specifically in the field of Intellectual Property, the Patent 
Library Office offer high value added services for the protection and valorisation 
of Intellectual Property. The office offer priority searches on trademarks, patents 
and designs and communicate all information needed to understand and afford 
national and international application procedures. Beneficiaries can also receive 
technical assistance on the definition of claims as well as support and legal 
assistance for the developing of strategic and market solutions.
Some Tech Transfer Projects carried out by Treviso Tecnologia are the following:
TITOLO PROGRAMMA SITO  
INTERNET
RUOLO DATA  
CONCLUSIONE
EMUVE – 
Entrepreneur 
Multi-User Virtual 
Environment
Toi Leonardo da Vinci
(Programma LLL)
www.emuve.euit/
news.php Capofila 30/09/2012
IP for SMEs - 
L’integrazione 
transfrontaliera 
nella gestione della 
proprietà intellettuale  
(IP) come leva 
di competitività 
regionale
InterReg 4c ITALIA - 
SLOVENIA 2007 -2013 www.innoskills.net Capofila 31/4/2014
LEONARDO 
REBASING - 
Research-based 
Competence 
Brokering
Toi Leonardo da Vinci 
(Programma LLL)
www.leonardorebas-
ing.eu
Partner 
operativo -
TRANS2CARE - Rete 
Transnazionale 
per l’Innovazione 
ed il Trasferimento 
Tecnologico per il 
miglioramento della 
sanità
InterReg 4c ITALIA - 
SLOVENIA 2007-2013 www.trans2care.eu
Partner 
operativo 30/09/2014
IPR for SEE: 
intellectual Property 
Rights for SEE
Interreg
SEE www.iprforsee.eu
Partner 
operativo 31/12/2012
IP-SMEs - IP 
Awareness and 
Enforcement 
innovative services 
for Mediterranean 
SMEs
Interreg MED www.ip-smes.eu Partner operativo 31/05/2013
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TITOLO PROGRAMMA SITO  INTERNET RUOLO
DATA  
CONCLUSIONE
RFID from Farm to 
Fork (RFID-F2F) CIP www.rfid-f2f.eu
Partner 
operativo 31/08/2012
TEMP Textile 
Excellence in EU-MED 
Partners
FP7 Kcitis 
Commissione Europea
www.temp-eumed.
eu
Partner 
operativo 30/11/2012
Rapid open 
Innovation - speeding 
time to market (Rapid 
OI)
Cooperazione trans-
frontaliera Italia-
Austria
www.rapid-innova-
tion.net Capofila 28/02/2015
Sviluppo di un 
sistema di diagnosi 
dello stato per il 
riciclo attivo degli 
accumulatori del 
futuro
Cooperazione trans-
frontaliera Italia-
Austria
- Partner operativo 30/06/2014
PIACE - Piattaforma 
intelligente, 
integrata, adattiva di 
microcogenerazione 
ad elevata Efficienza 
per usi residenziali
Industria 2015 - Partner operativo
30/6/2013 
(proroga ?)
PROsumer.NET FP7 Cooperation prosumernet.eu Partner operativo 01/06/2013
R.I.ECO - Rete 
innovativa per la 
valutazione della 
ECOcompatibilità dei 
prodotti
POR Azione 1.1.1 - Capofila 04/10/2012
Reaorienting Patent 
Information Centres EPO - Capofila 01/11/2013
SILE Legge Regionale 9 -
Partner 
operativo 01/01/2012
FAST FORWARD 2009 Contributo Camerale di Treviso - Capofila -
FAST FORWARD 2010 Contributo Camerale di Treviso - Capofila -
Trasferimento 
tecnologico, 
innovazione delle 
filiere produttive 
e rapporti con il 
mondo della ricerca 
universitaria
Fondo di 
perequazione -
Partner 
operativo 31/03/2011
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3 ROLES IN TRANS2CARE
3.1 What offer to T2C
The role of Treviso Tecnologia within the Trans2care project is put our services at disposal to all Partners and share our knowledge on innovation and technology 
transfer. We would like to act as facilitator for the creation of a network that includes 
several actors like Universities, big industries, research centres, hospitals, tech transfer 
offices, public institutions, SMEs, laboratories and the market. Treviso Tecnologia, as 
Project Partner of Trans2care, intend to transfer its approach to innovation methods 
to the Partners and to the Project, that include the consideration of the importance 
of technology transfer activities, with the aim of promote cooperation with external 
partners, expedite mobility of researcher and foster the exchange of knowledge and 
expertise among Partners.
4 CONCLUSION
Through Trans2Care project, we intend to contribute with our expertise to reach the common Project goal, that is to establish interesting collaborations and connect 
the Project Partners in order to eventually improve their expertise and to promote 
exchange of ideas and technology transfer activities. 
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Early diagnosis of contrast media-
induced nephropathy in intensive care 
 Matjaž Klemenc, Polona Likar
PP6-General Hospital of Nova Gorica  
Abstract — At the Research Department in hospital of Nova Gorica we are faced 
with new cathlab practice and problems connected with it. Together with other 
project partners we intend to investigate contrast media induced nephropathy 
by measuring the release of NGAL, which is considered to be a good biomarker 
for detecting reduced kidney function. Our first priority is extensive study of 
NGAL and develop special detecting lab-on-a chip that should be small and 
simple to use at every day hospital practice. Our second priority is to develop 
new and intensify pre-existing collaborations and exchange of knowledge 
between project partners.
Index Terms — Catlab practice, biomarker, Neutrophil gelatinease-associated 
lipocalin (NGAL)
————————————————————
1 GENERAL hOSPITAL OF NOVA GORICA
General Hospital of Nova Gorica is the youngest general hospital in Slovenia, from the health care program is the medium size Slovenian hospital, which is 
characterized by rapid growth and large dynamic processes. From an entrepreneurial 
point of view, the hospital is a large company and one of the largest companies in 
Primorska region.
The hospital was founded in 1956. At the beginning it was located in old adapted 
buildings and had four main departments: internal medicine, surgery, paediatrics 
and gynaecology. In the year of 1965 the state began to build new hospital which 
was finished in 1985. The new 536-bed hospital has a surgery, internal medicine, 
gynaecology, paediatrics, ophthalmology, ENT, orthopaedic departments. It has a 750 
employee, from which 82 specialists, 4 with PhD and 2 with BSc.
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2 RESEARCh DEPARTMENT
The research department in Hospital Nova Gorica is located at the unit of intensive care and cardiology. The rapid medical technology development requires constant 
education and follow new developments. At our research department doctors and 
researchers are working together to investigate appearing medical questions and 
seeking for new knowledge and better solutions. 
2.1 Research Areas 
The intensive care unit and cardiology were engaged in various research fields, such as (i) arterial hypertension, (ii) autonomic nervous system activity, (iii) baroreflex 
sensitivity, (iv) diastolic dysfunction of the left ventricle, (v) and vascular elasticity (vi). 
The ICU and cardiology department has already established a strong collaboration with 
University of Nova Gorica and Physiology and Pathology Department at University of 
Trieste through various studies exploring human nervous system [1-6]. We are also 
connected with researchers of Faculty of Computing and Informatics Institute (FRI) at 
University of Ljubljana .The result of this collaboration is special device and software 
for analysis of changes in velocity of blood in the arteries, which are now used in the 
study of elastic arteries in hypertensive patients [7-15]. Furthermore, The ICU and 
cardiology department has also established collaboration with Texas Heart Institute. 
As mentioned above, establishing collaborations with different institutions to reach 
constant flow of knowledge and technology transfer has always been our priority. We 
intend to continue with building a network of our collaborations through Trans2care 
project.
2.2 Activities in Trans2care project
Catheterization laboratory practice and contrast mediaLately medical contrast technology continues to evolve dramatically. As scanning 
technology advances so does the requirements for contrast media. At the hospitals 
we are faced with fast development of various types of contrast media with different 
enhancement effect and also wide range of side effects. The most common types of 
contrast medium for enhancing x-ray based imaging methods are iodine and barium. 
Various sorts of iodinated contrast media exist, with variations occurring between the 
osmolality, viscosity, absolute iodine content and concentration of iodine in different 
media [16]. However, recent surveys are shown that High Concentration Contrast 
Media (HCCM) allows a greater maximum enhancement in a shorter period of time 
using the same volume of contrast medium [16]. While modern contrast media are 
generally safe to use [17] medical conditions can be caused by the administration 
of various contrast media.  At the research department at Hospital of Nova Gorica 
we are focused on risk of contrast-medium induced nephropathy (CIN) in high risk 
patients, especially in patients with reduced kidney function. To diagnose the kidney 
failure the technology for diagnosis is required. For this reason we are interested in 
biomarkers for detecting early stages of CIN and supporting technology that should 
be small, simple, fast and with large data capacity.
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2.3 NGAL as biomarker
The recent studies show that Neutrophil gelatinase-associated lipocalin or NGAL (also known as lipocalin 2, oncogene protein24p33 or uterocalin) is appropriate 
biomarker for acute kidney injury [19]. This is small, robust protein that belongs 
to the lipocalin family of the proteins. It is expressed by neutrophils and various 
epithelia, including the renal proximal tubules. Because of its small molecular size 
and resistance to degardation it is readily excreted and detected in the urine. While 
the functions of NGAL are not fully understood, it appears to be upregulated in cells 
under stress. However, NGAL levels rise significantly in both urine and blood as a 
response to kidney injury what makes it a useful marker of such injury [18]. The NGAL 
is mostly quantified by researchbased ELISA assays, which are impractical in the 
clinical setting. The development of small lab-on-a chip for simple and quick clinical 
measurement of plasma and urine NGAL would make it easier. It would also enable 
clinical investigators to assess the potential of this molecule as a diagnostic marker 
or a marker for response to use of contrast media. 
3 hOSPITAL OF NOVA GORICA IN TRANS2CARE
Through Trans2care project we intend to study contrast induced release of NGAL. We will continue the collaboration with University of Nova Gorica to study the 
chemistry of NGAL and possibly develop specific lab-on-a-chip. We also see the 
possible connection with University in Trieste, where they can help us with specific 
studies of NGAL for instance reproducing in it vitro on endothelial cells, test NGAL 
on kidney cells (cytotoxicity assays). On the other hand we can offer other project 
partners data and knowledge of cardiovascular technology.
4 CONCLUSION
Through the initiated Trans2Care project we intend to contribute through the activities and studies aimed to a deeper understanding of NGAL function and 
developing detection technologies. That will help us at diagnostic of reduced kidney 
function and also at studies of contrast-media induced release of NGAL. On this way 
we can compare the safety of different types of contrast media. Our other goal is to 
connect with the research institutes, universities within the project partners to build 
the network of knowledge, innovation and technology transfer.
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Molecular diagnostics 
with electrochemical biosensors 
and arrays
Morena Silvestrini, Ligia M. Moretto, Paolo Ugo
PP7-University of Ca’ Foscari of Venice
Abstract — Biosensors are self-contained analytical devices in which a 
bioreceptor is integrated with a transducer. The interaction between the 
bioreceptor and a target analyte generates a signal suitable for analytical 
purposes. In electrochemical biosensors, a change in the redox state of the 
biorecognition/analyte system generates a change in an electrochemical 
quantity which can be monitored by electroanalytical techniques. 
Electrochemical sensors can be miniaturized using ultramicroelectrodes and 
nanoelectrodes and their arrays as transducers. These devices are characterized 
by high specificity and sensitivity and improved detection limits. Biosensors can 
be used by non-specialist operators at the point of care. For the above reasons, 
within the frame of the Trans2care project, the Laboratory of Electrochemical 
Sensors of the University Ca’ Foscari of Venice will collaborate with the project 
partners to develop electrochemical sensors suitable for specific clinical needs.
Index Terms — electrochemistry, biosensors, affinity, proteins, analysis, 
electrodes, array.
———————————————————
1 INTRODUCTION
Biosensors are analytical devices in which a molecular recognition layer is integrated with a transducer. The immediate environment of the bioreceptor can change as 
a consequence of the interaction with the target analyte so generating a measurable 
signal. With a biosensor it is possible to measure the target molecule directly, without 
using any additional reagent. 
In electrochemical biosensors a change in the redox state of the biorecognition layer 
produces a change in an electrochemical quantity (a Faradaic current or an electrical 
potential) which can be monitored by electroanalyticall techniques [1]. In this 
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research the focus will be on amperometric and voltammetric methods of detection. 
Interestingly, electrochemical systems can be miniaturized from the millimeter down 
to the sub-micrometer scale; moreover, it is possible to use individual micrometer 
or nanometer sized working electrodes as well as arrays of them. In particular, the 
use of arrays of ultramicroelectrodes (UMAs) or nanoelectrodes (NEAs) allows one 
to overcome problems related to the requirement for high signal amplification and 
careful shielding from electrical noise. Signals given by UMA and NEAs are indeed 
the summation (weighed by diffusion effects) of the signals generated at each single 
micro(nano)electrode [2]. UMAs and NEAs are characterized by very high signal/
noise ratios, therefore they allow one to achieve very low detection limits, of the 
order of nanomolar concentrations or, as absolute quantity, few picomoles or even 
femtomoles. 
In typical schemes used in electrochemical biosensors, a biorecognition layer is 
directly immobilized on the electrode surface and the signal is produced by exchange 
of electrons between this layer and the underlying electrode. Analytes which can be 
detected includes small redox molecules such as enzymatic co-factors, vitamins, 
oligopetides, enzyme substrates, antigens and antibodies, aptamers, oligo- and 
polinucleotides. Note that in the case of miniaturized electrodes, such as in the case 
of nanoelectrodes, the amount of immobilized biomolecules can be very small with 
obvious advantages in the case of expensive or difficult to purify bioreceptors.
Depending on the nature of the biorecognition layer, electrochemical sensors can be 
classified into two categories: biocatalytic and bio-affinity sensors. 
In biocatalytic sensors, the biorecogniton layer is composed by an enzymatic layer, 
(typically an oxido-reductase or a dehydrogenase, immobilized on the electrode/
array) which exchanges electrons with the metal surface of the electrode via a 
suitable redox mediator (see Figure 1). 
Figure 1. Recognition and signal generation in electrochemical enzymatic biosensor.
In bioaffinity electrochemical biosensors, the recogniton layer is obtained by 
immobiliation of antigen or antibody molecules; typically, redox enzymes are used as 
labels. The functioning scheme of some typical electrochemical immunosensors are 
summarized in Figure 2.
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Figure 2: Schematic illustration of the two detection approaches used with electrochemical immunosen-
sors: (A) the target protein is immobilized on the electrode/array, then it binds a primary antibody and 
secondary antibody with the enzyme label (EL); a soluble mediator (Med) shuttle electrons from the 
electrode to EL. (B) A primary antibody, specific for the target protein, is immobilized in order to capture 
the target protein. The other components follow as in scheme A.
The blood glucose sensor is a biocatalytic sensor which represents the most 
successful commercial biosensor developed so far. It employs amperometric 
detection and exploits the specificity of the enzyme glucose oxidase and a ferrocene-
based redox mediator to produce a measurable current proportional to the blood 
glucose concentration. About 5-6 % of the population in western countries suffer 
from diabetes so that the glucose biosensor market growth is continuously growing.. 
According to a recent report [3], the global market for glucose biosensors and 
strips will reach 11.5 billion USD by 2012. It is obvious to expect that other kinds of 
biosensors will be developed to be ready for practical application in the near future. 
Note that biosensors can be used by non-specialist operators at the point of care and 
this allows for immediate action to be taken.
2 ACTIVITy AT ThE UNIVERSITy CA’ FOSCARI OF VENICE
2.1 The University Ca’ Foscari of Venice
Established on August 6th 1868 as a Royal Business College, the University Ca’ Foscari University of Venice actively participates in the city cultural life, organizing 
over 400 events every year, collaborating with other prestigious cultural institutions. 
The activity in Ca’ Foscari is summarized by the following data:
4 main scientific-cultural areas: Economics, Humanities, Languages, Sciences; 
15 First Cycle Degree Programmes; 
29 Second Cycle Degree Programmes; 
28 Specialist Master’s Programmes; 
1 Doctoral School, 16 Research Doctorate Programs; 
9 Summer and Autumn Schools; 
8 Departments, 6 Interdepartmental Schools; 
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1 Learning Centre Library,4 subject-related Libraries, 7 Departmental Libraries;
20,000 students, 4,000 new enrolments per year, 3,300 graduates per year 
1,700 professors, lecturers, native language teachers and administrative staff.
Scientific research is carried out through Departments, Interdepartmental Schools 
and Doctoral Schools, which often work together on inter-disciplinary projects.
Ca’ Foscari holds relationships with several associations and institutions through 
agreements for cooperation in the area of scientific information, teaching and 
research.
The University is a member of various research bodies including the Venice 
International University - VIU, Consorzio Venezia Ricerche and VEGA Science and 
Technology Park of Venice. 
2.2 The laboratory of electrochemical sensors 
In the last sixteen years the group of Electrochemical Sensors at the University Ca’ Foscari of Venice, Department of Molecular Sciences and Nanosystems, has 
developed original know-how in the field of the fabrication and analytical application 
of ensembles and arrays of nanoelectrodes, nanostrutured electroactive membranes 
and polymer-based electrodes [2]. 
Among the other fabrication methods, the preparation of arrays of nanoelectrodes 
by controlled deposition of metal nanoelements within the pores of ultrafiltration 
membranes used as template, is an attractive and increasingly used nanofabrication 
procedure. Electroless deposition of gold in polycarbonate templates for producing 
NEAs was introduced some years ago by Menon and Martin [4] and was refined 
more recently in our laboratory [5]. Thanks to their peculiar geometry, NEAs are 
characterized by improved signal/noise ratios and by detection limits 2-3 orders of 
magnitude lower than those achievable with regular electrodes.
Among the bioanalytical applications of NEAs and nanostructured membranes 
developed in Venice it is worth listing:
-an electrochemical biosensor for the detection of nitrate which employs nitrate 
reductase as the biorecognition element [6];
-the direct electroanalysis of the redox enzymes such as cytochrome c with NEAs and 
with polymer coated electrodes [7, 8];
-an electrochemical sensor for glucose analyses based on NEAs which employs 
glucose dehydrogenase and a special redox mediator (a nitrofluorenone), developed 
by coworkers at the University of Bordeaux 1, which is very efficient in catalyzing 
NADH oxidation [9];
-the development of NEA-based electrochemical immunosensors applied, in 
collaboration with ICGB-Trieste (prof. G. Stanta) for the detection both of general 
model protein such as the single chain fragment variable (ScFV) protein [10], and 
of clinically relevant proteins such as the HER2 receptor [11]. The HER2 receptor 
is an important target protein for the identification of cancer that can be treated 
successfully with Herceptin (Trastuzumab) by the so called personalized therapies.
In recent studies carried out in collaboration with AB-Analitica srl (Padua), with CIVEN 
(Coordinamento interuniversitario veneto per le nanotecnologie; Porto Marghera-
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Venezia) and with the Karlsrue Institute of Technology (group of Dr. Ljljiana Fruk), we 
developed a new procedure suitable for immobilizing oligonucleotides on NEAs aimed 
at using the biofuntionalized electrodes for the electrochemical detection of viruses. 
3 ACTIVITy WIThIN ThE TRANS2CARE PROjECT
The collaboration with other Trans2care partners will be finalized to the development both of biocatalytic and bioaffinty electrochemical biosensors, 
to detect suitable target analytes relevant for the partners involved in clinical and 
diagnostic practice.
IAs far as biocatalytic sensors are concerned, the development of an enzymatic 
electrochemical sensor for bilirubin analysis will be studied. Bilirubin is the breakdown 
product of the haem moiety of haemoglobin and other haemoproteins. Because 
of internal hydrogen bonding, bilirubin is water-insoluble and requires enzyme-
mediated glucuronidation in the liver for biliary excretion. In normal circumstances, 
plasma bilirubin is mostly unconjugated and is tightly bound to circulating albumin. 
In cases of inherited or acquired deficiencies of bilirubin storage or excretion, both 
conjugated and unconjugated bilirubin accumulate in the plasma [9].The biosensor 
to be developed will be based on bilirubin specific enzymes such as bilirubin oxidase 
or biliverdin reductase, focusing on the discrimination between conjugated and 
unconjugated bilirubin. This work will be developed mainly in collaboration with the 
leader partner. 
In the field of bioaffinty sensors, the focus will be on electrochemical immunosensors 
with capabilities to detect allergens, gluten and related antibodies, to be developed 
in collaboration with the leader partner and with project partner 2. The work can be 
potentially extended to the analysis of other proteins taken as biomarkers of different 
diseases, so involving also other project partners. 
4 CONCLUSION
The know-how in the field of analytical application of electrochemical nano-biosensors acquired by the group at the University Ca’ Foscari thanks to the 
present project can be extended and find practical application to the determination 
of clinically relevant molecules. Our participation in the Trans2Care project together 
with the other specialized partners, each bringing different know-how ranging from 
biochemistry to clinical practice, constitutes an important occasion and a challenge for 
new developments in the field of molecular diagnostics. Electrochemical biosensors 
can indeed be very helpful for obtaining quick and reliable analytical information 
thanks to their sensitivity, relative low cost, possibility of decentralized use and 
simple applicability. 
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Exploring the biological properties 
and therapeutic potential 
of antimicrobial peptides 
Francesca D’Este, Barbara Skerlavaj, Linda Tomasinsig, 
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Abstract — The researchers involved in the Trans2Care project at the Department 
of Medical and Biological Sciences of the University of Udine investigate the 
biological properties of the antimicrobial peptides (AMPs) of the immune system 
and their therapeutic potential for human and veterinary application. In addition 
to potent and broad-spectrum antimicrobial activities, some AMPs display 
anti-inflammatory and immunomodulatory effects and hold promise as novel 
antiinfective agents combining antibiotic and immunostimulating properties. 
A detailed knowledge of their physicochemical, biological and pharmacological 
properties and of their impact on clinical settings is an important prerequisite 
to this end. The Trans2Care project offers an invaluable opportunity to share 
knowledge, technical expertise and laboratory facilities to achieve a better 
understanding of the biological features and therapeutic potential of AMPs.
Index Terms — antimicrobial peptides, anti-infective drugs, antimicrobial 
activity, cytokine release, immunomodulatory activity
———————————————————
1 UNIVERSITy OF UDINE
The University of Udine is a public institution founded in 1978 as part of the reconstruction plan of Friuli after the earthquake in 1976. It is devoted to higher 
education, research and technology transfer. The University is organized into 10 
faculties and 14 research departments with approx. 16000 enrolled students (a. y. 
2009-2010). The University is actively involved in student and staff exchange projects 
with universities within EU and other non-EU countries and participates in many 
national and international research projects. 
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2 WORKING UNIT 
The Udine working unit includes researchers interested in the characterization and development of plant-based models of drug transport (Department of Agricultural 
and Environmental Sciences), and others involved in the study of antimicrobial 
peptides (AMPs) as templates for the development of novel anti-infective drugs 
(Department of Medical and Biological Sciences).
3  ACTIVITIES AND ROLES IN TRANS2CARE PROjECT 
3.1 Antimicrobial peptides (AMPs) 
AMPs are small, evolutionarily conserved protein components of the innate immune system involved in first-line host defence against infection [1,2]. In mammals, 
two distinct families of such peptides, the defensins [3] and the cathelicidins [4], have 
been detected on epithelial surfaces and in circulating phagocytes. These peptides 
are either constitutively expressed or readily inducible upon infection, inflammation 
or injury [5]. AMPs are quite diverse by length, sequence and secondary structure. 
Common features of these peptides are a small size (12-50 amino acid residues), a 
net positive charge and an amphipathic character [1]. These features enable AMPs 
to interact with negatively-charged microbial membranes and affect the membrane 
integrity, leading to microbial killing [1,5]. Besides exerting direct antimicrobial 
activities, several AMPs have shown the ability to interact with host cells and influence 
cellular processes relevant to inflammation and immunity such as chemotaxis and 
cytokine and chemokine release, and to promote angiogenesis and wound healing 
[2,5].
Fig. 1. Molecular diversity of mammalian AMPs.
3.2 AMPs as templates for the development of novel antiinfective drugs 
Various AMPs have received attention as candidates for the development of novel anti-infective drugs [2,6] to be used in human and veterinary medicine. They 
show several attractive properties in this regard, including i) a potent antimicrobial 
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activity against a wide range of Gram-negative and-positive bacteria and fungi, also 
including multi-drug resistant clinical isolates [6,7]; ii) in vitro antimicrobial efficacy 
in the submicromolar range [6]; iii) low propensity to select resistant mutants 
[5,6]; iv) ability to neutralize proinflammatory microbial components such as the 
lipopolysaccharide and lipotheicoic acid [6,8]; v) ability to modulate host cell functions 
[2,5,7]. Our increasing awareness of the multiple activities of AMPs has encouraged 
studies aimed to evaluate the impact of these molecules on pathophysiological 
processes taking place at specific clinical settings, to define their anti-infective role 
and achieve a safe clinical application.
3.3 Ongoing research activities 
The AMPs under study in our group are examined for i) antimicrobial activity against clinical isolates from epithelial infections; ii) immunomodulatory potential; iii) cell 
proliferation or cytotoxicity-inducing effects. 
i) We are currently investigating the activities of selected AMPs against clinical 
isolates of Candida albicans from human vaginal infections and opportunistic yeast 
pathogens from other sources. The antifungal activity is determined as the minimum 
inhibitory and the minimum fungicidal concentration (MIC and MFC), according to 
the CLSI guidelines. The efficacy of AMPs is also examined using medically relevant 
fungal biofilms, implicated in increased fungal pathogenesis and resistance to drugs 
[9], and adhesion to biotic and abiotic surfaces [10]. Yeast viability is assessed by 
optical density, enumeration of colony forming units (CFU) and XTT tetrazolium salt-
based assay. The effect of AMPs on yeast membrane integrity is quantified by flow 
cytometric and spectrofluorimetric analysis of the cellular uptake of the fluorescent 
dye propidium iodide (PI).
ii) The ability of AMPs to induce cytokine and chemokine gene expression in epithelial 
and macrophagic cells is assessed by qPCR and ELISA. 
iii) Cell proliferation is assayed by a tetrazolium salt-based colorimetric assay. The 
cell membrane integrity is assessed by measuring the cellular uptake of PI and the 
extracellular release of the cytoplasmic enzyme lactate dehydrogenase. Apoptotic 
effects are evaluated by flow cytometry using the annexin V/PI assay.
4 CONCLUSION
A detailed knowledge of their physicochemical, biological and pharmacological properties is a basic prerequisite for translating native peptide molecules into 
innovative products for prevention of infectious/inflammatory diseases. The 
Trans2Care project offers an opportunity to share knowledge, technical expertise 
and laboratory facilities, that can be invaluable to increase our understanding of the 
biological features and therapeutic potential of AMPs. Critically important in this 
regard is the collaboration with Trans2Care partners involved in clinical activities, to 
set up experimental models of infection and inflammation and evaluate the role and 
efficacy of AMPs in specific clinical settings. 
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Biochemical and immunochemical 
similarities among mammalian 
bilitranslocase and 
a plant flavonoid translocator
Enrico Braidot, Elisa Petrussa, Carlo Peresson, Sonia Patui, 
Alberto Bertolini, Angelo Vianello, Marco Zancani
PP8-University of Udine
Abstract — Flavonoids are a large class of plant secondary metabolites, 
belonging to polyphenol family, which possess pharmacological and nutritional 
properties. Their synthesis takes place only in plants, while mammals can 
acquire them only with diet. It has been demonstrated that flavonoid uptake 
occurs in rat also by the activity of bilitranslocase, a carrier that is involved 
in anion transport in liver cell, vascular endothelium and gastric mucosa. A 
sequence of bilitranslocase interacting with flavonoid moieties is already known 
and characterized. Antibody raised against such protein epitope were shown 
to exhibit cross-reactivity against plant membrane proteins in tissues involved 
in flavonoid transport and accumulation, such as teguments of carnation 
petals and skin of grape berries. Further immunolocalization studies allowed 
to demonstrate the presence of cross-reacting protein not only at the level of 
tegumental tissues, but also associated to sieve elements and seed teguments 
in grape berries. 
Index Terms — flavonoid accumulation, plant bilitranslocase homologue, protein 
biochemical and structural characterization, secondary metabolite transport. 
———————————————————
1 UNIVERSITy OF UDINE
It is a recent University at the heart of Europe. Established by popular demand, the University of Udine has its reference point at the center of a region that has 
historically been a meeting place and crossroad of different worlds and cultures.
Since its origin, the University is strongly committed to the education of students 
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ready and able to face the challenges of a world, characterized by a global economy, 
that increasingly requires skills to be used at international level.
The internationalization represents the fourth mission of the University of Udine, 
alongside teaching, research and technology transfer. It grew through the constant 
increase and improvement of working relationships and partnerships with 
universities of Europe and other international institutions. This led, in particular, to 
the creation and offering of several graduate courses with international recognition 
of the certificate, masters, doctoral schools and European internships, as well as 
great development opportunities within the international mobility of students and 
teachers.
According to these aims, besides the traditional activities of higher education and 
scientific research, the University of Udine combines intensive transfer of innovative 
technologies and knowledge by serving the society and the world production and 
economics.
2 RESEARCh DEPARTMENT (UNIT)
The research unit consists of teachers/researchers involved in educational and research activities in Plant Biology. The most relevant field concerns some 
biochemical and plant physiology subjects focused on cell transport, mitochondrial 
respiration also in relation to oxidative stress and PCD manifestation. Approaches 
imply both membrane fraction as well as plant cell culture, grape in particular. The 
main task of such researches points to the acquisition of information about some 
fundamental metabolic plant process, as well as their role during stress responses.
The second field concerns taxonomical studies on higher plants and geobotany, as 
well as algal biology and ecology, with the aim to study both species diffusion and 
their dynamics in natural and anthropic environments.
3 ACTIVITIES AND ROLES IN TRANS2CARE PROjECT 
Several components of the grape berry have a straight influence on wine quality. Among these, polyphenols and other secondary metabolites are the major 
compounds affecting taste and flavour. Polyphenols are currently under a lively 
attention by researchers, particularly flavonoids, because they are relevant to grape 
and wine quality as well as for their pharmacological properties protecting human 
tissues against activated oxygen species (AOS), thus reducing cardiovascular and 
cancer risk [1]. These compounds, particularly anthocyanins and proanthocyanidins, 
are synthesized through the biosynthetic pathway of flavonoids [2]. 
There are several experimental evidences about the existence of a mammalian protein, 
named bilitranslocase (BTL), capable of a secondary active transport. This carrier 
transports not only plasmatic catabolites, but also anthocyanins [3,4]. In a previous 
work [5], it was reported that antibodies raised against mammalian BTL epitopes do 
cross-react with proteins obtained from a microsomal fraction of carnation petals 
(Dianthus caryophyllus L.). Moreover, some kinetic studies showed remarkable 
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similarities between bilitranslocase-mediated transport activity in hepatocytes and 
gastric epithelial cells and the plant carrier, although the latter has shown a different 
pattern of affinity for the substrates tested. Preliminary data, obtained in previous 
studies [6,7], have shown that a cross-reaction also occurs between antibodies raised 
against mammalian BTL and the microsomal fraction from grape berries. By means 
of immunochemical techniques, the presence of a translocator in white and red grape 
thin sections has been demonstrated. Carrier localization together with its expression 
profile, in different developmental stages, have been evidenced in both skin and pulp 
tissues. Therefore, it is relevant to verify, in Vitis vinifera berries of red cultivars, if 
proteins similar to the mammalian BTL mediate the accumulation of polyphenols, 
especially anthocyanins and tannins, and which effect on transport activity could be 
exerted by some environmental factors such as water deprivation.
4 CONCLUSIONS
In this framework the purposes of the project could be widespread in several topics. First, the study of the phylogenetic links between mammalian bilitranslocase and 
similar plant proteins.
Second the transport mechanisms regarding secondary metabolites, such as 
flavonoid and chlorophyll degradation products (biline-like compounds) would be 
characterized. Third, investigation on metabolic and environmental factors able to 
increase flavonoid production in plant cell cultures, would be also necessary. 
Fourth, research on plants, as a model living organisms, will represent an advantageous 
alternative to animal use, ethically acceptable in biological studies.
To obtain these goals, it is essential to establish a wide network among different 
partners able to share their specific skills and knowledge, in agreement with the main 
task of Trans2Care project.
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Early diagnosis of coeliac disease
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Abstract — At the Immunopathology Laboratory at the IRCCS Burlo Garofolo 
Hospital the research activity is based on autoimmune diseases, above all 
on celiac disease in order to diagnose it in an early stage. For this reason, we 
are collecting many serum samples and intestinal biopsies to analyse them 
with molecular (phage-display) and immunofluorescent (double staining and 
activated beads) assays. Within the Trans2Care project we intend to apply 
these methods in several areas related to the problems explored by the Project 
partners with the aim of promote collaboration, mobility of researchers and 
exchange of knowledge between partners. 
Index Terms — autoimmune diseases, immunofluorescent assays, intestinal 
biopsies, phage-display analysis, serum samples
———————————————————
1 ThE IRCCS BURLO GAROFOLO
The Burlo Garofolo Hospital was established on November 18th 1856, when the Spedale Infantile was instituted in order to grant free medical care to poor 
children. On 1968 the Institute was designated by the Ministry of Health as IRCCS. 
The Institute has promoted and implemented an innovative health culture, based on 
innovative policies aimed at reduction of hospital stay and humanization of medical 
care. The Hospital is the unique health care Institute for Mother and Child Health 
within the area the sourrounding region. The IRCCS Burlo Garofolo ensures clinical 
excellence in medical and surgical paediatric subspecialties, reproductive medicine 
and perinatology. The Institute offers graduate and post graduate courses and PhD 
programs. The Institute is a World Heath Organisation (WHO) Collaborating Centre 
for Maternal and Child Health. Fundamental, clinical, epidemiological and health 
services research are organised along 6 main subjects: Maternal and foetal medicine; 
neonatology; chronic diseases, including cancer, with onset in paediatric age; 
paediatric surgical and rehabilitation sciences; epidemiology prevention and quality 
of care; neuroscience in developmental age. 
Passamonti S. (Editor)
The Partners and the Objectives of Trans2Care, an Italy-Slovenia
cross-border network of science and healthcare institutions
pp. 87-90 / ISBN 978-88-8303-512-8 Transregional Network for Innovation and Technology 
Transfer to Improve Health Care
88
2 IMMUNOPAThOLOGy LABORATORy
The Immunopathology Laboratory has one professor and one assistant professor in clinical pediatrics, four PhD researchers. We use and develop 
immunohistochemical and molecular techniques to study autoimmune diseases to 
understand its inflammatory cascades. Furthermore, we apply at the patient’s bed 
side our assays to simplify the diagnosis of these pathologies. The research work 
is financed through national research programme schemes (NHS programme 2009: 
”Dilatative cardiomyopathy and gluten dependent autoimmunity”; Italian Ministry of 
University 2009: Anty-idiotypic network to anti-transglutaminase antibodies in the 
pathogenesis of celiac disease; XVII Executive programme of scientific and technology 
co-operation between Hungary and Italy 2010: LS17 Intestinal gluten-dependent 
immune response in the early stages of celiac disease) and from 2010 we are partners 
in an international strategic project Trans2Care.
2.1 Research Activities
Our interests are based on autoimmune disorders [1-3]. We organised a serum and tissue bio-bank from patients suffering from organ specific autoimmune 
disorders (e.g. type 1 diabetes, thyroiditis, celiac disease, rheumatoid arthritis) or from 
other inflammatory diseases (e.g. Crhon disease, eosinophyl-gastritis, ulcerative 
colitis) with a large samples stored at -80 C° (10000 serum samples and 1500 
intestinal biopsies). 
Our main goal is to study celiac disease (CD) [4-8], an autoimmune-mediated 
enteropathy characterised by gluten-triggered small bowel mucosal lesions in 
genetically susceptible individuals carrying the CD-related human leukocyte 
antigen (HLA) DQ2 or DQ8 haplotypes. The current diagnostic criteria for CD require 
intestinal mucosal villous atrophy and the presence of serum antitransglutaminase 
(anti-TG2) antibodies [9-13], even if many patients suffer from gluten-dependent 
gastrointestinal symptoms before the onset of villous atrophy and of anti-TG2 
antibodies in serum. Anti-TG2 antibodies are synthesised by specific B lymphocytes 
in the small bowel mucosa and they are deposited in the morphologically normal 
small intestinal mucosa before they can be detected in the circulation. Starting from 
these evidences, we try to identify these antibodies working on intestinal specimens. 
Creating phage-antibody libraries against TG2, we observed that celiac-specific 
anti-TG2 antibodies are primarily comprised of the IGHV5-51 gene from the VH5 
antibody variable gene family, indicating a possible preferential usage of this gene in 
the gluten-dependent autoimmune response to TG2. Indeed, using phage-antibody 
libraries against TG2, we demonstrated that a large proportion of HLA DQ2- or DQ8-
positive relatives of CD patients produce anti-TG2 antibodies in the intestine as a 
response to gluten, even in the presence of normal intestinal morphology and when 
no anti-TG2 antibodies can ever be found in the serum [14].
We are also able to investigate IgA anti-TG2 in frozen biopsies by using two other 
assays easier and faster than phage assay: the double immunofluorescence staining 
(Fig.1) and the IgA anti-TG2 antibodies quantification through TG2 activated beads 
and flow cytometric analysis. 
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Fig.1. Criosections from a celiac intestinal biopsy: (A) green signal for IgA, (B) red signal for TG2, (C) yellow 
signal for IgA deposits co-localised with TG2.
3 ROLES IN TRANS2CARE
3.1  What offer to T2C
We have focused our research project in the diagnosis of celiac disease in an early stage using immunofluorescent assays and phage-display analysis. We provide 
our knowledge to T2C partners, in order to facilitate the exchange of expertise and to 
study tissue biopsies may also be different from intestinal ones. 
As described in the paragraph above, we have an elevated number of biological 
samples (sera and intestinal specimens) suitable for exploration of large data sets. 
4 CONCLUSION
Through Trans2Care project, we intend to contribute with our expertise in order to reach the common goal, that is to establish collaborations and connect the project 
partners to eventually improve their expertise and to promote exchange of ideas and 
technology transfer. 
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Novel immuno– and 
stem cell–based therapies
Sendi Montanič, Uroš Rajčevič and Vladka Čurin Šerbec
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Abstract — The main areas of the research at the Blood Transfusion Center of 
Slovenia are cell therapies, stem cells and new diagnostic reagents, based on 
monoclonal antibodies (mAbs). Our laboratories are equipped for cell-culture 
work (certified GLP; GMP in reconstruction), molecular biology, immunological 
techniques and biochemistry. In the course of our research we conducted 
studies and applied projects (the last mainly industrial) beside production of 
reagents, with common topic - the antibodies. They were prepared and used 
to optimise and validate ELISA tests for quality control assessment of the 
end-product (polyclonal antibodies, in production of drugs), to study protein 
structure, for immunodiagnostics and as potential immunotherapeutics. Among 
different mAbs, which we produced in the last decade, a panel of mAbs against 
prion protein (PrP) and mAbs against bilitranslocase (prepared in collaboration 
with the University of Trieste) will be studied with different project partners in 
the scope of Trans2Care. We are fully dedicated to translate the results of the 
basic research onto applied, possibly clinical level and to contribute to improved 
healthcare in a sense of advanced modes of immunotherapeutics development 
and cell based therapies.
Index Terms — human prion protein, prion, bilitranslocase, monoclonal 
antibodies, immunodiagnostics, immunotherapy, stem cells, cell therapy 
———————————————————
1 INTRODUCTION
Blood Transfusion Centre of Slovenia (BTCS) is a national blood bank, responsible for the supply of safe blood and blood components in our country. Beside that, 
we are providing diagnostic and therapeutic services and blood-derived drugs to our 
hospitals. We are a strong partner of the University of Ljubljana, giving lectures and 
providing experimental work to students of graduate studies at Faculty of Medicine, 
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Faculty of Pharmacy, Faculty of Chemistry and Chemical Technology and Faculty 
of Health Sciences. We are also involved in postgraduate programs of Biomedicine 
and Biotechnology at the University of Ljubljana. The same personnel is engaged in 
research and development at BTCS, being members of three research groups: Tissue 
Typing Center, Transfusion Medicine and Biomedicine. As of 2004 BTCS has an ISO 
9001 standard and is a WHO Collaborating Center and an EFI (European Federation of 
Immunogenetics) member. 
2 RESEARCh AT ThE BTCS
Research activities at the BTCS started as early as 1953, when the institution was registered for the research and development in medical biotechnology and 
medical sciences. In the course of next four decades, activities in this field intensified, 
especially in the research. During last 15 years the three forementioned research 
groups, conducted 33 national research projects, 3 national programmes, 6 industrial 
projects and 6 international projects, financed by Slovene Research Agency, by 
Ministry for Higher Education, Science and Technology, by industrial partners as 
well as the European Comission. 18 young researchers/PhD students were trained 
at the BTCS in the scope of these projects, covering medicine, life sciences and 
biotechnology. Our development is closely related to our routine operations and 
services (blood collection and processing, blood grouping, cell therapeutical services) 
and assures constant education and follow-up in transfusion medicine. The main 
areas of our research are cell therapies, stem cells and new diagnostic reagents, based 
on monoclonal antibodies (mAbs). Our laboratories are equipped for cell-culture work 
(certified GLP; GMP in reconstruction), molecular biology, immunological techniques 
and biochemistry. On the basis of our research, we were invited to take part of the 
educational programmes at the University of Ljubljana (see introduction). 
2.1 Biomedicine research group 
Our research group evolved from the department for the producion of diagnostic reagents, in charge of production of diagnostic reagents for blood grouping under 
GMP (Good Manufacturing Practice) conditions. Our first research project included 
the production of potent mouse IgM monoclonal antibodies (mAbs) against AB0 blood 
group system in early ninetees of the last century, which were introduced into routine 
work in the form of diagnostic reagents, registered in 1998. In consequent years, we 
conducted research and applied projects (the last mainly for the industry) beside 
production of reagents, with common topic - the antibodies. They were prepared and 
used to optimise and validate ELISA tests for quality control assessment of the end-
product (polyclonal antibodies, in production of drugs), to study protein structure, for 
diagnostics and as potential therapeutics (mAbs). Among different mAbs, which we 
produced in the last decade, a panel of mAbs against prion protein (PrP) [1, 2, 4, 6, 9, 
10] and mAbs against bilitranslocase (prepared in collaboration with the University 
of Trieste, started in 2006) [11] will be studied with different project partners in the 
scope of Trans2Care. 
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3 CONTRIBUTION TO TRANS2CARE
3.1 Bilitranslocase 
Our current, ongoing collaboration with the T2C partners includes the research of mAbs against bilitranslocase in collaboration with University of Trieste (prof. S. 
Passamonti). This collaboration will further develop as we anticipate our first joint 
publications [11] .
Figure 1: ICC staining of HepG2 cells with anti-bilitranslocase mAb 6E4/1F2 (40x, 2.4s).
3.2 Prion diseases
In our research on prion diseases we constructed and tested a panel of mAbs against prion protein (PrP) enabling us to distinguish and differentiate between the wild type 
PrPc and its pathogenic form PrPSc, which is of a great diagnostic value in Creutzfeld 
Jacob’s disease (CJD). This research yielded EU and US patents for these antibodies 
as well as our common publications with T2C partners SISSA – prof. G. Legname and 
University of Trieste - prof. R. Gennaro [1, 6]. In the frame of T2C we are aiming at 
upgrading this collaboration in two possible directions: the use of proteomics for the 
identification of novel biomarkers of prion diseases using animal models of CJD as 
well as clinical samples of CJD. These biomarkers could help us elicit the molecular 
background of prion diseases as well as serve as potential diagnostic or therapeutic 
tools. 
Alternatively we aim at using the expertise and specialized infrastructure (GMP 
laboratory standards) of the BTCS in the field of cell based therapeutics to reaserch a 
potential of neural stem cell based therapies for prion diseases using animal models 
of CJD. 
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Figure 2: Immunohistochemistry of mAb V5B2 binding to the pathogenic form of PrPSc in CJD brain section, 
compared to normal brain section. (a) Diffuse PrPSc plaque depositions are visible in a synaptic section of 
cerebellum (40x). (b) PrPSc – negative staining of normal brain hypocampus (20x).
4 CONCLUSIONS
In the frame of T2C, we offer our above mentioned expertise to project partners, within the fields of development of immunotherapeutics, immunodiagnostics, cell based 
therapies and proteomics as well as whereever sinergies are anticipated. Thus far, we 
have proven our capacity of inter-regional collaborations and we are looking forward to 
expanding the ongoing and new collaborations with Slovene and Italian partners. We 
are fully dedicated to translate the results of the basic research onto applied, possibly 
clinical level and to contribute to improved healthcare in a sense of advanced modes of 
immunotherapeutics development and cell based therapies.
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Pathophysiological mechanisms 
of joint implant loosening
Andrej Cör, Julija Hmeljak, Mitja Rak, Maja Čemažar, Ingrid Milošev
PP11-Valdoltra Orthopaedic Hospital, Ankaran
Abstract—Overthe past half-century, there have been many advances in the 
design, construction, and implantation of joint prostheses, resulting in a high 
percentage of successful long-term outcomes. One of the most common 
concerns of both patients and physicians is the problem of joint replacements 
becoming loose over time. Causes of failure include infections, aseptic 
loosening, dislocations, and fracture of the prosthesis or bone. Multidisciplinary 
research team studies are needed for an improvement in understanding in 
pathophysiological mechanisms of joint implant loosening and failure, which is 
the key point to improve implant survival and to minimize revisions.
Index Terms — diagnosis, infection, loosening, prosthetic joints 
———————————————————
1 INTRODUCTION
As the average age of human population increases, the number of total joint arthroplasties performed is increasing dramatically. Nearly 4.500 such procedures 
are performed in Slovenia each year. Prosthetic joints improve the quality of life for 
many patients; however they may fail, necessitating a revision arthroplasty. It is 
believed that joint prostheses can reliably relieve pain and improve function in the 
majority of patients, with benefits lasting for a period of 15 to 20 years. However, 
approximately 14-28 % of prostheses need to be revised even before decade of 
service[1]. Causes of failure include infections, aseptic loosening, dislocations, and 
fracture of the prosthesis or bone. The incidence of revision surgeries almost doubled 
in the last 15 years and the revision frequency projections by 2030 are even more 
impressive [2].
Prosthetic joint infection (PJI), although uncommon, is the most serious complication, 
occurring in 0.8 to 1.9 % of knee arthroplasites and 0.3 to 1.7 % of hip arthroplasites 
[3]. Staphylococci account for more than half of all PJI cases. Since surgical treatment 
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of joint prosthesis loosening (septic or aseptic) is different, it is very important to 
establish the correct diagnosis of PJI, which is still a challenge in clinical practice. A 
misdiagnosed PJI has crucial consequences for the patients. Unfortunately, to date, 
there is no reliable preoperative or intraoperative test that is 100 % sensitive and 
specific for PJI diagnosis.
2 ACTIVITIES AND POSSIBLE ROLE IN TRANS2CARE PROjECT
The aim of our recent research project is to evaluate different intraoperative diagnostic tests, such as microbiological culturing, pathohistological analysis 
and molecular methods for PJI diagnosis.Ultrasonication of prostheses, followed by 
analysis of the dislodged material (sonicate) was suggested to improve the detection 
of prosthetic hip infections [4]. We therefore raised a question: how many cases 
diagnosed as aseptic failure are actually PJI?
Early diagnosis of PJI and a better understanding of biofilm production should lead to 
novel, effective treatment strategies and improved care and rehabilitation of patients 
with joint prostheses.
Currently, the most common cause of clinical failure of joint prostheses is aseptic 
loosening of the implant components [5]. Aseptic loosening of a joint prosthesis is 
hypothesised to be the result of a harmful combination of mechanical and biological 
events, which cause the destruction of the bond between implant and bone bed. In 
the long term,aseptic loosening is a significant clinical, as well as economic problem. 
The pathogenesis of prosthetic joint loosening continues to be a major focus of 
research in orthopaedics. The fibrous membrane that forms around the joint 
prosthesisis composed mostly from granulomatous tissue, namely macrophages, 
giant cells and also of immune cells (Figure 1). Although numerous descriptions of 
histological features of the fibrous membrane have been published [6, 7], the origin of 
this membrane and its role in progressive bone resorption, which is associated with 
prosthesis loosening, are still poorly understood. The gliding surfaces (counterfaces) 
of joint implants produce wear debris which stimulate macrophage activation[8]. 
Macrophages are generally recognized for their ability to phagocytise even 
immunologically non-opsonized wear particles and produce cytokines that stimulate 
osteoclast bone resorption. Our group has extensive expertise in pathohistological 
analyses of periprosthetic tissue obtained at revision surgery allowing as to be 
included in several national, as well as international multidisciplinary teams, involved 
in investigation of pathophysiological mechanisms of aseptic loosening. 
Since wear debris produced in site of joint prosthesis and the resulting tissue reaction 
is the most important cause of prosthesis loosening, the idea of reducing wear debris 
is an important issue for improvement of long-term results of total joint replacement. 
It has in fact re-stimulated interest in evaluation of alternative bearing materials. 
We are currently participatingin different international projects, in which our in vitro 
studies investigate biocompatibilities and toxicities of different bearing alloys and 
surface layer improvements, as well as biological response of different cell lines to 
biomaterials. 
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Fig.1.Histological analysis of periprosthetic tissue. A: Metal particles (black) phagocytosed by macrophages; 
B: Imunohistochemically stained slide under polarisation microscope with CD68 positive macrophages and 
giant cells (brown) with birefingent polyethylene particles (white); C: Infiltration with polymoprphonuclear 
leucocytes and plasma cells in periprosthetic tissue is a diagnostic for infection; D: Immunohistochemical 
staining with CD15 with positive granulocytes (brown) in tissue around infected joint prosthesis.
3 CONCLUSION
Total joint arthroplasty is one of the most successful orthopaedic surgery procedures; however, a number of joint replacements ultimately fail due tocomponent 
loosening. Because of the increasing need to implant joint prostheses in younger and 
more active patients, studies of interdisciplinary research teams are necessary to 
improve our understanding of the pathophysiology of joint implant loosening.
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Mechanical, biological, material 
and clinical aspects of performance 
of joint prostheses
Ingrid Milošev, Vesna Levašič, Andrej Cör, Venčeslav Pišot
PP11-Valdoltra Orthopaedic Hospital, Ankaran
Abstract — At the Research department at the Valdoltra Orthopaedic Hospital 
the surgeons and researchers are joined in an interdisciplinary team which 
performs research work and activities directed to the understanding of 
prosthesis performance from several aspects including mechanical, biological, 
material and clinical aspects. Studies are largely based on the hospital’s 
Arthroplasty Register which represents a valuable source of information for 
data-based analysis of arthroplasty treatments. Our register is special in that 
it includes the implant retrieval program for explanted prosthetic components 
and periprosthetic tissue samples. Research is versatile and interdisciplinary, 
and is a challenge for young researchers searching for new knowledge and 
scientific results.
Index Terms — orthopaedic implants, survival, register, materials for biomedical 
applications, biological impact, statistics
———————————————————
 1 VALDOLTRA ORThOPAEDIC hOSPITAL
Valdoltra Orthopaedic Hospital has celebrated its 100th anniversary in 2009. Over the years the hospital has developed from a marine sanatorium for 
scrofulous diseases in ancient Austro-Hungarian monarchy to a modern orthopaedic 
institution today. Hospital is the oldest and largest specialized hospital in Slovenia, 
comprising more than 50% of Slovene orthopaedic activities with 2,600 surgeries, 
25,000 orthopaedic examinations and 5,500 patients in hospital care. The Hospital 
collaborates with domestic and foreign orthopaedic institutions aimed at developing 
new surgical and therapeutic methods. The Hospital is equipped with modern 
operating rooms, sophisticated IT and diagnostic equipment including MR and CT, 
endoscopic technology and highly qualified medical staff. The hospital has around 300 
employees, of whom more than 30 are MDs. 
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2 RESEARCh DEPARTMENT
Constant education and follow-up of the latest results of clinical studies has always been very important for everyday practice at the hospital. The Research department 
at the Valdoltra Orthopaedic hospital was formally founded in 2002. It is devoted to 
the research studies in orthopaedics, primarily to long-term performance of various 
prostheses. Our aim was to join the surgeons and researchers in an interdisciplinary 
team which would perform research work and activities directed to the understanding 
of prostheses performance from several aspects including mechanical, biological, 
material and, of course, clinical aspect. The research work proceeds through the projects 
within the hospital targeted to solve specific problems within the hospital practice, and 
through projects financed by the Slovenian Research Agency, i.e. basic and applied 
research projects, young researcher program and bilateral projects. The hospital is 
involved in two international strategic projects (e-health and Trans2Care). 
3 ACTIVITIES AND ROLES IN TRANS2CARE PROjECT
3.1 Arthroplasty Register
Research studies at the hospital are largely based on the hospital’s Arthroplasty Register which represents a valuable source of information for data-based analysis 
of arthroplasty treatments. Following the example of Scandinavian arthroplasty 
registries we have established the Arthroplasty Register of the Valdoltra Orthopaedic 
Hospital in 2002 in order to assure the results of arthroplasty treatment and long-term 
follow-up of clinical results. The Register comprises all primary and revision hip and 
knee operations. For that purpose, forms and date-base have been developed. Based 
on the analysis of the data given in the forms, annual reports are prepared. There 
are numerous advantages of Arthroplasty register, among them the most important 
are long-term follow-up of individual types of prostheses and the possibility of early 
recognition of possible deviations from the expected results and subsequent fast 
reaction, i.e. alarm.
3.2 Long-term survival of prostheses 
Our goal is to carefully follow the long-term survival results of the implanted hip and knee prostheses and relate them to other clinical scores or indicators. In the 
last decade we have published several papers reporting mid- and long-term results 
of various prostheses [1-5]. We were especially interested in the effect of type of the 
bearing on the long-term performance of hip prosthesis. There are namely several types 
of bearings, so called traditional metal-on-polyethyene and ceramic-on-polyethylene 
bearings, and alternative metal-on-metal and ceramic-on-ceramic bearings, aimed 
for younger, more active patients. Polyethylene has been used as a bearing material 
for more than fifty years. It represents a golden standard in orthopedics. However, 
wear of polyethylene and consequent formation of wear particles are the key factor 
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in the mechanism of aseptic loosening of total hip replacements. Pathophysiology 
of loosening is a complex process. Osteoclasts and their precursors have crucial role 
in bone resorption. The differentiation of these multinucleated cells and activation is 
regulated with RANK/RANKL/OPG regulatory axis. 
3.3 Retrieval studies
The specialty of our Register is that it includes the implant retrieval program for explanted prosthetic components and samples of periprosthetic tissue (Fig. 1). 
Collected samples are the basis for various research analyses aimed to reveal the 
changes at the surface of the component and in the periprosthetic tissue induced 
during in vivo functioning of the prosthesis [6-8]. Of special interest are mechanical, 
chemical and structural changes at the surface of retrieved metal and polyethylene 
components. For that purpose we use microscopic analysis of the surface by scanning 
electron microscopy combined with chemical analysis, computer coordinate machine 
for determination of wear, roughness measurements, and other analyses of interest. 
Histological analysis of periprosthetic tissue samples is performed in order to determine 
the biological impact of wear debris products. Wear debris particles are isolated from 
tissue samples in order to study their morphology and size distribution. Of special 
interest are also studies aimed to investigate incidence of infection of joint prosthesis 
and its mechanism.
Fig. 1. Block-diagram of the Arthroplasty Register at the Valdoltra Orthoapedic Hospital.
4 CONCLUSION
Through the initiated Trans2Care project we intend at our hospital to contribute through the activities and studies aimed to a deeper understanding of prosthesis-
biological environment interactions and, consequently, contribute to the improvement 
of approaches, materials, design and treatment selection, and eventually promote 
the prolongation of the life-time of prostheses in general.
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Nanocoatings for preventing 
orthopaedic implant–associated 
bacterial infections  
Franja Šulek, Ingrid Milošev
PP11-Valdoltra Orthopaedic Hospital, Ankaran
Abstract — The Research department of the Valdoltra Orthopaedic Hospital 
is determined to conduct more extensive research studies on modification of 
materials for orthopaedic implants. The starting research in the newly founded 
Research laboratory shall include basic and applied studies which results shall 
be potentially considered and eventually implemented in daily clinical practice 
of Valdoltra Orthopaedic Hospital. With an accurate inspection of the emerging 
medical needs in the field of orthopaedics we envisaged the urgent need to 
provide a long-term protection for orthopaedic prostheses. By means of using 
nano-engineering approaches for the functionalization of orthopaedic implant 
surfaces with suitable antimicrobial agents, it is possible to protect orthopaedic 
implants against harmful bacteria, which trigger the initiation of implant-
associated bacterial infection. As the implant-associated bacterial infection can 
affect the longevity of the prosthesis, thus, the scientific and financial efforts, 
with the help of the project Trans2care, will be focused substantially on the 
design and fabrication of protective antibacterial coatings for orthopaedic 
implants.  
Index Terms — research activity, bacterial infections, prevention, orthopaedic 
implant surface
———————————————————
1 RESEARCh LABORATORy
The Research Department takes an important role in the scientific activities of Valdoltra Orthopaedic hospital. The build-up of the new Research laboratory will 
be financially covered in great part by the hospital itself, whilst, the basic equipment 
and some necessary apparatus for research activities will be co-financed by the 
cross-border project Trans2care. Additionally, the laboratory will be equipped in a 
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modern fashion to provide all the comforts and ideal working environment to perform 
scientific research in the field of new biocompatible materials for orthopaedics. The 
financial plan shall include the acquisition of the following laboratory equipment and 
some apparatus, divided into two segments. Within the preparatory activities we will 
provide:
•	 Basic laboratory furniture, as benches and stools;
•	 Fume cupboard with safety storage cabinets for liquids and other reagents;
•	 Precision and Laboratory weights;
•	 Laboratory fridge and waste containers;
•	 General labware and consumables; 
•	 Complete system for vacuum filtration;
•	 Magnetic stirrer with digital hotplate and vortex mixer;
•	 Shakers and ultra-sound bath;
•	 Centrifuges.
Within the analytical activities we plan to purchase:
•	 Laboratory microscope and
•	 Spectrophotometer with integrated measurement modes for absorbance, 
fluorescence and luminescence.
Till now, the majority of the research work at the Research department has been 
dedicated to the measurement and analysis of wear of implants surface and wear 
particles, histological analysis, as well as the analysis of periprosthetic tissue [1]. 
The wear of orthopaedic implants leads to loosening of the prosthesis, classified as 
»aseptic« and »septic« loosening. The septic loosening is always combined with the 
contamination of implant surface with bacteria (Figure 1).
2 ACTIVITIES AND ROLES IN TRANS2CARE PROjECT
2.1 Infections associated with orthopaedic implants
Implant-associated infections are the result of bacteria attachment to an implant surface and subsequent biofilm formation at the implantation site. Biofilm 
formation usually takes place in several phases, starting with rapid bacteria surface 
adherence, followed by multilayered cellular growth and intercellular adhesion in an 
extracellular polysaccharide matrix [2,3]. If bacteria adhesion occurs before tissue 
regeneration takes place, host defenses often cannot prevent surface colonization 
for certain bacterial species that are capable of forming a protective biofilm layer. 
Therefore, inhibiting bacterial adhesion is necessary to prevent implant-associated 
infection, because biofilm are extremely resistant to both the immune system 
and antibiotics [3]. The ability of the biofilm of detaching some individual bacteria 
into surrounding tissues and the circulatory system, it might lead to unavoidable 
spread of the inflammation thorough the body of the host [4]. Pathogenic bacteria, 
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particularly gram(+) S. aureus and S. epidermidis, are found at the implantation site 
of approximately 90% of all implants [5]. Gram(-) bacteria, as E. coli and P. aeruginosa, 
have also been diagnosed in implant-associated infections [6]. The average infection 
rate has been reported to range between 0,5% and 3% for total hip replacement 
arthroplasties and the rate of reinfection after revision of infected hip prostheses 
is stated to be up even to 14% [7,8]. On the basis of these data, it is evident, that 
orthopaedic implants require better protection to avoid or at least diminish the 
incidence of prosthetic joint-associated bacterial infections, and consequently, the 
loosening of the implant with time might be prevented as well. All of these contribute 
to the extension of the longevity of an orthopedic implant. 
2.2 Antimicrobial agents used in coating techniques
New strategies for the design of safer orthopaedic devices have been proposed to control and prevent bacterial contamination of implants. One of the promising 
approaches is to adjust, at the nano-meter scale, the antimicrobial capabilities of 
the implant surface [9]. This might be achieved by the utilization of different surface 
functionalization strategies in use, as the direct impregnation of implant surface with 
antibiotics or any other antimicrobial agent, as well as the coating technique with 
antimicrobial metals such as copper and silver. Titanium-oxide coatings deposited on 
a) b)
Fig.1. Components of a joint hip replacement: acetabular shell and liner, femoral head and femoral hip stem 
(a); surface of joint hip replacement infected by bacteria (b). 
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the implant surface have been also successfully examined [10]. However, the usage 
of certain coatings is still partially restricted to implants, thus, new coatings need to 
be developed to gain better protection against post-operative infection and provide a 
barrier to minimize metal ion release into the body. 
2.3 Nanostructured coatings for better protection of orthopaedic implants  
In comparison to conventional coatings, the advantages of using nanostructured coatings for orthopaedic implants are multiple. In addition to adding antibacterial 
properties to implants, it is possible, by the nanoengineering approaches, to attain 
other functionalities such as higher biocompatibility and mechanical stability as 
well as the ability of the implant to stimulate the process of new bone formation 
[11,12]. Moreover, due to higher surface area the modified implant surface with nano-
scaled topography might provide additional available sites for protein adsorption, 
thereby enhancing cellular interactions directly at implantation site [12,13]. This is 
very positive, because even the implant acts against bacteria, at the same time, it 
influences the bone and the surrounded tissue to heal more rapidly and in a more 
proper way, respectively.  
3 CONCLUSION
The working objectives of the new Research laboratory within the project Trans2care are to develop a new, multifunctional nanocoating with desirable properties such 
as, to be antibacterial and osteoinductive. We believe that the project goals shall 
be attainable also with the collaboration with other scientific and clinical partners, 
involved in the project network.  
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Gene – nutrient interactions
Zala Jenko Pražnikar, Ana Petelin and Mojca Bizjak 
PP12-University of Primorska, Izola
Abstract — at the University of Primorska College of Health Care Izola the 
researchers are joined in an interdisciplinary team which will perform a 
research entitled “A multidisciplinary approach in the treatment of obesity”. 
Obesity and overweight pose a major risk for diet-related chronic diseases. So, 
understanding the role of obesity is of major importance in the prevention and 
treatment of these related diseases. It is known that genetic factors related to 
food intake, basal metabolic rate and adipocyte differentiation contribute, but 
also life style, psychological factors, and tradition, may provide to the etiology 
of obesity, that is why obesity will be studied from different aspects. The aim of 
the research is in addition to nutritional treatment also attempt to understand 
the regulation of the secretion of adipokines by different food components. 
Research is versatile and interdisciplinary, and is a challenge for researchers.
Index Terms — obesity, adipokines, gene-nutrient interactions, dietary fats
———————————————————
1 ACTIVITIES AND ROLES IN TRANS2CARE PROjECT
At the University of Primorska College of Health Care Izola interdisciplinary team of young researchers will use multidisciplinary approach in the treatment of 
obesity. Study corresponds to the trend of public-health problem. The goal is clear: 
to determine the appropriate diet to an individual, to improve the quality of life and 
maintain personal health. The project will be important also for the development of 
nutrigenomics at the University of Primorska College of Health Care Izola. Moreover, 
the knowledge obtained in this study will be useful also in the pedagogical processes 
that take place at the university of Primorska College of Health Care Izola.
1.1 Scientific background
The prevalence of overweight is increasing globally and has become a serious public health problem (1). Obesity is associated with low-grade chronic inflammation 
characterized by inflamed adipose tissue with increased macrophage infiltration. 
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This inflammation is now widely believed to be the key link between obesity and 
development of insulin resistance and metabolic disease development (2). 
Adipose tissue is crucial for the inflammatory status associated with obesity, primarily 
because of macrophage infiltration (3). Adipocytes secrete both pro- and anti-
inflammatory adipokines, including pro-inflammatory tumor necrosis factor- (TNF-), 
interleukin-6 (IL-6), and the anti-inflammatory adiponectin. Reduced adiponectin and 
increased C-reactive protein (CRP) concentrations are associated with cardiovascular 
diseases and type 2 diabetes (4). 
1.2 Presentation of the problem
A reduction in inflammatory status may prevent the occurrence of disorders and diseases related to overweight. Many food compounds have been reported to 
have anti-inflammatory and/or antioxidant effects in various populations and the 
hypothesis is that these specific dietary components (polyunsaturated fatty acids 
(PUFAs), vitamin C, vitamin E, ...) are able to reduce low-grade inflammation as well as 
metabolic and oxidative stress. For example anti-inflammatory effects of n–3 fatty 
acids have been shown by reduced plasma concentrations of CRP, TNF-, and IL-6 (5). 
But the border between health and disease is often set by a complex equilibrium 
between two elements, genetics on one hand, and lifestyle (including diet) on the 
other (Figure 1). So, heterogeneity in circulating plasma concentrations of CRP, TNF-, 
IL-6, adiponectin, and other adipokines in response to specific dietary compounds may 
be due, in part, to genetics variations. Therefore at the same dietary intake of specific 
compound, their respective health effects may differ due to genetic differences (6).
Fig. 1. Interactions between nutrients and biological macromolecules. Approaches to evaluate these 
interactions are genomics, transcriptomics, proteomics, and metabolomics.
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1.3 Research objectives
In the study, we assume that changes in adipokines gene expression are caused by the ingestion of different kinds of nutrients and particularly of different types of 
fat. The objective of the study is to determine the relationship between TNF-, IL-6, 
adiponectin, resistin, and visfatin gene polymorphisms with obesity and investigate 
whether specific dietary compounds intake modulates these associations and how 
the specific dietary compound modulates adipokines secretion. 
1.4 Methods
Different polymorphisms, and biochemical measurements, will be determined in the study of obese people and matched controls, comparable in age and sex. 
Dietary intake will be assessed on the basis of a food frequency questionnaire, 
adapted to Slovenian dietary patterns and with dietary record. Each participant 
in the study will be individually discussed. The nutritional status will be assessed, 
resting metabolic rate with indirect calorimeter will be measured and the proportion 
and distribution of fat will be determined with bioelectrical impedance analysis. 
DNA will be isolated from peripheral white blood cells and genotyping of different 
polymorphisms will be performed by using real time polymerase chain reaction. For 
the quantitative determination of adipokines in human plasma ELISA method will 
be performed. Moreover, all biochemical analysis will be done at the biochemical 
laboratory at Izola General Hospital following established procedures. In the end all 
results will be analyzed and evaluated using different statistical programs. Using 
various statistical analyses the interactions between food components and genes 
will be calculated.
2 CONCLUSION
Through the initiated Trans2Care project we intend at the University of Primorska College of Health Care Izola to contribute through the activities and studies to 
understand gene – nutrient interactions and, consequently, contribute to the 
improvement of the quality of life and to maintain personal health.
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Biomedical application of 
electroporation: electrochemotherapy 
and electrogene therapy
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Abstract — Electroporation refers to exposure of cells to external electric 
field thatresults in transiently or permanently increased permeability of cell 
membranes. Cancer treatment, where local application of electroporation 
to tumor nodules is combined with chemotherapeutic drugs bleomycin 
or cisplatin is called electrochemotherapy. The antitumor effectiveness of 
electrochemotherapy is primarily based on direct killing of tumor cells due to 
the increased chemotherapeutic drug uptake, but other mechanisms, such 
as vascular disrupting action was also demonstrated. Our group is involved 
in elucidating the underlying mechanism of vascular disrupting action by 
studying the changes in cytoskeletal proteins after electrochemotherapy in 
endothelial cells by immunocytochemistry. In addition, metastatic potential 
and global changes in gene expression of melanoma cells that survived 
electrochemotherapy were also studied, demonstrating that metastatic 
potential of cells is not changed and that a very low percentage of genes are 
down or up regulated after electrochemotherapy, which further supports 
its safe use in the clinical setting. Another application of electroporation is 
delivery of plasmid DNA into the cells for gene therapy. Our group is involved in 
preparation of plasmid DNA with tissue specific promoters and without genes 
for antibiotic resistance, thus enabling safe use of gene therapy in line with USA 
Food and Drug Administration (FDA) and European medicines Agency (EMA) 
recommendations.
Index Terms — electrochemotherapy, electrogene therapy,electroporation, 
preparation of plasmids without genes for antibiotic resistance.
———————————————————
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1 INTRODUCTION
Due to the physical nature of the method, all types of living cells (prokaryotic and eukaryotic) can be efficiently electroporated. Currently electroporation is used 
in food and biomass processing and as a cancer treatment. In food processing, the 
aim is to kill the microorganisms, while preserving the color, taste and the level of 
antioxidant in the processed food. Electroporation was successfully used for extraction 
of intracellular components from plant and has shown a potential in pretreatment 
of sludge and other substrates leading to increase in biogas production. Other 
applications, such as water treatment, extraction of oil from algae, sugar extraction 
from sugar beet are also being investigating. In cancer treatment, electroporation 
is currently used in combination with the chemotherapeutic drugs bleomycin and 
cisplatin for treatment of cutaneous and subcutaneous metastases of various 
histological types of tumors. Electroporation can also be used for introduction of 
genetic material - plasmid DNA - into the cells and therefore used for DNA vaccination 
and gene therapy of various diseases.
2 ELECTROChEMOThERAPy – EFFECTS ON ENDOThELIAL CELLS
Electrochemotherapy consists of chemotherapy followed by local application of electric pulses to the tumor to increase drug delivery into cells. Drug uptake can 
be increased by electroporation only for those drugs whose transport through the 
plasma membrane is normally impeded. Among many drugs which have been tested 
so far, only bleomycin and cisplatin have transitioned from preclinical testing to 
clinical trials. In vitro studies demonstrated a several-fold increase in their cytotoxicity 
after electroporation of cells. In vivo, electroporation of tumors after local or systemic 
administration of either of the drugs, i.e. electrochemotherapy, proved to be an 
effective antitumor treatment. Several clinical studies were performed demonstrating 
that electrochemotherapy is effective in local tumor control of cutaneous and 
subcutaneous tumor nodules of different histology. So far, predominantly melanoma 
skin metastases have been treated, with ~70% long-lasting complete responses of 
the treated nodules [1]. Electrochemotherapy is also used in veterinary oncology, 
where it is used also for treatment of primary tumors and with similar results as in 
human medicine [2].
Besides membrane electroporation, which facilitates drug transport and its 
accumulation in the cell, other mechanisms that are involved in antitumor 
effectiveness of electrochemotherapy, have been described, potentiation of immune 
response, blood-flow modifying effect and vascular disrupting action. The application 
of electric pulses to tissues induces a transient but reversible reduction in blood 
flow. In vitro studies have shown that application of electric pulses to a monolayer 
of endothelial cells results in a profound disruption of microfilament and microtubule 
cytoskeletal networks, loss of contractility, and loss of cadherin-formed cell-to-cell 
junctions in the vascular endothelial lining immediately after electroporation, which 
recovered within 60 minutes after electroporation, without any significant loss of cell 
viability. The cytoskeletal effects of electroporation were paralleled by a rapid increase 
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in endothelial monolayer permeability, giving an indication of putative mechanisms 
responsible for the observed increase in permeability and cessation of blood flow in 
vivo[3]. When electroporation is combined with chemotherapeutic drugs the effects 
on vasculature are even more pronounced and resulted in electrochemotherapy with 
bleomycin in complete abrogation of blood flow in vivo. Currently, we are exploring 
the underlying mechanisms of this effect at the cellular level, by studying the effects 
of electrochemotherapy on adherent microvascular endothelial cells. We found that 
nuclear morphology changes as well as changes in microtubules and actin filaments 
network are more profound and long lasting after electrochemotherapy with 
bleomycin compared to changes induced by electroporation or bleomycin alone (Fig. 
1). In addition, endothelial monolayer intactness was severely compromised after 
electrochemotherapy.
Fig. 1.Monolayers of Human Microvascular Endothelial Cells (HMEC-1) are differently affected by elec-
troporation (EP) and electrochemotherapy (ECT).Monolayers stained for F-actin with FITC conjugated phal-
loidin. Note the honeycomblike appearance at 0 hrs for both 300V EP and ECT. Recovery is present at 24 
hrs post-treatment, while in the presence of 300 nM bleomycin (ECT) cells start to die.
3 ELECTROChEMOThERAPy – EFFECTS ON METASTATIC POTENTIAL 
 OF MELANOMA CELLS
Another topic of our research in the field of electrochemotherapy was to address the clinical relevant question i.e. if metastatic potential and global 
gene expression of melanoma cells that survive electrochemotherapy is changed. 
Namely, it is known that metastatic progression is a multi-step process that requires 
acquisition of many specific cell properties, each fulfilling a unique function in the 
metastatic cascade for successful establishment of metastases. Alterations in tumor 
cells and their microenvironment induced by therapy can play an important role in 
metastasis induction. We studied on viable cells 48 hours after electrochemotherapy 
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their ability to migrate and invade through Matrigel coated porous membrane. In 
addition, microarray analysis was used to detect changes in gene expression after 
electrochemotherapy. Cell migration and invasion were not changed in melanoma 
cells surviving electrochemotherapy. In addition, only a low number of tumorigenesis 
related genes was differentially expressed after electrochemotherapy (Fig. 2), 
demonstrating that the metastatic potential of melanoma cells was not affected by 
electrochemotherapy and confirming its safety in the clinics [4], [5].
Fig. 2.Differentially expressed tumorigenesis related genes after electrochemotherapy. From 0,5% to 1,3% 
of all evaluated genes were differentially expressed after exposure to electroporation (EP), cisplatin (CDDP), 
bleomycin (BLM) or electrochemotherapy (ECT) with CDDP or BLM. Bars represent percentage of down 
regulated or up regulated genes of the total number of tested genes.
4 ELECTROGENE ThERAPy – PREPARATION OF PLASMID DNA WIThOUT   
 ANTIBIOTIC RESISTANCE GENE
Another application of electroporation is delivery of genetic material i.e. plasmid DNA into the cells. Due to the concerns connected to viral vectors, non-viral 
approaches for transfection are becoming very attractive [6]. One of the goals of 
researchers dealing with gene therapy or DNA vaccination is to develop safe and 
efficient systems for gene transfer into the target cells. Namely, this topic is still 
one the major hurdles in the progress of different approaches in gene therapy and is 
crucial factor for success of the therapy. Other factors that should be considered for 
development of gene therapy are the choice of appropriate therapeutic gene, regulation 
of its expression and administration route. Our group at the College of Health Care 
Izola in collaboration with Institute of Oncology Ljubljana, National Institute of Biology 
and University of Ljubljana Biotechnical faculty is planning to address two of these 
factors for the use in cancer gene therapy: safety of plasmid DNA by preparation of 
plasmid DNA without marker for antibiotic resistance and regulation of therapeutic 
gene expression by linking the therapeutic gene to cellular promoters to achieve 
either stress induced (p21 and radiation) or physiological regulation (tissues specific 
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promoters for endothelial and muscle cells and fibroblasts) of expression. We are 
planning to prepare plasmids encoding reporter or therapeutic genes under the 
control of tissue specific or inducible promoters using standard molecular biology 
techniques and plasmids without gene for antibiotic resistance according to the 
instructions of the producer of ORT® plasmid. The results of this on-going project, if 
successful, may have impact on design and execution of gene therapy trials.
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Abstract — Polymerase chain reaction (PCR) has enabled enormous progress in 
the field of molecular biology in the last twenty-five years. It became popular due 
to its high sensitivity and specificity and was introduced to numerous scientific 
fields. Today many different variants of PCR exist, with real-time PCR being 
the most common. This method is being successfully used at our institution 
for a variety of different applications, among which gene expression analyzes 
and development of protocols for clinical diagnostics currently dominate. But 
the extreme flexibility and customizability of real-time PCR, coupled with our 
team’s expertise, ensures efficient application of this technique to various new 
research projects.
Index Terms — real-time PCR, SYBR Green, TaqMan, quantification, gene 
expression  
———————————————————
1 INTRODUCTION
Principle of  PCR reaction
Polymerase chain reaction (PCR) is a technique that has had a tremendous influence on development and research in molecular biology. Nowadays, it 
has become common and is an essential laboratory tool, on which the majority of 
molecular biological studies are based.  
The primary purpose of PCR is rapid amplification of single or few copies of template 
DNA, generating thousands to millions of copies of the original (template) DNA 
sequence. Key components that enable this process are primers, deoxyribonucleotides, 
and a DNA polymerase. The first are short nucleotide sequences that specifically bind 
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to a region of the template DNA and enable selectivity of amplification and initiation 
of DNA synthesis. DNA polymerase is a thermostable enzyme that synthesizes a DNA 
strand complementary to the template. PCR reaction is composed of 30-40 cycles of 
alternated steps of heating and cooling, which are necessary for the separation of 
the two strands of DNA double helix, annealing of primers and for the DNA synthesis. 
Based on the detection method of PCR amplicons, two main PCR techniques exists: 
i) end point PCR, where the product is detected after the PCR reaction is completed, 
usually with gel electrophoresis, and ii) real-time PCR, where the product is detected 
during the reaction, as it is being
Detection dyes in real-time PCR
Fluorescence-producing chemistries used in real-time PCR can be grouped into two main types: nonspecific and specific. The most commonly used nonspecific 
chemistry is SYBR® Green I, where the nonspecific dye emits fluorescence only when 
it reversibly binds to any double stranded DNA that is generated during PCR reaction. 
Therefore, distinguishing between specific and nonspecific products based only on 
the amplification curve is impossible. Post-amplification analyses are needed to 
confirm specificity of the amplicon with the use of dissociation-curve analyses. 
The most commonly used specific chemistry is TaqMan® chemistry. What makes this 
chemistry appealing is that it integrates an additional level of specificity, obtained 
thanks to the use of specific oligonucleotide probes. A fluorescent reporter dye is 
bound to the 5’-end of the probe and a quencher dye is bound to the 3’-end. As long 
as the probe is intact, the quencher inhibits the fluorescence of the reporter dye. But 
when the probe hybridizes to its target sequence, the 5’-exonuclease activity of DNA 
polymerase degrades the probe, thereby separating the reporter and quencher dyes, 
which results in increased fluorescence of reporter dye. Since only specific products 
are detected that way, no post-amplification analyzes are needed. Nevertheless, 
TaqMan® has a unique drawback. In order for the chemistry to function as desired, 
one must pay special attention at the choice of DNA sequences of both primers 
and probe. A poorly chosen probe or mismatched annealing temperatures of all 
three oligonucleotides in the reaction can severely handicap detection of amplicons, 
producing a false result. 
Moreover, labeling specific TaqMan® probes with different reporter dyes enables 
detection and quantification of different target sequences in the same reaction tube 
(multiplexing), which significantly reduces the reaction costs. SYBR® Green chemistry 
also enables multiplexing, but distinguishing between two different products is much 
harder, since there must be apparent differences in dissociation-curve peaks of the 
different multiple amplicons. On the other hand, when using TaqMan® chemistry, 
multiplexing is limited only by the choice of dyes with emission spectra compatible 
with the detection spectra of the real-time PCR machine.    
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2 OUR EXPERIENCE WITh REAL-TIME PCR 
Our research facility is equipped with a 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). It is being used for a variety of different 
applications. Because PCR is a very sensitive method, designated areas and separate 
pipetting tools are used for PCR reaction set-up.  
Not only that PCR is very sensitive, it also has high specificity, thus it can be used to 
distinguish highly similar template DNA sequences. This means that closely related 
species or even subspecies and strains, depending on the variability of nucleotide 
sequence being amplified, can be identified. Thus choosing an appropriate template 
gene and a region in that gene is essential for successful identification. At our 
institution, both TaqMan® and SYBR® Green I chemistries are currently being used 
for species detection and identification. 
SYBR® Green I chemistry is used for detection and identification of bacteria and 
viruses in a variety of different clinical samples. Samples of periprosthetic tissue 
from patients who had undergone revision arthroplasty were analyzed with the 
use of broad-range primers for the presence of the 16S rRNA bacterial gene, while 
identification was done by sequencing of the amplified products. In clinical samples 
from patients with malignant pleural mesothelioma, species-specific primers were 
used for detection and identification of SV40 virus , thus dissociation-curve analyses 
in combination with appropriate controls were sufficient for confirmation of specificity 
of the amplified products.  
The use of species-specific primers and sequencing of amplicons for identification 
can be overcome with the use of TaqMan® chemistry. An example of user-
friendly TaqMan® chemistry is “Custom TaqMan gene expression assays” (Applied 
Biosystems), which include a validated and optimized mix of a fluorogenically labeled 
probe and primers. Besides analyzing gene expression (as the name implies), these 
assays can also be used for species identification, in our case bacteria. The advantage 
of these assays is that no post-amplification manipulation and analyses are needed 
for confirming the specificity of the fluorescence signal. No primer-probe validation 
needs to be performed by the user, which significantly reduces cost and labour.  
Quantitative PCR analyses are also being performed at our institution. Currently, only 
TaqMan® chemistry is used for quantitative analyses. Gene expression was relatively 
quantified for analyzing transcriptional silencing of genes that are involved in cancer 
phenotype regulation . Residual amounts of therapeutic plasmids, containing the 
IL-12 gene, and used in electrogene therapy of canine skin tumors, were absolutely 
quantified using TaqMan® assays.
Standard detection and identification techniques in virology have already been 
replaced with modern molecular methods and used for diagnostic purposes enabling 
us to detect and subtype different viruses.
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3 CONCLUSION
The use of the polymerase chain reaction (PCR) in molecular diagnostics has increased to the point where it is now accepted as the gold standard for detecting 
nucleic acids from a number of origins and it has become an essential tool in the 
research laboratory. Real-time PCR has engendered wider acceptance of the PCR due 
to its improved rapidity, sensitivity, reproducibility and the reduced risk of carry-over 
contamination. The technology has been applied to different areas of microbiology 
as well as studies of gene expression and genetic disease. Within our institution, 
real-time PCR method has been applied to various research fields, granting our team 
valuable expertise for implementation of this technique to several possible research 
projects in the future.  
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Abstract — Although mathematics finds large application in physical 
sciences, its use in the medical and biological field is less usual. Nevertheless, 
mathematical models can help in understanding many medical and biological 
phenomena and they can be a powerful tool in the designing process of many 
technological devices connected to the above mentioned phenomena. Of course, 
fundamental pre-requisite for building up a reliable mathematical model is the 
deep cooperation of different competences such as those of medical doctors, 
biologists, pharmacists and engineers. This paper deals with four different 
examples of mathematical models developed by our group and dealing with 
restenosis, enzyme action on two dimensional DNA brushes, oral delivery of 
drug in amorphous or nano-crystalline form and tumour cell behaviour.
Index Terms — Biology, Mathematical model, Medicine
———————————————————
1 INTRODUCTION
If it is well known that mathematics is largely employed in the engineering, physic 
and chemistry fields, less obvious is its utility in medicine and biology. This probably 
depends on both cultural and practical reasons. Indeed, the human necessity of 
knowledge categorising favoured, in the past, the formation of impermeable barriers 
among knowledge fields that hindered the diffusion of transversal tools such as 
mathematics. Accordingly, mathematics remained in its historical nest, i.e physical 
sciences field. In addition, the typical complexity of many medical and biological 
problems did not surely encourage crossing the above mentioned barriers [1]. 
Nowadays, fortunately, the diffusion of mathematics in the medical and biological 
sciences is well established and a huge variety of examples can be cited. For example, 
Freguglia [2] edited a book dealing with theoretical aspects of evolutionary biology, 
mathematical interpretation of Darwin’s evolutionary theory, bacteria motion 
and heartbeat. Additionally, mathematics can find application, for example, in 
cardiovascular system, neuroscience, ecology, environment, evolution, immunology, 
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infectious diseases, tumor growth and therapy [3]. The spreading of mathematics 
is witnessed by the existence of many societies, such as the European Society for 
Mathematical and Theoretical Biology [4], the Society of Mathematical Biology 
[5] and the Japan Association for Mathematical Biology [6] that actively promote 
mathematics use in the medical and biological fields. Ultimately this is nothing 
more than a modern translation of the Leonardo da Vinci idea according to which “.. 
niuna umana investigazione si può dimandare vera scienzia, s’essa non passa per le 
matematiche dimostrazioni ...” (no human research can be defined true science if it 
cannot be mathematically demonstrated) [7].
While the utility of mathematics in the medical and biological fields is obvious when 
thinking to the statistical analysis of experimental findings, the help that it can 
provide in the everyday research emerges also through the mathematical modelling 
activity. Indeed, the mathematical model, defined as a mathematical metaphor of 
some aspects of reality (drug systemic spreading after oral administration, for 
example) [8], consists of the theoretical representation (imitation or emulation) of 
something or in the visualisation of something that cannot be seen (a molecule, for 
instance). Consequently, mathematical modelling can be viewed as a cognitive activity 
of the human mind aimed to the description of how devices behave or phenomena 
and processes take place. This means that a reliable mathematical model can be 
built on condition that a clear idea of how a phenomenon develops is known. Thus, 
mathematical modelling means knowledge. Accordingly, it is evident the great 
advantage that can be gained by the use of mathematical models in the medical and 
biological field in order to support and to prove very different theories.
The aim of this paper is to show some examples of mathematical models developed 
by our groups and devoted to medical and biological problems. In particular, the 
attention will be devoted to restenosis, enzyme activity in self-assembled DNA layers, 
oral drug delivery and tumor cell behviour. 
2 RESTENOSIS
Traditionally, coronary stenosis, a common atherosclerosis complication, has been matched by means of percutaneous transluminal coronary angioplasty (PTCA), 
a procedure leading to the enlargement of the stenotic portion of the coronary by 
means of an expanding balloon. Nevertheless, the high incidence of re-stenosis 
(30-40%) following PTCA [9], obliged to consider alternative approaches. The use of 
stents, rigid scaffolds positioned in correspondence of the coronary stenotic portion, 
emerged as an interesting therapeutic strategy due to the consistently reduction of 
re-stenosis occurrence with respect to the simple PTCA treatment [10]. However, 
stents did not completely solve the re-stenosis problem. Although they can really 
prevent the coronary wall early elastic recoil and late re-modelling, two known 
events leading to re-stenosis, they induce neointima iperplasia (In Stent Restenosis 
– ISR) due to the hyper-proliferation of vascular smooth muscle cells (VSMCs) [11]. 
At this purpose, the employment of drug eluting stents releasing anti-proliferative 
drugs (DES) substantially reduced the VSMCs iper-proliferation and the consequent 
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re-stenosis rate [12]. Unfortunately, however, recent studies evidence that the re-
vascularization benefit with DES is attenuated in high-risk patients (diabetes; the 
acute coronary syndromes; smaller-diameter lesions and longer lesions; several 
stents or overlapping stents), compared to low risk patients [13]. Moreover, their 
use is connected to a higher incidence of late thrombosis (due to an incomplete 
endotelisation of the stented zone) in comparison with uncoated stents [14].
In the attempt of overcoming these problems, our group and other researchers 
proposed to use of new therapeutic agents such as, nucleic acid based drugs (NABD) 
that have been proved to hinder VSMCs hyper-proliferation by suppressing the 
expression of relevant cell cycle promoting genes [15, 16, 17]. The fragile nature and low 
cellular transfection attitude impose NABD complexation with proper delivery agents 
(DA; liposomes, polycations and fatty substances, for instance) in order to make this 
approach effective and reliable from the therapeutic point of view. In addition, NABD-
DA properties (dimensions and physic-chemical characteristics) make their release 
from traditional DES problematic and alternative solutions need to be considered. 
A possible choice is represented by the endoluminal gel paving technique (EGP) [18], 
together with the implantation of a bare metal stent. EGP consists of the catheter 
application of a biocompatible polymer solution on the endoluminal vessel surface 
followed by in situ polymerization or crosslinking. The potential advantages of the gel 
paving-stent technique are an easy and safe complex loading within the gel matrix 
and the opportunity of creating a physical barrier between the damaged coronary 
wall and the overflowing thrombogenic and inflammatory elements present in the 
blood stream [19].
In the light of this frame, the developed mathematical model accounts for 1) NABD-
DA diffusion out of the gel layer towards the coronary wall and the blood stream 
2) NABD-DA convective motion in the coronary wall portion not shielded by the gel 
layer (this convective contribute is due to the radial hydrostatic pressure gradient 
between lumen and coronary wall) and 3) NABD-DA metabolism and internalisation 
into cells. In order to reduce the intrinsically three dimensional problem to a simpler 
two dimensional problem, the stent is schematised by a series of equally spaced rings 
that cannot be crossed by NABD-DA. In addition, with the aim of accounting for really 
occurring situations, two different stent positions with respect to the coronary wall 
are considered: stent strut totally embedded or totally out of the coronary wall [20]. 
The performed simulations make clear that in order to hinder all the stages leading 
to re-stenosis (thrombi deposition 0-10 days, VSMCs proliferation 2.5 – 25 days, late 
remodelling and inflammation 25 – 300 days) it is necessary to complex the NABD 
with at least two DA differing in size. Indeed, small DA guarantees a rapid diffusion 
of the NABD-DA complex that can hinder the fast re-stenosis phenomena (thrombi 
deposition and beginning of VSMCs proliferation). Big DA ensures a slow diffusion of 
the NABD-DA complex that can hinder the long occurring re-stenosis phenomena 
(late VSMCs proliferation, late remodelling and inflammation).
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3 ENzyME
The immobilization of dense DNA structures on solid supports (ultra-flat gold surface), obtained by self-assembly and enzymatic manipulations, holds a central 
role as a tool for developing miniaturized devices with innovative applications, ranging 
from biosensing [21] to next-generation information technology [22]. For example, 
restriction enzymes, that cleave double-stranded (ds) DNA molecules, are widely 
utilized in cloning as well as in a number of DNA-based assays [23] because they 
target very specific dsDNA sites. Moreover, these enzymes have the ability to diffuse 
in one-dimension by sliding on the backbone of long dsDNA filaments during their 
site-searching process [24]. Recently, it was studied the behaviour of a restriction 
enzyme reaction (DpnII) with dsDNA oligomers packed into relatively large (and flat) 
surface-bound brushy matrices consisting of patches of monolayer with controlled 
density [25]. The enzyme action was followed by measuring the height reduction of the 
dsDNA brush because of cleavage using atomic force microscopy (AFM). It was found 
that the restriction reaction depends on the DNA density, and it was demonstrated 
the existence of a threshold above which the reaction is inhibited (essentially in a 
stepwise manner). This result, which has been later confirmed by other groups [26], 
suggested that the accessibility of dsDNA molecules in these surface-bound brushy 
matrices critically depends on the inherent steric hindrance. In particular, we saw that 
while enzyme cannot enter inside the dsDNA monolayer through the upper surface 
(i.e. that formed by dsDNA free end), the access is only allowed through the lateral 
dsDNA brush side. We explained these results by modelling the steric hindrance of 
the dsDNA brush in the upper and side surface [27]. This model was inspired by an 
established theory describing the diffusion of solutes inside polymer matrices [28]. 
Once this peculiar behaviour was elucidated, the attention was focussed on the 
mathematical description of enzyme diffusion and reaction inside the two dimensions 
dsDNA brush. In particular, the model was based on the idea that the 2D enzyme 
movement occurs according to Fick’s law while enzyme reaction kinetics took place 
according to the Michaelis-Menten scheme where the reaction constants are those 
experimentally determined in bulk. On the basis of this model, it was then possible 
simulating the enzyme action (dsDNA cutting) on the two dimensions brush.
4 ORAL DELIVERy
Many pharmaceutical systems are essentially made up of a polymeric carrier hosting the active agent (drug) inside its three-dimensional network [29]. 
Especially in the case of oral administration, they are often prepared as particulate 
systems since these forms present remarkable advantages over the single unit 
devices. The easier dispersion inside the stomach reflects into an appreciable 
reduction of the local drug concentration which is usually responsible for gastric 
irritation. Moreover, they are very versatile and powerful as drug loading into cross-
linked polymers can represent a profitable tool to increase the drug dissolution rate 
in aqueous media and, thus, the bioavailability of slightly water-soluble crystalline 
drugs [1]. Indeed, by means of different techniques such as solvent swelling, co-
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grinding or supercritical CO2 it is possible loading drug nanocrystals and amorphous 
drug inside polymeric matrices [1]. The interesting aspect of nanocrystals is that 
their solubility increases with reducing their dimension up to the amorphous state 
that can be viewed as a crystal of vanishing dimension [30]. Thus, they are more 
bioavailable than bulk (macro) crystals [31] and their use implies dose reduction, with 
clear benefits for what concerns the reduction of side effects and costs. In order to 
theoretically study the in vivo behaviour of these “activated” systems, we built up 
a mathematical model accounting for the simultaneous processes of drug release 
from the particulate systems and the drug spreading into the body. In particular, 
the release stage considered the phenomena concerning particle swelling, drug 
solubilisation and drug diffusion in the polymeric network. The spreading step, 
instead, accounted for drug absorption, partitioning among tissues and elimination/
metabolism (ADME processes) [32]. This model proved to be a reliable tool to fit both 
in vitro and in vivo experimental data. Accordingly, it is a powerful mean to properly 
design delivery systems based on polymeric particles containing drug nanocrystals 
and amorphous drug.
5 TUMOUR CELL BEhAVIOUR
We have employed mathematical models also to describe the behaviour of different forms of tumour cells including prostate cancer cells. From the medical 
point of view, we are interested in studying the behaviour of prostate tumour cells 
as this kind of tumour is the main cause of cancer death in males in the Western 
World and also in Friuli Venezia Giulia (Registro Tumori 199-2003). By mathematical 
modelling, we could properly compare the growth rate of different types of prostate 
cancer cells and make interesting correlations with the expression genes (eEF1A1 
and eEF1A2) representing potential markers for prostate cell transformation and/or 
of cancer progression [33]. Shortly we will use the mathematical approach developed 
to study the growth behaviour of prostate cancer cell upon the treatment by NABD 
(work in progress); this approach will allow us to shorten the experimental procedure 
providing a sharp picture of the effect of our molecules in different prostate cancer 
cell lines. Finally, it should be noted that a similar approach will be followed for NABD 
molecules directed against genes involved in the generation and development of 
hepatocellular carcinoma [34, 35], another relevant tumour pathology in Friuli Venezia 
Giulia. 
6 CONCLUSIONS
Mathematical modelling can be a powerful tool for the understanding of many phenomena occurring in medicine and biology and, consequently, a powerful 
tool for the designing of devices connected to these phenomena. Of course, due 
to the complexity of the phenomena occurring in medicine and biology, a reliable 
mathematical model can be obtained on condition that many different competences 
concur in its building up. Accordingly, for example, the deep cooperation of medical 
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doctors, biologists, pharmacists and engineers is requested. We believe that this is 
the winning strategy for the challenges proposed by the modern research.
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 Abstract — Perhaps the most appealing opportunity is represented by gaining 
inspiration from nature for the precise tailoring of biomaterials with finely 
tuned unique functional properties. A very promising model is represented by 
Human Elastin-Like Polypeptides (HELP), repetitive artificial polypeptides based 
on penta- or hexa- peptidic motifs that characterize elastin. These protein 
polymers retain several peculiar biophysical properties as, the reversible inverse 
phase transition, changing the solubility and aggregation state in response to 
temperature variation. The smart nature of this class of compounds makes 
them attractive for many applications in the biomedical and biotechnological 
fields, in particular for biomaterial development. The Trans2Care project aiming 
to translating scientific and technological expertise into products for the 
biomedical field represents an exciting and challenging environment to best 
exploit the potential these biomimetic macromolecules. 
Index Terms — recombinant protein, elastin, biomimetic strategy, advanced 
biomaterials
———————————————————
1 INTRODUCTION
1.1 Elastin, a model for protein-based artificial biopolymers
Bio-mimicry, the concept of taking inspiration from nature is perhaps among the most appealing strategies to create customized biomaterials with finely tuned 
peculiar features. 
Elastomeric proteins, well represented among Vertebrates are among the 
components that received considerable attention. Elastin, one of the components 
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of the extracellular matrix, possesses rubber-like elasticity undergoing deformation 
without rupture and provides an important model for biomaterials design. Another 
peculiar extensively studied characteristic of elastomeric proteins is coacervation. 
Under appropriate conditions of concentration, ionic strength and increasing 
temperature, the protein is known to separate from solution as a second phase. It 
has been shown that this behavior is mainly due to the presence of the hydrophobic 
(VPGXG) pentapeptide, typical of the mammalian protein. 
In 1974, Urry et al. first developed artificial polypeptides mimicking these repeated 
hydrophobic motifs characterizing bovine tropoelastin. [1]. 
In the human protein, the most structurally regular sequence is represented by the 
repetition of the (VAPGVG) hexapeptidic motif. It has been shown that the VAPGVG 
motif is biologically functional. 
By a molecular biology approach, a regularly repeated domain from human tropoelastin 
was chosen as a basic modulus to obtain the Human Elastin-Like Polypeptides 
(HELPs). These artificial proteins can be employed in the production of innovative 
micro- and nano-structured biomaterials with a huge potential for employment in 
the biotechnological and biomedical fields.
1.2 HELP biopolymers family 
In our lab the HELP macromolecule, based on the most structurally regular module of human tropoelastin was developed and expressed in bacteria [2]. The polypeptide is 
soluble in aqueous solution below a critical temperature, whereas it forms aggregates 
above this temperature. This process, known as “inverse” phase transition, is fully 
reversible. 
A second synthetic gene was developed, and a polypeptide, named HELP1, based 
only on the most consistently repeated peptide sequence of human tropoelastin was 
obtained (Figure 1). 
Figure 1. Schematic representation of the two HELP and HELP1 prototypes. 
147
Overall, the work carried on in our lab is aimed at the production of a family of artificial 
polypeptides that exhibit different and variable physicochemical properties. The two 
prototype macromolecules HELP and HELP1 that differ in their primary structure 
have been characterized from the physic-chemical point of view, showing a different 
behaviour in relation to the different environmental conditions [3]. Both biopolymers 
are able to give reversible hydrogels under defined conditions by raising temperature 
(30-37°C). 
Relatively large yields have been recently achieved upon optimization of biopolymer 
expression and of the purification steps, in the range of hundreds of milligrams of 
purified product per liter of bacterial culture. [4] 
A key feature of these recombinant products is related to the modular structure 
of the synthetic genes that allows the tailoring of the macromolecule for a specific 
application. 
In this light, the HELPs can be viewed as prototypes whose functionality can 
be implemented by simply fusing peptidic regions to the C-terminal part of the 
biopolymers. The addition of a bioactive domain of choice will result in the conferring 
specific function to the whole product. 
2 BIOTEChNOLOGICAL AND BIOMEDICAL APPLICATIONS
Many recent examples show the potential of these polypeptides for a wide range of biomedical applications, and to build structures with highly controlled 
properties and behaviour [5]. 
The thermoresponsive self-assembly properties of these macromolecules are of 
particular interest to develop functional biomaterials, especially in the field of targeted 
delivery and controlled release of active molecules.
A method for preparation of 3D matrices with hydrogel features has been patented 
recently [6] and prosecution procedures are currently ongoing in Europe and USA 
(Figure 2).
Figure 2.  Stable HELP hydrogel matrix.
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This method represents a valuable option to preserve cell viability and functions 
as it avoids the use of harsh chemical reagents commonly used for preparation of 
matrices [7]. A huge potential for biomaterial development is foreseen. For example, 
one interesting feature is represented by the possibility to encapsulate cells in the gel 
maintaining their viability. 
As shown in Figure 3, cells spheroids can grow within the gel.
Figure 3. Viable cell encapsulation in 3D HELP matrix.
3 AIMS IN TRANS2CARE PROjECT
Proteinaceous material represents a promising alternative to chemically synthesised, traditional biomaterials still commonly employed in the biomedical 
field. HELPs represent promising innovative macromolecules and show high potential 
for a wide range of applications. Thus, we intend to exploit the Trans2Care partners’ 
expertise and knowledge to:
a) exchange ideas between traditionally distinct research areas and bringing together 
the competences to devise the employment of HELP biopolymers for specific demand;
b) provide the HELP compounds to the partners to setup experimental work;
c) develop commercial applications of HELPs and biomaterials derived. 
In particular, collaboration with:
•	 University of Nova Gorica (PP3), on development of innovative environmental 
biosensors;
•	 Treviso Tecnologia (PP5), on supporting technology transfer of existing and future 
HELP products;
•	 ZTM (PP10), on development of advanced cell growth and delivery systems.
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Bilitranslocase and anthocyanins role 
in the gastrointestinal tract
 Jovana Čvorović, Federica Tramer
LP-University of Trieste
Abstract —Bilitranslocase (BTL) is a organic anion transporter expressed in liver 
and in several extra-hepatic tissues. This membrane protein transports different 
substrates as pyrrolic molecules, nucleotides, flavonoids. Anthocyanins, one of 
the most represented flavonoids class are known to have antioxidant activity. 
They act as anti-inflammatory, anti-cancer and anti-proliferative molecules by 
interfering with different intracellular pathways. Some chronic colon diseases 
results in an increase in the pro-inflammatory machinery that are associated 
with a 5-fold increased risk of developing colon cancer. The expression and the 
role of BTL in the gastrointestinal tract in normal and pathological condition, as 
well as its role as anthocyanins transporter in colon cancer cells will be take into 
account in Trans2care project. 
Index Terms — bilitranslocase, organin transporter, flavonoids, anthocyanins, 
colon cancer, chronic colon diseases
———————————————————
1 INTRODUCTION
1.1 Bilitranslocase (BTL)
Bilitranslocase (BTL) is a plasma membrane transporter of 340 amino acids that displays no homology with known proteins [1]. However, its coding sequence 
shares 96% identity with a segment of the antisense strand of ceruloplasmin. BTL 
was originally identified in rat liver, and subsequently found also in absorptive 
(stomach and intestine) and excretory (kidney) epithelia. Its sub-cellular localization 
is suitable for the uptake of its substrates from the gastro-intestinal lumen, 
suggesting its nutritional role. Concerning BTL expression in pathological conditions, 
preliminary data show reduction in its expression in kidney cancer cells. BTL has also 
been detected in colon cancer cell line Caco-2 where the transport activity is strongly 
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inhibited by anti-bilitranslocase antibodies [2]. However, there are no available data 
on the presence of this transporter in chronic colon diseases. 
Bilitranslocase transports various polyaromatic compounds such as 
bromosulfophthalein (BSP) and indocyanine green, dyes used in the evaluation of 
hepatic function, but also bilirubin and nucleotides. BTL presence in the stomach [3] 
with the functional properties identical to those in the liver [4] might explain why 
flavonoids, as dietary anthocyanins for example, are absorbed a few minutes after 
their ingestion [5]. On the other hand, BTL high turnover might explain why flavonoids 
are rapidly metabolized and excreted. The detection of BTL on the luminal surface of 
the intestinal epithelium could also speak in favor of its role in flavonoid uptake since 
they are absorbed at this level as well.
1.2 Anthocyanins and chronic bowel diseases 
Flavonoids are a large group of phytonutrients that may provide beneficial effects on human health. They are divided into several classes: flavanones, flavones, 
flavonols, flavanols and anthocyanins. The main dietary sources of flavonoids are 
fruits, vegetables and grains. Epidemiological, clinical and experimental studies have 
indicated that dietary intake of flavonoids confers protection against multiple chronic 
diseases [6]. Their possible role in cancer prevention and progression has gained 
increased attention over the last years. Anthocyanins, which are the most abundant 
flavonoid constituents of fruits and vegetables [7] might be of special interest in 
this respect. Recent data show that these compounds are excellent intracellular 
antioxidants even at very low concentrations [8] and it is their antioxidant activity 
that confers protection against carcinogenesis. However, in cells that have already 
undergone malignant transformation, anthocyanins, act as prooxidants and 
induce apoptotic death [9]. Various studies confirmed the antiproliferative and 
anticarcinogenic activities of anthocyanins in different cell lines originating from 
colorectal cancer [10, 11]. Colorectal cancer is the second most frequent cause 
of cancer-related death. A combination of various risk factors, including obesity, 
sedentary lifestyle, increased prevalence of smoking, excessive alcohol consumption, 
a diet rich in red and processed meat and low intake of fruits and vegetables, can 
trigger the carcinogenic process [12]. Anthocyanins have been shown to exert strong 
cytotoxicity on highly tumorigenic and metastatic Lovo/ADR colon cancer cell line 
while being less harmful to cells with low proliferation rate (Caco-2), which brings 
up their selective action [9]. Animal studies have also reported anticarcinogenic 
properties of anthocyanins. In induced rat colon cancer cell models they significantly 
decreased total tumors as well as aberrant crypts [13, 14]. Anthocyanins have also 
shown anti-inflammatory activity through targeting NF-ĸB pathway and COX-2 
[15], which might have implications in tumorigenesis [16]. Even more, their ability 
to inhibit matrix metalloproteinase activity [17] could additionally contribute to 
both their anticancer and anti-inflammatory action. These activities, together with 
anthocyanins antioxidant properties, might also suggest their beneficial role in 
inflammatory conditions of the small intestine and colon, such as celiac disease and 
inflammatory bowel disease (IBD), yet there are no studies confirming this hypothesis. 
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Celiac disease is an immune-mediated disorder that affects primarily the small 
intestinal mucosa. It is characterized by chronic inflammation which occurs when 
gluten-activated Th1 cells start secreting cytokines (INF-γ and TNF-α) which in turn 
activate the release of enzymes such as metalloproteinases that can damage the 
intestinal mucosa leading to atrophy of intestinal villi. The progressive destruction 
of the small intestinal mucosa causes malabsorption, and a variety of clinical 
manifestations. Ulcerative colitis (UC) and Crohn’s disease (CD) are the two main 
forms of inflammatory bowel disease. They are multifactorial conditions, where both 
genetic and environmental components play their parts. However, at the basis of 
UC and CD lays aberrant immune response and consequent inflammation regulated 
mainly by NF-ĸB. Both CD and UC are associated with a 5-fold increased risk of 
developing colon cancer [18].
2 AIMS IN TRANS2CARE PROjECT
Concerning the importance of diet on human health and the still scarce knowledge of the role of anthocyanins and bilitranslocase in both physiological and pathological 
conditions of the gastrointestinal tract, we will try to:
A) Set dietary guidelines (based on the molecular mechanisms underlying 
anthocyanins bioavailability: their membrane transport at the level of the epithelial 
barrier of the gastrointestinal mucosa, and the role of BTL in it) for the prevention 
of chronic disorders of the intestine ;
B) Study and exploit the drug transport potential of BTL in order to develop new 
orally-deliverable drugs on the basis of bilitranslocase substrate specificity;
C) Exploit BTL as a biomarker: it might be an indicator of cell health (intactness), 
whereas its expression might be lost in cancer. It would be interesting to see how 
early the loss of expression occurs in disease development.
To reach these aims we will work in collaboration with IRCCS Burlo Garofalo (PP9), 
taking advantage of their tissue bank and expertise in gut histopathology in order to 
study BTL expression and determine any changes depending on the state of mucosa; 
with University of Nova Gorica (PP3), who has at its disposal sophisticated techniques 
for  anthocyanins separation and analysis in order to measure their uptake and 
transport across different cell monolayers; and with ZTM (PP10), who can help us to 
prepare a monoclonal antibody against BTL for immunohistochemistry procedures. 
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The enigma of flavonoids 
and bilitranslocase activity 
in the cardiovascular system
Lovro Žiberna, Sabina Passamonti
LP-University of Trieste 
Abstract — Numerous epidemiologic studies showed an inverse correlation 
between dietary flavonoid consumption and cardiovascular risk, but the exact 
mechanisms are still largely unknown. Flavonoids exhibit hormetic properties, 
where low concentrations activate adaptive cellular stress response pathways 
and thus lead towards cytoprotection, whereas high concentrations are 
cytotoxic. However, the limited bioavailability of dietary flavonoids doubts the 
relevance of effective flavonoid intracellular concentrations to induce bioactivity 
in endothelial cells. Therefore, translocation of flavonoids through the cell plasma 
membrane must occur via specific transporter proteins. Hereby, we describe the 
involvement of the membrane transporter bilitranslocase (TC #2.A.65.1.1) as 
the key underlying molecular mechanism for membrane transport, which might 
help resolve the enigma of flavonoids bioactivity.
Index Terms — bilitranslocase, flavonoids, cardiovascular health, hormesis, 
TRANS2CARE
———————————————————
1 FLAVONOIDS AND CARDIOVASCULAR hEALTh
Numerous epidemiological studies have shown that regular intake of flavonoids is associated with an improved cardiovascular prognosis [1,2]. In the setting 
of primary prevention, individuals with the highest flavonoid intake have modestly 
reduced risks for developing cardiovascular disease [3-5]. In addition, flavonoid intake 
benefits individuals with established cardiovascular disease. This can be seen from 
clinical signs like lowered blood pressure [6-8], improved endothelial function [9-11], 
inhibited platelet aggregation [7,12-14], decreased low density lipoprotein oxidation 
[15,16], and reduced inflammatory responses [17-19]. 
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To promote the idea of healthy diet, it is now clear that the medical researcher must 
put big efforts in providing concise explanations how the potential beneficial effects 
of flavonoids can arise. Scientists have a responsibility to investigate this issue, 
and provide the general public evidence-based guidelines on a healthy diet. Even 
more, researchers must try to isolate the therapeutic lead molecules, and chemically 
improve them, to obtain new potential drugs for treating specific pathophysiological 
conditions. So far, exact mechanisms of how flavonoids act are still largely obscure, 
and thus represent a big challenge for research, whether in academia or in the 
pharmaceutical and the nutraceutical industry. 
2 PhARMACOKINETIC CONCERNS RELATED TO ThE FLAVONOIDS    
 PhARMACODyNAMICS
The biggest pharmacological concern of dietary flavonoids can be attributed to their limited bioavailability, which results in very low plasma concentrations 
(0.1-1 μM) [20]. This questions whether intra-cellular concentrations attain levels 
that are of any relevance to the endothelial function [21]. In fact, it is not clear if 
flavonoids interact with any endothelial plasma membrane receptors and thus act by 
triggering an intracellular signal transduction cascade, or they penetrate into the cells 
and, consequently, bind to intracellular molecular targets. In the latter hypothetic 
pathway, translocation of flavonoids through the cell plasma membrane must occur 
via specific transport proteins [22].
On the other hand, high plasma flavonoid concentrations might have deleterious 
systemic effects, as it is suggested by some of theirs on the cardiovascular system 
[23]. Though still isolated, these observations warn against the potential alternative 
routes of administration, i.e. parenteral, which would avoid the low absorption and 
first-pass metabolism issues, or utilization of the enhanced absorption delivery 
systems.
It is widely accepted that flavonoids are good antioxidants when chemically tested 
in in vitro non-biological systems, but little emphasis is put on the fact that most of 
those studies showed effects in the supra-physiological concentration ranges, many 
magnitudes of order higher than reported in vivo. Thus, there is now a more plausible 
hypothesis that the in vivo beneficial effects of these phytochemicals are unlikely 
to be explained just by their per se antioxidant capability. Flavonoids may exhibit 
hormetic properties, by acting as `low-dose stressors’ that may prepare cells to resist 
more severe oxidative stress, while high concentrations are cytotoxic [24]. In this 
biphasic manner, low concentrations of flavonoids induce cardiovascular protection, 
while high concentrations are cardiotoxic [23]. 
This is meaningful since low and transient concentrations of flavonoids in the plasma 
contribute little per se to the overall plasma antioxidant status, when compared to 
the relatively higher concentrations of other antioxidants in plasma, e.g. vitamin C, 
uric acid, bilirubin, etc. Taken altogether, the diverse chemical structures of flavonoids 
exhibit molecular mimicry with many mammalian endogenous molecules, thereby 
leading to manifold biological effects, i.e. altering intracellular signaling pathways and 
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enzyme activities. Compared to the specific activity of other plant-related chemicals, 
for example morphine’s high affinity targeting of the opiate receptors, flavonoids 
have been always on the borderline between pharmaceuticals and xenobiotics. Since 
they don’t have any specific cellular targets, as indirectly confirmed by all flavonoids-
related studies with only partial inhibition and/or activation of numerous examined 
molecular targets, they should, in our opinion, fall in the category of xenobiotics. 
From an evolutionary perspective, flavonoids are primarily produced by plants to 
prevent insects and other animals to eat plants, and this again speaks in favor that 
the observed bioactivity of flavonoids from animal and human studies is actually 
resulting from the activation of adaptive cellular stress response pathways [25,26]. 
On the other hand, we must also consider the plausibility that there do exist some 
conservative proteins in nearly all animals, who eat the flavonoid-rich plants, and 
there are also similar proteins found in both the plant and animal kingdoms. Many 
of these are still largely unknown in humans, but can profoundly influence both the 
pharmacokinetic or pharmacodynamics properties of flavonoids.
3 BILITRANSLOCASE TRANSPORTS FLAVONOIDS INTO ThE CELLS 
There is a big question in the science: how can flavonoids enter into the cells? A potentially involved carrier is bilitranslocase (TC #2.A.65.1.1) [27], a bilirubin-
specific membrane protein that is also responsible for ATP-independent transport 
of flavonoids across cell membranes in various rat organs, e.g. on the epithelium 
of liver, gastrointestinal system, kidney, brain, lungs, etc., and also on the vascular 
endothelium [28]. Even though the investigation has not yet covered all mammalian 
tissues or other species, data already suggest that bilitranslocase might be a 
ubiquitous membrane protein, therefore playing a major role in biology.
Based on extensive transport activity assays performed on a battery of flavonoids 
subclasses, bilitranslocase can be considered as an anthocyanin-selective transporter, 
since other flavonoids are not effective ligands [27]. This selective interaction can be 
explained in terms of molecular mimicry between bilirubin and anthocyanins, as well 
as by specific structural characteristics of anthocyanins, such as the planar system 
of conjugated aromatic rings and pH-dependent tautomerism, which by protonation 
converts the quinoidal form into the phenolic form [29].
Bilitranslocase is expressed both in the vascular system, on the endothelium and 
vascular smooth muscle cells [28], and also in the cardiac system, on the endocardium 
and cardiomyocytes (data not yet published). This presence enables to understand 
some of the cardiovascular effects of flavonoids, which are summarized in the Table 1. 
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1. DIMINUTION OF OXIDATIVE STRESS
Direct scavenging of free radicals (antioxidant action in 
the narrow sense of the word)
Metal interaction (iron and/or copper chelation)
Inhibition of ROS producing enzymes, in particular xan-
thine oxidase, NADPH oxidase and lipoxygenases
Stimulation of endogenous antioxidant defense mecha-
nisms, increase in expression of eNOS, intracellular 
glutathione
2. DECREASE IN ThE EXPRESSION OF 
INFLAMMATORy SIGNALING MOLECULES
Inhibition of iNOS expression (endothelium)
Inhibition of COX-2 expression  (endothelium)
Inhibition of leukocyte activation
3. INhIBITION OF PLATELET AGGREGATION
Increase in platelet NO production
Decrease in platelet production of superoxide anion
4. DIRECT VASODILATORy ACTION
Activation of eNOS signaling pathway in the endothe-
lium, leading to release of NO
Activation of EDHF-mediated vasorelaxation in the 
endothelium
Direct effects on ion channels
Inhibition of cyclic adenosine monophosphate-
dependent phosphodiesterase
5. OThER CARDIOVASCULAR ACTIVITIES
Isoflavones improve endothelial function through an 
effect on α estrogen receptor
Positive/negative inotropic effects
Activation of PPARy
Table 1. List of potential protective effects of flavonoids in the cardiovascular system. Adapted from [30].
4 ROLE OF BILITRANSLOCASE IN ThE CARDIOVASCULAR SySTEM
We have made a significant progress in our understanding of the functional role of the bilitranslocase protein in the cardiovascular system. Original approach 
towards studying the protein function was based upon the inhibition of the 
bilitranslocase activity by using anti-sequence bilitranslocase antibodies. They target 
distinct extracellular epitopes of the carrier, and thereby inhibit the transport of the 
substrates into the cytoplasm. 
The data obtained from our experiments suggest that even low concentrations (in 
nM range) of flavonoids, which are comparable to post-absorption plasma levels, are 
rapidly (<1min) taken up into the endothelium via bilitranslocase (Ziberna, FRBM, 
under review). This rapid uptake into endothelial cells can be explained only by the 
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involvement of specific membrane transporters that catalyze the passage of polar 
substances, such as flavonoids, through the phospholipid bilayer.
Furthermore, bilitranslocase represents a key step in the flavonoids-induced 
endothelial cell-signaling cascade leading to the activation of intracellular PI3- 
kinase/Akt/eNOS pathway (Ziberna, not yet published), as schematically shown on 
Figure 1. Accordingly, bilitranslocase mediates the vasorelaxation responses induced 
by flavonoids [31].
Figure 1. Scheme indicating that flavonoids are potent inducers of the endothelial formation of NO and 
EDHF with their corresponding different intracellular signaling pathways. BTL – bilitranslocase, EDHF 
– endothelium derived hyperpolarizing factor, NO – nitric oxide, eNOS – endothelial NO synthase, PI3K 
– phosphatidyl-inositol 3-kinase, PDK1 – posphoinositide-dependent kinase 1, ROS – reactive oxygen 
species, sGC – soluble guanylyl cyclase. Adapted from [30].
In the cardiac system, we introduced an innovative approach of retrograde 
coronary perfusion with the bolus of the bilitranslocase antibodies. Thus, specific 
immunocomplexes were formed on the surface of the coronary endothelium and in a 
lesser extent, if at all, on the endocardium of the left atrium and ventricle. Importantly, 
unbound immunoglobulins were removed by continuous perfusion. We found that 
bilitranslocase mediates the cardioprotective activity of flavonoids in ischemia-
reperfusion model of the isolated heart, as observed by measuring coronary flow, 
cardiomyocyte lysis and duration of arrhythmias (Ziberna, FRBM, under review). 
5 INTERPLAy BETWEEN FLAVONOIDS AND BILIRUBIN
Given the mutual metabolic interference between flavonoids and bilirubin, it can be speculated that the transient increase in the antioxidant capacity of endothelium 
following ingestion of flavonoids [32] might be, in part, ascribed to a transient and 
reversible decrease of bilirubin clearance by the endothelial cells. Furthermore, it can 
be speculated that flavonoids occupy the activity of bilitranslocase, thus decreasing 
the endothelial efflux of intracellular (endogenous) bilirubin, which is constantly 
produced by heme oxygenase-1 and biliverdin reductase. Since bilirubin is a strong 
162
endogenous antioxidant, it can be speculated that even a very small increase in basal 
levels of free bilirubin can provide significant antioxidant protection of endothelium 
[33]. In fact, patients with Gilbert’s syndrome, a hereditary condition characterized 
by slightly elevated bilirubin plasma levels and occasional mild and intermittent 
jaundice, show a decreased risk of cardiovascular diseases in comparison to normo-
bilirubinemic populations [34,35].
6 CARDIOVASCULAR RESEARCh ON ThE BILITRANSLOCASE WIThIN    
 TRANS2CARE PROjECT
In the framework of TRANS2CARE project, we will continue to further elaborate our cardiovascular research on the role of bilitranslocase, jointly with our project 
partners:
•	 collaboration with PP1 – Chemical Institute of Ljubljana: in the field of computational 
modeling and chemometrics (QSAR); 
•	 collaboration with PP3 – University of Nova Gorica: studying the metabolism and 
fast-uptake of flavonoids and bilirubin into endothelial cells; 
•	 collaboration with PP10 – Blood Transfusion Center of Slovenia: development 
of novel monoclonal antibodies against bilitranslocase, which are crucial for 
our platform of functional studies, as well as having the potential to be used as 
biomarkers; 
Furthermore, we will also expand our network, in accordance with WP7 - Enlargement 
and consolidation of the network, towards the research groups outside the network:
•	 collaboration with University of Trieste, Department of Materials and Natural 
Resources, CENMAT, contact person Alois Bonifacio: employing SERS Raman 
spectroscopy to detect low concentration of bilirubin in the extracellular and 
intracellular environment;
•	 collaboration with IASMA Research and Innovation Center, Food Quality and 
Nutrition Area, San Michele all’Adige, contact person Fulvio Mattivi: metabolomics 
experiments on the effects of flavonoids in cardiovascular tissues.
7 CONCLUSION
The knowledge presented is important for the better understanding of diet-based preventive medicine, which is an affordable and efficient way of improving 
worldwide health. Academic world must, therefore, provide the rationale for specific 
dietary guidelines about including flavonoids-rich food in the diet. And the people 
will have no hesitation to make excellent life choices in the direction of achieving 
significant health benefits.
163
ACKNOWLEDGMENTS
This work was supported in part by the TRANS2CARE Project. 
REFERENCES
[1] Sofi, F., Cesari, F., Abbate, R., Gensini, G., Casini, A., Adherence to Mediterranean diet 
and health status: meta-analysis. BMJ 2008, 337, a1344.
[2] Hertog, M., Kromhout, D., Aravanis, C., Blackburn, H., et al., Flavonoid intake and 
long-term risk of coronary heart disease and cancer in the seven countries study. 
Arch Intern Med 1995, 155, 381–386.
[3] Hertog, M.G., Feskens, E.J., Hollman, P.C., Katan, M.B., Kromhout, D., Dietary 
antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study 
Lancet 1993, 342, 1007–1011.
[4] Knekt, P., Kumpulainen, J., Järvinen, R., Rissanen, H., et al., Flavonoid intake and risk 
of chronic diseases Am J Clin Nutr 2002, 76, 560–568.
[5] Rimm, E.B., Katan, M.B., Ascherio, A., Stampfer, M.J., Willett, W.C., Relation between 
intake of flavonoids and risk for coronary heart disease in male health professionals 
Ann Intern Med 1996, 125, 384–389.
[6] Hooper, L., Kroon, P.A., Rimm, E.B., Cohn, J.S., et al., Flavonoids, flavonoid-rich foods, 
and cardiovascular risk: a meta-analysis of randomized controlled trials Am J Clin Nutr 
2008, 88, 38–50.
[7] Erlund, I., Koli, R., Alfthan, G., Marniemi, J., et al., Favorable effects of berry 
consumption on platelet function, blood pressure, and HDL cholesterol Am J Clin Nutr 
2008, 87, 323–331.
[8] Desch, S., Schmidt, J., Kobler, D., Sonnabend, M., et al., Effect of cocoa products 
on blood pressure: systematic review and meta-analysis American Journal of 
Hypertension 2010, 23, 97–103.
[9] Dal-Ros, S., Zoll, J., Lang, A.-L., Auger, C., et al., Chronic intake of red wine polyphenols 
by young rats prevents aging-induced endothelial dysfunction and decline in physical 
performance: role of NADPH oxidase Biochem Biophys Res Commun 2011, 404, 743–
749.
[10] Schroeter, H., Heiss, C., Balzer, J., Kleinbongard, P., et al., (-)-Epicatechin Mediates 
Beneficial Effects of Flavanol-Rich Cocoa on Vascular Function in Humans. Proc Natl 
Acad Sci USA 2006, 103, 1024–1029.
[11] Heiss, C., Finis, D., Kleinbongard, P., Hoffmann, A., et al., Sustained increase in 
flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week J 
Cardiovasc Pharmacol 2007, 49, 74–80.
[12] Pearson, D.A., Paglieroni, T.G., Rein, D., Wun, T., et al., The effects of flavanol-rich 
cocoa and aspirin on ex vivo platelet function Thromb Res 2002, 106, 191–197.
[13] Rein, D., Paglieroni, T.G., Wun, T., Pearson, D.A., et al., Cocoa inhibits platelet 
activation and function Am J Clin Nutr 2000, 72, 30–35.
[14] Keevil, J.G., Osman, H.E., Reed, J.D., Folts, J.D., Grape juice, but not orange juice or 
grapefruit juice, inhibits human platelet aggregation J Nutr 2000, 130, 53–56.
164
[15] Mathur, S., Devaraj, S., Grundy, S.M., Jialal, I., Cocoa products decrease low density 
lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in 
humans J Nutr 2002, 132, 3663–3667.
[16] Wan, Y., Vinson, J.A., Etherton, T.D., Proch, J., et al., Effects of cocoa powder and 
dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations in 
humans Am J Clin Nutr 2001, 74, 596–602.
[17] Pan, M.-H., Laia, A.C.-S., Ho, C.-T., Anti-inflammatory activity of natural dietary 
flavonoids. Food and Function 2010, 1–17.
[18] Mao, T.K., van de Water, J., Keen, C.L., Schmitz, H.H., Gershwin, M.E., Modulation 
of TNF-alpha secretion in peripheral blood mononuclear cells by cocoa flavanols and 
procyanidins Dev. Immunol. 2002, 9, 135–141.
[19] Schramm, D.D., Karim, M., Schrader, H.R., Holt, R.R., et al., Food effects on the 
absorption and pharmacokinetics of cocoa flavanols Life Sci 2003, 73, 857–869.
[20] Manach, C., Williamson, G., Morand, C., Scalbert, A., Remesy, C., Bioavailability and 
bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin 
Nutr 2005, 81, 230S–42S.
[21] Ghosh, D., Scheepens, A., Vascular action of polyphenols. Mol Nutr Food Res 2009, 
53, 322–331.
[22] Dobson, P.D., Kell, D.B., Carrier-mediated cellular uptake of pharmaceutical drugs: 
an exception or the rule Nat Rev Drug Discov 2008, 7, 205–220.
[23] Ziberna, L., Lunder, M., Moze, S., Vanzo, A., et al., Acute cardioprotective and 
cardiotoxic effects of bilberry anthocyanins in ischemia-reperfusion injury: beyond 
concentration-dependent antioxidant activity Cardiovasc Toxicol 2010, 10, 283–294.
[24] Speciale, A., Chirafisi, J., Saija, A., Cimino, F., Nutritional Antioxidants and Adaptive 
Cell Responses: An Update. Curr Mol Med 2011, 11, 770–789.
[25] Chirumbolo, S., Hormesis, resveratrol and plant-derived polyphenols: some 
comments Hum Exp Toxicol 2011, 30, 2027–2030.
[26] Son, T.G., Camandola, S., Mattson, M.P., Hormetic dietary phytochemicals 
Neuromolecular Med 2008, 10, 236–246.
[27] Passamonti, S., Terdoslavich, M., Franca, R., Vanzo, A., et al., Bioavailability of 
flavonoids: a review of their membrane transport and the function of bilitranslocase 
in animal and plant organisms. Curr Drug Metab 2009, 10, 369–394.
[28] Maestro, A., Terdoslavich, M., Vanzo, A., Kuku, A., et al., Expression of bilitranslocase 
in the vascular endothelium and its function as a flavonoid transporter Cardiovasc 
Res 2010, 85, 175–183.
[29] Brouillard, R., Markakis, P., Chemical structure of anthocyanins, 1982.
[30] Ziberna, L., The Role of Bilitranslocase in the Protective Activity of Flavonoids 
Against Hypoxia-Reoxygenation Injuries in the Cardiovascular System, Doctoral 
Thesis, University of Ljubljana, Faculty of Medicine, Ljubljana 2011.
[31] Ziberna, L., Lunder, M., Tramer, F., Drevensek, G., Passamonti, S., The endothelial 
plasma membrane transporter bilitranslocase mediates rat aortic vasodilation 
165
induced by anthocyanins Nutrition, metabolism, and cardiovascular diseases : NMCD 
2011.
[32] Pietta, P.G., Flavonoids as antioxidants J. Nat. Prod. 2000, 63, 1035–1042.
[33] Vítek, L., Schwertner, H.A., The heme catabolic pathway and its protective effects 
on oxidative stress-mediated diseases Adv Clin Chem 2007, 43, 1–57.
[34] Schwertner, H., Vitek, L., Gilbert syndrome, UGT1A1*28 allele, and cardiovascular 
disease risk: possible protective effects and therapeutic applications of bilirubin. 
Atherosclerosis 2008, 198, 1–11.
[35] Vitek, L., Does hyperbilirubinemia protect from coronary heart disease Am J 
Cardiol 2001, 88, 1218.
CONTACT INFO
Lovro Žiberna and Sabina Passamonti are with the Department of Life Sciences, University of Trieste, 
Via L. Giorgieri 1, 34127 Trieste, Italy. E-mail: lziberna@units.it; spassamonti@units.it
166
167
PART III 
ThE UNIVERSITy OF TRIESTE 
AND ITS STRATEGIC PROjECT 
TRANS2CARE
168
169
Entry of the University of Trieste in the 
Cross-Border Cooperation Programme 
Italy-Slovenia 2007-2013
Sabina Passamonti
LP-University of Trieste 
The CBC Programme Italy-Slovenia 2007-2013 and the University of Trieste: 
correspondence between Programme’s objectives for the European territorial 
cooperation and the institutional University mission
The CBC Programme Italy-Slovenia 2007-2013 (hereinafter, the Programme) aims at accomplishing the strategic European Union priorities set out by the Lisbon and 
Göteborg strategy, according to the other European Territorial Cooperation Programmes 
that are financed by the European Regional Development Fund  (ERDF). The Programme 
aims at “promoting knowledge and transfer of know-how, developing cross-border 
economic activities and the potential in the education, technical training and health 
sectors, as well as integrating the cross-border labour market and jointly manage both 
the environment and common risks. Where the grounds of cross-border cooperation 
have already been laid, the cohesion policy should be aiming mostly at actions that 
will bring added value to the cross-border activity, like for example the improvement 
of cross-border competitiveness through innovation, research and development, 
connecting intangible (services) or tangible networks (transport), …” 1
In simple words, the main objective of the CBC Programme Italy-Slovenia 2007-2013, 
i.e. “Enforcing the attractiveness and the competitiveness of the Programme area”, 
can only be feasible, if the following specific objectives are pursued: 1) Guaranteeing a 
sustainable territorial integration; 2) Increasing competitiveness and the development 
of a knowledge-based society; 3) Improving communication and social, as well as cultural 
cooperation as to overcome the persistent obstacles. Each objective corresponds to a 
Priority Axis that is divided into precise operational objectives 2. 
The Priority Axis 2, “Competitiveness and knowledge-based society”, includes four 
operational objectives, among which “Promote research and innovation for the 
development of knowledge-based economy” and “Improve and qualify employment 
potentials through coordinated higher-education and training”.
Those operational objectives correspond to the most important institutional purposes 
of the University of Trieste, as stated in its first Social Responsibility Report 2008: The 
1 Operating Programme number CCI: 2007 CB 163 PO 036, page 44 (www.ita-slo.eu/documenti_di_riferimento/
documenti_di_programma/).
2 Therein, page 63. 
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University of Trieste is “the promoter of the economic and social development in the 
territory. Its role is crucial for the success of the Nation in the knowledge economy. The 
University of Trieste must be involved in various action areas. Depending on the case, 
the University is seen as the actor, involved in the technology transfer, or background 
of intellectual capital … a true territorial mission, carried out by the University of Trieste: 
an attractive function and promotion of cross-national scientific mobility that can help 
contrasting Trieste’s population decline and regain a decisive role in the European 
integration process that has been steadily advancing in its ancient reference area.” 3 
Given the common grounds of both the programme’s objectives, on one side, and 
the institutional purposes, on the other side, and the a network of active links with 
public and private bodies, located in the Programme’s Area, the University of Trieste 
has participated to the selection process of Call n. 1/2008 4 , presenting an Expression 
of Interest. The EoI contains a project for setting up a “Transregional Network for 
Innovation and Technology Transfer to Improve Health Care-TRANS2CARE” that 
includes 13 research organisations, technology transfer bodies and health service 
organizations. The six partners from Slovenia are the National institute of Chemistry 
from Ljubljana, the University of Nova Gorica and the Primorska University, the Slovene 
national Institute of Transfusion medicine, the Orthopaedic hospital Valdoltra and the 
General Hospital Dr. Franc Derganc from Šempeter pri Novi Gorici. The six partners 
from Italy are the International School for Advanced Studies of Trieste, the University of 
Udine, the University Ca’ Foscari of Venice and the University of Ferrara, the Scientific 
Research Institute and Hospital “Burlo Garofalo” of Trieste and Treviso Tecnologia, the 
Treviso Chamber of Commerce’s special agency for innovation. 
Objectives of the TRANS2CARE project
The Project proposal aims at implementing the objectives of the Priority Axis 2. With regard to the knowledge economy, the Project would like to map the scientific, 
technological and industrial expertise of the Partners, as well as correlate it to the 
intangible or unmet needs of healthcare workers (unmet medical needs) by providing 
thematic group meetings (on neuropathologies, allergic diseases, cardiac diseases, and 
so forth); by creating and updating a database of innovative technological solutions 
(Work package n. 5); consultations with biomedical companies (Work package n. 6); 
by signing the agreements among the companies as to gain regional, national and 
European funds (Work package n. 7); and lastly by creating a spin off (Work package 
n. 7) that would enable a physiological continuation of the established cooperation 
and scientific-technological exchange. Such activities were set out mainly to overcome 
the critical state of the past years due to poor knowledge of research results among 
healthcare personnel and, viceversa, poor knowledge about healthcare issues among 
research personnel; weak integration among Public Health services, academic and 
industrial research and development activities; discontinuous cooperation among 
research bodies, health institutions and companies, that had as consequence poor 
3 Corporate Annual Report 2008, page 18 
(www.openstarts.units.it/dspace/bitstream/10077/3560/1/BS_Units_sez_1.pdf).
4 Published in the Official Bulletin of the Region n. 42 from 15th Oct 2008.
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attractiveness of the Programme area for young researchers (pages 88-89 of the 
TRANS2CARE Project Application form).
With regard to the employment potentiality, the Project foresees recruiting, training 
and employing fourteen junior researchers with a doctoral degree that are to carry out 
Technology Training with the Partners (TRANS2CARE Project Application form, Work 
packages n. 3 and n. 4). At the end of the training period the Project foresees their 
employment in biomedical companies (Work package n. 7).
After evaluation, the Expression of Interest has scored maximum points (100/100) 5 
and thus, the University of Trieste could present the complete project, qualified as a 
strategic project according to art. 3 of Call n. 1/2008, for a value of Euro 2,611,188,00 in 
response to Call n. 1/2009 (“Second phase Call notice”) 6. 
Outcome of quality evaluation of the complete project proposal: funding denial
In the classification of the project proposals published in the Official Bulletin of the Region n. 17 from 28th April 2010 and related integrations, published on the official 
web site of the Programme on the 3rd June 2010 7, the project ranked fifth and first 
among the projects without funding. The outcome was thoroughly analysed as to 
understand why the funding was denied to the project. It seemed peculiar that funds 
were denied to a network of academic and research bodies, institutionally aiming at 
implementing ante litteram the Lisbon and Göteborg Strategies and carefully identified 
to accomplish the latter in the entire Programme area, as indicated in the Call.  
The participants to the project TRANSCARE have been cooperating for a long time 8 and 
were aiming at setting a long-term and financially sustainable institutional cooperation 
that would outlive the time limit of the Programme 9. The University of Trieste had 
invested substantial human and financial resources in preparing the project proposal 
and did, most of all, feel responsible to provide a rational self-analysis of the evaluation 
results to its Partners.  
A request was presented to the Managing Authority, to access the documents, related 
to the evaluation procedure of the TRANS2CARE proposal and the strategic projects 
financed in the Priority Axis 2, as recommended by the European commission and 
granted by the regional, national and European legislation 10. 
5 MoI classification after the quality evaluation (www.ita-slo.eu/progetti/bandi_pubblici/2009062509164240/).
6 Published in the Official Bulletin of the Region n. 26 of 1st July 2009.
7 www.ita-slo.eu/progetti/bandi_pubblici/2010060313454214/. 
8 Explicitly stated in the introduction, preceding the description of the project, under section B3 (State of the Art) of the 
Project application form (page 87) (www.trans2care.eu).
9 Objective, included in one of the project activities, namely the work package 7 of the Project application form (page 115) 
and the strategic requirement under section C.6 (Sustainability and/or duplicability of the project) (page 143).
10 Art. 42, Charter of Fundamental Rights of the European Union, EUR 21620 — the European Charter for Researchers. 
The Code of Conduct for the Recruitment. 2005. ISBN 92-894-9311-9. Law n. 241 of 7th Aug 1990 (Legge 7 agosto 1990, 
n. 241) “New provisions on administrative procedure and right to access to administrative documents.” Regional law n. 7 
of 20th March 2000 (Legge regionale 20 marzo 2000, n. 7) Single text of the provisions on administrative procedure and 
right to access.
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University of Trieste filing a case at the Regional administration court (T.A.R.) of the 
Friuli Venezia Giulia region
After thorough analysis of the documents, the University of Trieste filed a complaint at the Regional administrative court of FVG on the 16th Sept 2010 against the 
Autonomous Region of Friuli Venezia Giulia, in the person of the President of the 
Regional Council, and the Programme’s Managing Authorities, in the person of its legal 
representative, to suspend and cancel:
a) The final ranking list related to the Public Call n. 1/2009 and regarding the lists of 
Strategic Projects, which were either granted or denied financing in the Priority Axis 
2; 
b). All document and minutes of the comparative evaluation procedure, as well as the 
evaluation form with the scores assigned by the evaluators during the preliminary 
phase of “Quality control”;
c) Actions that lead to the appointment of the evaluators, briefly indicated with the 
abbreviations FVG ITA, VEN ITA, E-R ITA;
d) Art. 6 of the Public Call for the presentation of Strategic projects n. 01/2009 
published in the Official Bulletin of the FVG region n. 26 of 1st July 2009, more 
specifically the part that sets the deadlines for presenting expenses and reports of 
the financed projects on the 30th Oct 2010, 30th Sept 2011 and 30th Sept 2012.
The complaint was withdrawn after the reply of the Friuli Venezia Giulia region.  
The reply of the Friuli Venezia Giulia region 
The letter dated 10th March 2011, sent by the Central Directorate for culture, sport, international and EU relations of the Friuli Venezia Giulia Region to the University 
of Trieste, stated: “The Monitoring Committee of the Cross-border Cooperation 
Programme Italy-Slovenia 2007-2013 approved on the 8th March 2011 […] the 
allocation of additional resources for the above mentioned Call [1/2009]. As a result of 
such decision, the project […] TRANS2CARE qualifies for EU funding.” 
As specified in a press release of the Friuli Venezia Giulia Regional council dated 9th 
March 2011 11, the agreement achieved in the Monitoring Committee“… shall bring EU 
funding (for a total of almost 10 million Euros) to three additional strategic projects, 
presented in the Public Call n. 01/2009 (the projects that ranked first among those 
denied funding for each Priority Axis)”. The entire Programme funding amounts at 
about 136 million euros, meaning that the reprogramming reallocated the budged for 
a total of 7.35%. 
The later press release of the Regional council12  published some details of that 
considerable financial operation: the funding for strategic projects increased from 40 to 
11 Regional Council news,  09.03.2011 11:35, Cross-border cooperation: Programme Italy-Slovenia unblocked (www.regione.
fvg.it/rafvg/comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedallagiunta/&nm=20110309113521001).
12 News from the Regional Council, 28.03.2011 19:29, FVG/SLO: De Anna-Pelikan, Additional 10 Millions of Euro for 
strategic projects (www.regione.fvg.it/rafvg/comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedallagiunta/&
nm=20110328192903010).
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50 million euros (+25%), the funding for standard projects (Call n. 2/2009) stayed at 60 
million euros, whereas the available funding for “cross-border” projects (Call n. 3/2011 
for partnerships between the Region of Friuli Venezia Giulia and Slovenia, considered as 
land border areas) and  “small projects” (Call to be issued) was reduced. Since the Call n. 
3/2011 was granted funding of 17.5 million euros 13, rather then 22 million (-20%)14 and 
8.2 million euros have already been allocated to the Priority Axis 4-technical assistance, 
the residual funding for small projects is calculated at 0.3 million Euros together with 
any contingent “funds from the 3 projects - assured the councillor De Anna”15 , justifying 
thus the deferment of the Call for small projects 16.
From crisis to successes in the Programme Italy-Slovenia 2007-2013
The CBC Programme Italy-Slovenia had been going through a tough period due to the disagreements among the Programme Partners. 
By appointing Elio De Anna on the 15th October 2010 as Regional councillor for culture, 
sport, community and international relation17 and relaunching the Mixed Commission 
between the Region of Friuli Venezia Giulia and Slovenia, approved by the President 
Renzo Tondo18 , the bilateral relations were restored after three years of disengagement: 
this European Community organ meeted in Trieste on the 26th January 2011 under the 
presidency of the Regional councillor Elio De Anna and the State Secretary Dr Boris Jesih 
of the Office for Slovenes Abroad19.  The Mixed Commission met again in Brdo pri Kranju 
(Slovenia) on the 9th February 2011. During that occasion various Working Tables were 
started. One of them was dedicated to the “scientific research and technology […] sector 
where four strategic actions were identified. The first action concerns the mobility of 
qualified human capital through professional formation scholarships for graduates 
and young researchers that would involve research institutions […] At the end of the 
meeting both the State Secretary at the Ministry of Foreign Affairs, Dragoljuba Benčina, 
and the Regional councillor, Elio De Anna, expressed their satisfaction” 20. 
13 Regional Council news, 09.03.2011 11:35, Cross-border cooperation: Programme Italy-Slovenia unblocked.
14 Regional Council news, 03.12.2010 15:37, International relations: De Anna in Ljubljana with Slovene Deputy Minister 
for Foreign Affairs (www.regione.fvg.it/rafvg/comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedallagiunta/&
nm=20101203153746005).
15 Regional Council news, 28.03.2011 19:29, FVG/SLO: De Anna-Pelikan, Additional 10 Millions of Euro for strategic projects.
16 Cross-border Cooperation Programme Italy-Slovenia 2007-2013. News-09.03.2011 Official implementation of the 
agreement among Programme partners (www.ita-slo.eu/notizie_ed_informazioni/notizie/2011030916472457/).
17 Regional Council news, 15.10.2010 16:53, the Region: new mandates for regional councillors (www.regione.fvg.it/rafvg/
comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedallagiunta/&nm=20101015165310013).
18 Regional Council news, 26.11.2010 15:30, International relations: Tondo with the new Slovene ambassador 
in Italy (www.regione.fvg.it/rafvg/comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedallagiunta/&
nm=20101126153025007).
19 Regional Council news, 21.01.2011 17:34, International relations: De Anna, minorities useful for EU competitiveness 
(www.regione.fvg. it/rafvg/comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedal lagiunta/&
nm=20110121173434006).
20 Regional Council news, 09.02.2011 18:21, International relations: Meeting at Brdo pri Kranju - Mixed Commission for the 
development of FVG-Slovenia (www.regione.fvg.it/rafvg/comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedal
lagiunta/&nm=20110209182136010).
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The renewed cohesion inspired the Monitoring Committee to achieve an overall 
agreement via a written procedure (without the college meeting) on various issues and 
thus decided to finance the Call n. 1/2009 with additional 10 million euros. By doing 
so the Programme implementation process was restarted, consisting of the passage 
to the quality evaluation phase of the standard projects (Call n. 2/2009) and issuing 
of the cross-border projects Call (Call n. 3/2010)21. The European Union expressed 
its satisfaction, since these actions have prevented the automatic disengagement of 
European funds due to the inability to meet the expenditure requirements 22.
Uncertain truce or long-lasting peace?
The call for the strategic projects with beneficiaries spread over the entire Programme Area benefited enormously from the above mentioned cuts, but the funds cut hit 
the call for small projects, thus leaving out the small initiatives near the state border. 
However, that Programme’s agreement aimed at ensuring a uniform and wide-spread 
economic and social development at the cross-border level. 
Some parameters show that the border still exists in a virtual form and is far from being 
abolished: according to the Eurostat data from 2010, 19.8% of the Italian population 
aged between 30-34 has a University degree in comparison to the 34.8% of the Slovene 
population23. Slovenia is ranked better than Italy in seven out of eight indicators taken 
into consideration for the 2010 Innovation score, placing thus Slovenia in the Innovation 
followers group, after the Innovation leaders group. Italy, on the other hand, is ranked 
in the Moderate Innovators group, just before the group, ranked as last - the Modest 
Innovators . 
The Commission’s Report “State of the Innovation Union 2011”  states that Slovenia 
is believed to improve its innovation performance, due to the fact that it has saved 
large part of its structural fund for research and development, in line with the political 
guidelines of the European Commission’s Programme “Innovation Union” , whereas Italy 
keeps decreasing its investments in this sector. “There is clearly a risk of widening the 
innovation divide between the Member States”: is the alarming message of the Report. 
The University of Trieste racing for innovation and development
The financing granted to the TRANS2CARE project diminishes the risk for the 2007-2013 period and lays the grounds for limiting it in the future programming period, 
when the Universities will be called to give their vital contribution to the economic 
and social development, well argued in the document “Connecting universities to the 
regional growth” published by the DGRegio in September 2011  with the Universities to 
21 Regional Council news, 9.03.2011 11:35, Cross-border cooperation: Programme Italy-Slovenia and the Cross-border 
Cooperation Programme Italy-Slovenia 2007-2013 unblocked. News- 09.03.2011 Official implementation of the agreement 
among Programme partners (www.ita-slo.eu/notizie_ed_informazioni/notizie/2011030916472457/).
22 Regional Council news, 12.03.2011 11:23, International relations: EU plaudit for unblocking Interreg Italy-Slovenia 
funds (www.regione.fvg.it/rafvg/comunicati/comunicato.act?dir=/rafvg/cms/RAFVG/notiziedallagiunta/ nm=20110312112311003).
23  epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&plugin=1&language=en&pcode=t2020_41.
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be held responsible for the creation of synergies among various financial instruments , 
such as those of Horizon 2020  and those of the future Cohesion Policies.
It is more than obvious that without funding for the TRANS2CARE project, the distance 
between the university system of the Friuli Venezia Giulia Region and the Slovene 
system would have become even greater: with the Italian system on one side, not 
sufficiently expert for attracting and managing wide range innovation and technology 
transfer, and the Slovene system on the other side, projected in realizing these 
challenging operations, carrying forward constant communication with the public 
authorities and enterprises and ready to face the accession of Croatia to the European 
Union in terms of constant attraction of new European Structural and Research funds.
In this race towards Innovation and development the University of Trieste has 
nevertheless discovered the power of deep internal innovation - the power of a radical 
change of mentality. 
Change of mentality: from spectators to actors 
Usually those responsible for the project proposals take unconditionally note of the assigned evaluation. The lack of understanding why a specific score was assigned 
to a project breaks the virtuous circle of criticism (and self-criticism), crucial for any 
innovative cultural activity (learning by lessons). 
Through the analysis of the documents, related to the comparative evaluation procedure 
for strategic projects, it was possible to discover not only procedure faults, but also 
fault in the TRANS2CARE application form: the quality of the text, put in in the project 
application form, can be improved and provide a better way of bringing up the proposals, 
as well as better compliance with  the objectives of the Operational Programme and the 
European Policy Documents. 
By exercising its right to access the procedure documents, the University has shown 
its intention to compete for EU funds, based only on technical and meritocratic 
principles and refusing to opt for abnormal forms of two-sided interactions such as 
confidentiality, indiscretion, undeserved pressure (lobbying). Consistently with its 
orientation, the University of Trieste is a member in the EU Register  that consists of 
a list of organisations and freelancers committed to processing and implementing EU 
policies, and openly express   their opinions by participating to Public consultations.
CONTACT INFO
Sabina Passamonti is with the Department of Life Sciences, University of Trieste, Via L. Giorgieri 1, 34127 
Trieste, Italy. E-mail: spassamonti@units.it
176
177
The contribution of Trans2Care 
to the European Cohesion Policy: 
not just an administrative fulfilment
Giorgio Tessarolo
Within the “2007-2013 European Territorial Cooperation” objective, on 20th December 2007, the European Commission issued a decision to adopt the 
“Italy-Slovenia 2007-2013 Cross-border Cooperation Programme”.
The program has a total budget of over € 136 million and is divided into four Priority axes: 
“Environment, transport and sustainable territorial integration”, “Competitiveness 
and knowledge-based society”, “Social integration” and “Technical support”.
In Italy the Programme is implemented in the provinces of the Friuli Venezia Giulia 
Region (Trieste, Udine and Gorizia), in the Veneto Region (Venice, Rovigo, Padua) and 
in Ferrara and Ravenna in the Emilia Romagna Region. In Slovenia the project is 
implemented in the so-called NUTS 3 areas of Gorenjska, Goriška and Obalno-kraška.
To a limited extent, the project may be implemented in the Italian provinces of 
Pordenone and Treviso and in Slovenia in the NUTS 3 areas of Osrednjeslovenska and 
Notranjsko-kraška.
The Operational Programme has its origin in the Community Strategic Guidelines on 
Cross-border Cooperation spelled out in the Regulations of 2006 which indicate that 
among the priorities laid down in the so-called “Lisbon strategy”, there is the need 
to promote “innovation, entrepreneurship and the development of a knowledge-
based economy through the development of research and innovation’’ including new 
information and communication technology.
This priority has been encompassed by the Italian and Slovenian National Strategic 
Frameworks. The Operational Programme stresses that Territorial Co-operation (in 
this case, cross-border) can effectively contribute to the general objective through the 
creation of scientific and technological cross-border networks and the enhancement of 
regional research and development, thus promoting the development of partnerships 
between producers of knowledge, increasing the degree of internationalization of the 
centers, developing new applied research skills and emphasizing existing excellence 
systems by making them available to local production systems.
That said, it is worth remembering what the overall objective of the Italy-Slovenia 
2007-2013 Programme is: “Strengthening the attractiveness and competitiveness of 
the Programme area”.
When listing the main operational objectives of Axis no. 2, emphasis is given to joint 
actions promoted by business incubators, innovation centers, science and technology 
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parks, that can recognize the added value resulting from the sharing of experiences 
between Italy and Slovenia, in order to develop new capabilities to be made available 
to young entrepreneurs and researchers. The excellence of knowledge, the presence 
of experienced personnel and technical equipment and facilities should be shared 
within selected research themes and projects.
The Operational Programme foresees three types of projects: strategic projects, 
standard projects and small projects. All projects are selected through special calls.
Today, we will examine the characteristics of strategic projects, since TRANS2CARE 
belongs to this category.
Strategic projects should:
•	 contribute to the achievement of the objectives of the European strategies and 
Programme and have a significant sustainable impact on the Programme area, 
also through the identification of appropriate indicators;
•	 have a genuine cross-border character and meet the four requirements of Article 
19 of the Regulation (EC) no. 1080/2006: joint development, joint implementation, 
joint staffing and joint financing;
•	 ensure that the cooperation continues even after the conclusion of the project 
through the creation of permanent cross-border networks and organizations;
•	 be designed and implemented by partners, who have an adequate level of expertise 
on project issues and are able to ensure the achievement of results.
This is the overall reference framework within which the TRANS2CARE project has 
been selected among those eligible for funding under the Call for strategic projects.
The project has a duration of three and a half years (until the 30th September 2014) 
and a budget of  € 2,611,118. The partnership consists of thirteen partners which 
constitute an “Interregional network for innovation and technology transfer for health 
improvement” in order to continuously develop new protocols and biotechnological 
devices for the prevention, early diagnosis and treatment of neurodegenerative, 
cardiovascular, oncologic and orthopaedic diseases.
Then, there are some characteristics that make this project original and unique: 
firstly, the mix of innovation, knowledge transfer and creation of new jobs for young 
and qualified researchers, who will be trained within the project.
Secondly, the project is built on a robust large partnership involving various subjects 
and possesses multiple skills and complementary and diversified knowledge since 
it involves universities and research institutions, hospitals and organizations for 
technology transfer.
In my opinion, the most important challenge TRANS2CARE will have to deal with is its 
consolidation beyond the time limits set by the Programme: as in Brussels they like to 
say, the project should lay the foundations for its future “sustainability”: this could be 
achieved by implementing its activities in the next 2014-2020 programming period, 
by expanding the current partnership and by creating a project spin-off, that will 
ensure a stable and structural employment to the fourteen young researchers. The 
project should be able to involve the companies operating in the sectors concerned, 
but it should also be able to acquire the necessary skills in order to obtain additional 
funds, both public and private, to support the future of the network.
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In this regard, I would like to emphasize that TRANS2CARE already has the 
characteristics and meets the requirements that the European Commission has 
identified for future programming within its document entitled “Europe 2020: a 
strategy for smart, sustainable and inclusive growth”:
•	 smart, since it is aimed at developing an economy based on knowledge and 
innovation;
•	 sustainable, to promote a more efficient economy in terms of resources, and a 
more green and more competitive economy;
•	 inclusive, aimed at promoting an economy with a high rate of employment so as to 
promote the economic, social and territorial cohesion.
That said, a final thought is now required: what should we expect from the project 
results as not to reduce it to a mere fulfilment of administrative and accounting 
tasks?
This has always been the problem of all problems as community planning in 
concerned!
I believe it is important to remember, first of all, what is the purpose of the cohesion 
policy: promoting growth and economic development and, therefore, create wealth 
and additional employment.
IS TRANS2CARE IN LINE WITh ThIS ”MISSION”?
At present, it certainly is, but the problem that will arise after 2014 will be the need to consolidate the current project in order to make it stable, both in terms of 
employment of researchers and reduction of welfare costs for the community, and 
structural enlargement of the partnership: if that happens, and there is no reason 
to doubt it, TRANS2CARE will have fully achieved the objectives for which it was 
designed and it will not be limited to a proper spending of the funds allocated by the 
European Commission, but it will have spent them EFFICIENTLY!
CONTACT INFO
Giogio Tessarolo, Expert of European Regional Policy, formerly Director of the Office of International Affairs 
of Regione Friuli Venezia Giulia. E-mail: giorgio.tessarolo@tin.it
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Trans2Care in pole position 
to implement Innovation Union
Giorgio Perini
First of all, I would like to thank the University of Trieste in the person of Prof. 
Passamonti for this most welcomed invitation to attend the launch event of the 
Trans2Care project in my city, Trieste, where unfortunately I can only rarely return 
because of work commitments in Brussels.
I greet you, the University of Trieste and all the participants in the name of the Italian 
Ambassador to the EU, HE Ferdinando Nelli Feroci.
NOTES ON ThE PERMANENT DIPLOMATIC REPRESENTATION OF ITALy  
TO ThE EUROPEAN UNION
Let me begin with a brief presentation of the role of the Permanent Diplomatic Representation of Italy to the European Union, where I am honoured to serve as a 
regional expert, appointed by the Conference of Regions and Autonomous Provinces.
The EU institutions cannot know the often-changing internal structure and internal 
distribution of powers of each Member State. For this reason the “Permanent 
Representations of the Member States” are a collector or a “funnel” for all EU 
communications at any level of the Member State government (central government, 
regions and municipalities). The same process happens in the other direction: the 
European institutions must be sure that official communications sent to them are 
attributable to the Member State and cannot be subsequently disregarded and the 
only way to achieve this is to send them through the permanent representations, 
usually through an electronically encrypted e-mail system. The Permanent 
Representation of Italy ensures this flow of official information in both directions (a 
different thing is of course the flow of unofficial communications, where many other 
actors are involved).
It is also worth mentioning, that the direct participation of the Regions in the 
ascending phase of Community law (the one where one decides the new “European 
laws”) is now possible as a result of the reform of the Constitution and acts that have 
followed (the so-called La Loggia Law and the State-Regions agreement of 2007), 
but have not yet been implemented for Italy. Thus far the ascending phase is the 
exclusive prerogative of the Representation of Italy in Brussels, which is assisted by 
experts in various subjects, usually from ministerial background, which is why it is 
important to be there.
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ThE “TRANS2CARE” PROjECT 
But let me immediately move on to the Trans2Care project for which we are here today: this project encompasses the virtuous model of the triple helix, where 
universities (higher education and research), public administrations and enterprises 
interact; it represents Europe2020 aimed at a smart, sustainable, supportive and 
inclusive growth, and of course there is the cohesion policy, in particular the territorial 
cooperation, presently under the Italy-Slovenia 2007-2013 Programme, but already 
projected in the next 2014-2020 programming period.
No wonder then that this project has been selected and I am sure it will be a big 
success: better health for longer periods, rationalization and sustainability (including 
financial) of health services, research and innovation spin-offs are also the goals of 
the Pilot partnership on healthy and active aging initiative launched by the Council of 
the European Union in February 2011 as part of the newly founded partnerships for 
innovation, in order to facilitate the achievement of the Union for Innovation, one of 
EU2020 flagship initiatives.
ThE STRATEGIC PLAN FOR ThE IMPLEMENTATION OF ThE “PILOT PARTNERShIP”
On November, 7th - exactly two weeks ago - the strategic plan for the implementation of this pilot partnership was approved. The plan aims to reduce 
barriers to innovation in the field of “good” aging and promote a more efficient use 
of European funds, through a first series of concrete actions to be launched in 2012, 
among which I will mention only two:
•	 Disseminate and promote innovative models of integrated care of chronic diseases 
of the elderly, such as remote monitoring. A number of EU regions will take the lead 
in this field, according to the steering group which includes three Commissioners 
(for Health, ICT Technology and Research, development and innovation);
•	 Develop interoperable ICT solutions (in particular within the so-called AAL - Ambient 
Assisted Living) to help older people to stay independent, mobile and active for 
longer periods of time. In this regard, I would like to remember that the Friuli Venezia 
Giulia Region, through the Liaison Office in Brussels I was responsible for over the 
past five years, is part of CORAL or Community of Regions for Assisted Living. 
Also in 2012, the European Commission will launch the calls for broadening 
stakeholders’ involvement, beyond those already involved in the steering group, in 
order to implement with them  the priorities and actions identified in the Plan. It goes 
without saying that “Trans2Care” and its partnership should be in “pole position” to 
play a leading role.
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ThE OUTLOOK FOR ThE 2014-2020 PROGRAMMING PERIOD 
We have said that “Trans2Care” was created in the current programming period, but in many ways it looks even more at the next 2014-2020 period. Therefore, 
we should briefly comment on the prospects for the next programming period on the 
basis of what we know today.
Firstly, we should keep in mind the increasing integration of European policies: 
EU2020, national reform plans, stability and convergence programs (and the so-
called “European semester”), review of the EU budget, regional policy, strategic 
framework for research, development and innovation (Horizon 2020), agricultural 
policy, development cooperation and financial perspectives are all strongly correlated 
with each other.
In particular, with regard to the future of the cohesion policy, there are some aspects 
of the proposal currently under discussion that we like more and among them the 
cohesion policy for all European regions as a catalyst for EU2020, preserving the 
competitiveness (thanks to the strong lobbying efforts at EU institutions - the 
European Commission in the first place - made by 174 European regions, including 
the FVG through the Liaison Office in Brussels), the proposed financial budget made 
by the European Commission, etc. But there are also some aspects that we like less, or 
rather we are concerned about, such as the ex-ante performance indicators (not the 
ex-ante conditionality), the external conditionality (or macroeconomic conditionality) 
linked to national performance with respect to the Stability and Growth Pact which is 
obviously beyond the control of individual regions; the partnership agreements to be 
signed with the EC (here the role of the regions is not clear). But there is also reason 
for concern given by the EU Financial Perspectives for the 2014-2020 period (i.e. the 
level of contribution of the Member States in terms of GDP percentage).
MACRO-REGIONAL STRATEGIES
The Friuli Venezia Giulia Region, co-founder of a wide-area strategy ahead of its time - the ALPE ADRIA Working Community - could be left out from all macro-
regional strategies, i.e. the Baltic (obviously), the Danubian, the Adriatic-Ionic and the 
Alpine, while our neighbours are already playing across the board.
Of the three no’s that the European Commission needed to digest the macro-regional 
strategies (no new institutions, no new laws, no new funds), the last one is the one 
that convinces us less, since macro-regional strategies could play an important role 
in the next programming period, not only for the greater ability of virtuous regions to 
spend and perform, but also for their recognized role in territorial cooperation (the 
former Objective 3), in particular in transnational cooperation.
That’s why we have begun to take action with respect to existing and future macro-
regions with initiatives such as the promotion of the Baltic-Adriatic transport axis 
based on a partnership of 14 regions along the former Iron Curtain, which already has 
considerable success due to the inclusion of new Corridor no. 1 in the Trans-European 
transport networks), the promotion and visibility of the Conference of Rectors of 
Alpe Adria and Danube Universities for the development and implementation of the 
184
third pillar of the Danubian strategy aimed at developing the Society and Economy 
of Knowledge, and finally a reorientation of the CPMR (Conference of Peripheral 
Maritime Regions) to the eastern Mediterranean - that is, the Adriatic-Ionian area - 
rather than just to the western Mediterranean, and in this context, a more equitable 
balance between a North-South and a West-East axis.
EGTC (EUROPEAN GROUPING FOR TERRITORIAL COOPERATION)
It’s hard not to mention it, seen the industry within which the “Trans2Care” project is settled: health, which will probably become the priority area of  cooperation and 
integration, together with transport, within the EGTC. It is important to emphasize 
that after 2013 non-EU subject will be able to participate to EGTCs. This will represent 
an opportunity to relaunch the Euroregion project called “Without Borders,” in which 
Trans2Care may already be part of.
CONCLUSIONS
The Europe2020 strategy is not - and especially should not be - an unclear strategy for a selected group of experts in Brussels. It’s a compulsory handbook for 
Europe and to become successful it needs to be known, understood, accepted and 
implemented at all levels.
Whether we like it or not (but we have to like it: we have no alternative, as it has 
become clear in recent months, when we thought we had seen it all, but we had not 
seen anything yet - think about the political earthquakes in Greece, Italy, Spain and 
even France), it will provide the guidelines for all European policies from now on to 2020.
The project that begins here today goes exactly in this direction and I am sure we will 
illustrate it in Brussels as a best practice at European level and beyond.
Brussels-Trieste, November 2011
CONTACT INFO
Giorgio Perini, Permanent Diplomatic Representation of Italy to the EU in Brussels. 
E-mail: giorgio.perini@regione.fvg.it
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Translation of Trans2Care concept 
to the West-African countries: 
looking beyond tomorrow
Ayokunle O. Ademosun, Sabina Passamonti, Lovro Žiberna
Abstract — The regional partnership established between Italy and Slovenia 
under the TRANS2CARE Project aims at creating innovative products and 
services to improve public healthcare system through enhanced knowledge 
transfer between project partners and stakeholders. This framework of 
borderless partnership has potential to be translated to the West-African region 
to effectively utilize the available resources of member states. Such synergistic 
cooperation is needed to tap into the abundant ethnopharmacological 
potentials of the region to create an affordable healthcare system and economic 
advancement. Consequently, research networks and improved healthcare 
system in the region will drastically reduce braindrain of researchers and 
physicians.
Index Terms — European Union, knowledge translation, TRANS2CARE, West 
Africa
———————————————————
1 RESEARCh IN EUROPE: IS GLOBALIzATION hARMONy?
It has been said that arguing against globalization is like arguing against the laws of gravity. – Kofi Annan, Secretary General of UN
European Union research programs are quite complex, but enable researchers, 
research institutions and businesses to increasingly circulate, compete and co-
operate across borders. The objective is to give them access to a Europe-wide 
open space for knowledge and technologies in which transnational synergies and 
complementarities are fully exploited.
While most research activities, programs and policies take place at regional and 
national levels, no single country offers sufficient resources to be competitive on 
the world scale. To strengthen the penetration of European research ideas, joint 
activities and policies are increasingly designed and operated from a transnational 
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perspective, including, where relevant, cross-border co-operation. It is now clear that 
transnational co-operation enables the most efficient and effective use of national 
and regional resources.
The success of globalization within the EU can be seen in many dimensions. In health 
care, all EU and some other European countries, offer their citizens a free European 
Health Insurance Card, which provides insurance for emergency medical treatment 
when visiting other participating European countries. Another important field is 
education, where EU strongly supports globalization of universities via the Bologna 
process, which brings comparable standards and compatible degrees across Europe, 
and the Erasmus Program, a university international exchange program, which 
is nowadays a symbol of European student life. However, although Europe’s 4000 
universities have big potential, most of it unfortunately dies instantly because of 
various rigidities and hindrances primarily due to conservative politics practiced by 
universities. 
Scientific development in the EU is encouraged by various programs. Some are strictly 
researchoriented and based on scientific excellence, while others are funded through 
European regional development funds. The latter aim to strengthen economic and 
social cohesion between regions in the EU intending to underpin regional capacities 
for research and technological development. The ultimate goal is creating a more-
or-less harmonious research space inside the EU. In this manner, EU trans-regional 
projects, such as TRANS2CARE, can function as a reference regarding science and 
health organization for developing countries.
Can we translate the EU’s successful experience of globalizing science to another 
continent? 
2 PROBLEMS IN WEST AFRICAN hEALTh SySTEM
A replication of this kind of working relationship between countries in the West-African sub-region is long overdue as the health care system in this region has 
been in dire need of a boost. About 250 million people reside in the 15 independent 
states of West Africa and this is about a quarter of the whole of Africa [1]. According 
to the Sahel and West Africa Club of ECOWAS [2], the last major world region where 
mortality rates are still very high is Sub-Saharan Africa. The disease burden in West 
Africa is characterized majorly by malaria, which is the primary cause of morbidity 
and mortality. Furthermore, 100% of cases of trypanosomiasis and 90% of cases 
of yellow fever [3] are recorded in West Africa, while cholera and HIV/AIDS also 
present a serious threat. Others include schistosomiasis, meningitis, dracunculosis, 
onchocerciasis and leprosy. Furthermore, the average doctor to population ratio in 
Africa is 2.3 per 10,000 inhabitants and this does not compare favorably with 33.3 per 
10,000 inhabitants in Europe [4]. More so, estimates show that about 70% of West 
Africa’s doctors are found in Nigeria alone while countries such as Niger, Liberia and 
Sierra Leone have less than 1 doctor per 33,300 inhabitants [3]. Taken altogether, 
average life expectancy at birth in Africa is 54 years, while in EU is 75 years [4].
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3 EThNOPhARMACOLOGICAL POTENTIAL OF WEST AFRICA
It is not all bleak in this part of the world as the pharmaceutical potentials of African medicinal plants are immense, and West Africa has the human and natural 
resources to become an even greater producer of natural plant products of medicinal 
value [5]. Furthermore, in contrast to the 1:40,000 ratio for medical doctors to the 
rest of the population in sub-Saharan Africa, the ratio of traditional healers to the 
population is approximately 1:500. This means that there are 80 times as many 
traditional healers as biomedical doctors [6]. More specifically in West Africa, in the 
Kwahu district of Ghana the ratio of traditional healer to people is 1:224 compared to 
1:21,000 for medical doctors. West Africa, like other regions in Africa and Asia, has had 
a long history of traditional medicine practice, however, unlike the Chinese and Indian 
medicinal plants, much of the phytochemical compositions and medicinal values of the 
natural products have not been fully researched and documented. Each community in 
West Africa has its unique approach to health and disease management. It can thus 
be argued that “there are as many traditional medicines as there are communities” 
in the West African region [5]. The World Health Organization (WHO) has stated that 
traditional medicine is one of the strongest tools for taking “total health care” to the 
world’s unreached population [5]. Due to constraints such as paucity of funds, high 
cost of chemicals, lack of equipment and shortage of manpower, research oriented 
into the bioactive components of medicinal plants in West Africa has been hampered. 
Even more, in countries where research activities are on-going, they have become 
mere academic exercises, as there is no “benchtobedside” transmission of research 
results. 
To elaborate potentials, there is an immense challenge for the research community in 
studying traditional medicines used for hundreds of years. Specific climate conditions, 
such as high temperatures with intra-season drought and rainfall unpredictability, 
can lead to a plethora of novel, not yet isolated, plant chemicals specific to this region. 
Isolation, coupled with computational in silico molecular docking studies, can lead to 
the characterization of novel lead compounds with therapeutic potential, and possibly 
to the development of novel drugs. 
4 TRANSLATION OF EUROPEAN NETWORKING TO WEST AFRICA
The concept of TRANS2CARE borderless partnership, as implemented in Europe between Slovenia and Italy, provides a ‘light at the end of the tunnel” - serving as 
an excellent framework that should be copied by the countries in the West African 
region. The idea of Trans2care networking project can be summarized as “aiming 
at establishing a permanent, bi-directional flow of knowledge transfer among the 
project partners, industry and other stakeholders, so to establish an environment 
generating innovative products and services for the public healthcare system. In 
particular, the project addresses questions about prevention, diagnosis and treatment 
of widespread diseases”[7]. As such, it appears appropriate for West Africa to start its 
implementation. 
One obvious fact is that co-operation is needed among West-African countries to 
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fight the scourge of diseases and ensure efficient health care delivery through applied 
research on the abundant medicinal plants to be found in the region, training the 
numerous traditional healers, and development of phytomedical and nutraceutical 
industry. The latter is important for ensuring that the abundant natural products 
serve as raw materials and that these plants do not become over-exploited or 
extinct. Pharmaceutical production is normally capital-, knowledge- and technology-
intensive, but ethno-pharmacological studies of indigenous plants will enhance the 
discovery of plant bioactive compounds that will improve the health of the population 
through nutrition. These studies will also help to identify plant bioactive compounds 
to open perspectives for the local pharmaceutical industry, especially for over-
the-counter products, which would aid the economic development of the region. 
Networking of health care professionals and leading researchers amongst countries 
in West Africa can bring benefits to both the health care system and industry by 
promoting production of low-cost drugs. Primary production of pharmaceuticals in 
the region will also encourage technology transfer between academic research and 
industrial production [8,9].
Ensuring equal access and fair treatment for all interested parties across the West 
Africa can be a daunting task, which requires certain rules and procedures, as well 
as bringing attention to the need for better articulating the importance of such 
networking at a high political level. To improve research systems, a more favorable 
environment for transnational mobility throughout research career in West Africa 
must be created. Research should not be perceived as a closed system, but instead as 
an open and dynamic systems based on partnership and dialogue with researchers 
from all over the world, as already successfully implemented in the EU. Furthermore, 
removing obstacles to mobility can bring together countries in a community whose 
aim is to achieve integration via joint research activities with a commitment to 
economic expansion.
5 AFRICAN BRAIN GAIN – BRAIN DRAIN PROBLEM
A translation of this type of project to West Africa will not only create an environment that will attract foreign researchers for international (brain gain) collaboration, 
but will also stem the rising tide of brain drain. About six years ago, a New York Times’ 
article [10] revealed that legal immigration into the United States by Africans had 
reached a similar magnitude to the days of the slave trade. Scientists, researchers 
and medical personnel are the worst hit by the brain drain. This was confirmed by 
French President Nicolas Sarkozy, who stated, during a visit to Senegal, that “there are 
more doctors from Benin (West Africa) in France then in Benin itself” [11]. Moreover, 
about ten years ago, it was observed that there were more Sierra Leonean (West 
Africa) medical doctors in Chicago than in Sierra Leone [12], while the WHO observed 
in 2006 that more than 25% of doctors trained in Africa work abroad [13]. However, it 
is anticipated that science students would choose to study and work in Africa if they 
had access to high-quality training [14]. There is therefore an increasing need for 
networking among West African countries to develop “centers of excellence”, where 
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researchers can have access to modern research facilities, and where their research 
findings can be translated to products and services, which will improve the quality of 
service in healthcare centers.
6 CONCLUSION
Such a network will bring about a “pulling-together” of resources among member countries that will have a synergistic effect on health care delivery, new 
employment generation, pharmaceutical/nutraceutical product development, and 
training of medical personnel. Moreover, pragmatic cooperation that defies cultural, 
language, religious and economic barriers and transcends the political differences that 
have isolated member states is what will indeed give a birth to a united community 
of West African states. 
A central objective of such joint activities is to establish the “fifth freedom”: the 
freedom of movement of knowledge. Research and innovation arising from this will 
offer solutions to overcome the great challenges that face West African countries 
these days.
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